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Although in the recent decades the advances made in order to treat cancer have 
led to great improvements in terms of patient’s survival, many cancer types present 
resistance to treatments, relapse, and metastasize, compromising patient’s life. In 
addition, radiotherapy and chemotherapy high doses present serious side effects. 
Heterogeneity is one of the factors that causes tumor therapies resistance. It can be inter- 
and intratumor. Intertumoral heterogeneity, meaning the molecular and cellular 
differences between different tumors, interferes in establishing effective standard 
patient’s treatments, thus increasing the need for personalized therapy. In turn, 
intratumor heterogeneity is due to the existence of a set of cancer stem cells (CSCs), 
responsible for tumor initiation, metastasis, recurrence and therapy resistance. Hence, 
the main challenge is finding targeted therapies to eliminate CSCs. 
Dysregulation of genes related to embryonic development and essential in the 
maintenance of stem cells is critical for cancer malignant phenotype’s development and 
progression. It is why in this thesis, we studied different molecular mechanisms involved 
in the regulation of stem cells and embryonic development in medulloblastoma (MB) and 
glioblastoma (GBM) tumorigenesis.  
MB is the most common solid tumor in childhood, developed in the cerebellum. 
This tumor arises as a result of cerebellum development dysregulation. Although patient 
survival has increased up to 70-90 % in recent years, the high chemotherapy and 
radiotherapy doses required to eliminate the tumor cause serious permanent 
neurological sequelae, highlighting the urgent need to develop new therapeutic 
strategies. Due to intertumoral heterogeneity, these tumors are classified into different 
subgroups, according to the altered signaling pathways (WNT, SHH, Group 3 and Group 
4). Moreover, MB tumors show a MB stem cells subpopulation (MBSCs), which cause 
both tumor recurrence and resistance to treatments. 
Besides, GBM is the most common, aggressive and malignant adult brain tumor. 
Recent studies reveal several genetic mutations and molecular alterations that direct the 
tumorigenesis process. This implies different disease subgroups and the existence of 
glioma stem cells (GSCs). Currently there is no effective treatment to treat this tumor and 
therefore no long-term patient recovery is possible. These data reveal the importance of 
new therapeutic strategies discovery, targeting specifically GSCs. 
ERBB4 is a tyrosine kinase type membrane receptor that has been associated with 
nervous system embryonic development and related to various tumorigenesis processes. 
This receptor plays different roles depending on the tumor type. In this work we observed 
that it plays a crucial role in cerebellum development and in the control of progenitor 
cells migration. Moreover, its activation in progenitor and MB cells made them more 
resistant to apoptotic stimuli. This suggests that its abnormal activation might protect 
cells from apoptosis, providing resistance to chemo- or radiotherapy. When analyzing 
ERBB4 expression in the different MB subgroups, we observed that it was highly 
expressed in subgroup 4 MBs, and that was related to a lower survival, more significantly 
in this subgroup. Interestingly, in this subgroup an altered signaling pathway has not yet 
been described. Therefore, these results show the ERBB4 importance as a subgroup 4 
and a prognostic marker. To elucidate ERBB4 function in MB cells, we inhibited in vitro its 
expression and observed a reduction in cell viability and apoptosis activation. In line, we 
showed in vivo a reduction in self-renewal, initiation and progression capacity. Likewise, 
we observed ERBB4 expression enrichment in the MBSC subpopulation. Moreover, 
ERBB4 silencing significantly decreased the proliferative and self-renewal capacity of 
MBSCs. Thus, in this work we reveal ERBB4 as a potential new therapeutic target in MB 
and we propose its inhibition as a complementary strategy in combination with existing 
therapies, with the aim of reducing chemo- and radiotherapy doses to alleviate its serious 
side effects. 
On its part, SOX1 transcription factor plays a fundamental role in embryonic 
development and stem cell maintenance in adulthood. Its role in oncogenesis has been 
widely described, revealing it as a tumor suppressor in different cancer types. However, 
in contrast to what has been published so far, in our work, SOX1 oncogenic role has been 
demonstrated in both GBM and MB. 
Specifically, regarding SOX1 role in MB, we demonstrated that its expression is 
elevated in SHH subgroup tumors compared to others, using public databases. Related to 
 
 
this, we observed a higher SOX1 expression in MB cell lines belonging to the SHH 
subgroup. Likewise, we showed that high SOX1 expression levels correlate with a worse 
patients’ prognosis, and more significantly in SHH subgroup patients. Furthermore, when 
we analyzed the different SHH pathway genes in these patients, we observed that SOX1 
could be a better subgroup and prognosis biomarker than any of the SHH pathway genes. 
With the aim of clarifying SOX1 role in the MB progression and malignant phenotype, we 
silenced its expression in MB cells, and observed a decrease in cell proliferation and 
viability in vitro, and in tumor formation and progression in vivo. In line, we observed that 
SOX1 expression increases in MBSCs and that its genetic silencing decreases their self-
renewal capacity. Notably, this phenotype was more drastic in SHH subgroup cells, 
further relating SOX1 to this MB subgroup. Altogether, these results point out a SOX1 
fundamental role in MB progression, and more specifically in the SHH subgroup, 
suggesting that SOX1 could constitute a new therapeutic target in MB.  
In the GBM context, we showed SOX1 over-expression compared to healthy 
tissue, both in our cohort and in accessible databases. In addition, we observed that SOX1 
high expression levels are directly associated with a worse prognosis in patients, as we 
observed in MB, suggesting its potential utility as prognostic marker. With regard to 
intratumor heterogeneity, we found SOX1 high enrichment in GSCs, both in patients-
derived cells and in cells grown in stem cells selective medium. Regarding its regulation 
in GBM, we showed that SOX1 is regulated by SOX2, a key transcription factor of SOX 
family involved in embryogenesis and neurogenesis processes. Thus, SOX1 silencing in 
GBM cells led to a significant decrease in their proliferation capacity, self-renewal ability, 
and differentiation potential. In line, we observed in vivo a reduction in their tumor 
initiation and progression capacity. All these results demonstrate an important role of 
SOX1 in GBM development and GSCs maintenance, which are responsible of treatment 
resistance and tumor recurrence. 
Altogether, this thesis has demonstrated a hitherto undescribed ERBB4 and SOX1 
role in MB and GBM, as essential genes for these tumors’ maintenance. Furthermore, we 
have described in this work for the first time that SOX1 acts as an oncogene in brain 
tumors such as MB and GBM. Considering the characteristics of these tumors and the 
urgent need to find new therapeutic targets and alternative strategies, this work 
postulates ERBB4 and SOX1 inhibition as promising therapeutic approaches to combat 
chemo- and radiotherapy resistance and reduce the current doses toxicity. In addition, 
ERBB4 and SOX1 might be used as prognostic markers, and also as markers for two 






A pesar de que en las últimas décadas los avances realizados para tratar el cáncer 
han supuesto grandes mejoras en lo que respecta a la supervivencia de los pacientes, 
muchos tipos de tumores presentan resistencia a sus tratamientos, recurren y se 
diseminan, comprometiendo con ello la supervivencia de los pacientes. Además, las altas 
dosis de radioterapia y quimioterapia necesarias acarrean graves secuelas permanentes, 
especialmente en pacientes pediátricos. Uno de los factores que contribuyen a los 
procesos de resistencia a la terapia de los tumores es la heterogeneidad celular, tanto 
inter- como intratumoral. Por una parte, la heterogeneidad intertumoral dificulta el 
establecimiento de tratamientos efectivos para todos los pacientes, lo que aumenta la 
necesidad de una terapia personalizada. A su vez, la heterogeneidad intratumoral, es 
decir, la presencia de distintos tipos celulares dentro del mismo tumor, se debe a la 
existencia de una población de células madre tumorales que son las responsables no solo 
de la iniciación tumoral, sino también de la metástasis, recurrencia y resistencia a las 
terapias utilizadas. Debido a la presencia de estas células también en tumores del sistema 
nervioso central, el objetivo principal de esta tesis fue el de encontrar terapias dirigidas 
para eliminar dichas células madre tumorales.  
La desregulación de aquellos genes relacionados con el desarrollo embrionario y 
el mantenimiento de las células madre embrionarias y adultas parece ser crítica para el 
desarrollo y la progresión del fenotipo canceroso. En este trabajo, se ha estudiado el 
papel de diferentes mecanismos moleculares implicados en la regulación de las células 
madre y del desarrollo embrionario en los procesos de tumorogénesis del 
meduloblastoma (MB) y del glioblastoma (GBM), dos tumores del sistema nervioso 
central.  
El MB es el tumor sólido más común en la infancia, y se localiza en el cerebelo. Se 
origina debido a la desregulación del proceso de desarrollo del cerebelo, por lo que el MB 
se considera un tumor de origen embrionario. Aunque la supervivencia de los pacientes 
ha aumentado hasta alcanzar el 70-90 % en los últimos años, las altas dosis de 
quimioterapia y radioterapia necesarias para eliminar el tumor causan graves secuelas 
neurológicas permanentes en los pacientes, haciendo patente la necesidad de hallar 
nuevas estrategias terapéuticas que permitan reducir los efectos secundarios de los 
tratamientos actuales. El MB presenta una elevada heterogeneidad intertumoral, 
identificándose distintos subgrupos en función de qué vías de señalización están 
alteradas, clasificando los tumores en los subgrupos WNT, SHH, Grupo 3 y Grupo 4. Cabe 
destacar que en los últimos dos subgrupos todavía no se ha encontrado qué vía de 
señalización es la causante de la formación y la progresión del tumor. En el MB también 
se ha demostrado la existencia de una subpoblación de células madre de MB (MBSCs), 
que son las causantes tanto de la recurrencia del tumor como de la resistencia a los 
tratamientos actuales.  
Por otro lado, el GBM es el tumor cerebral más común, agresivo y maligno que se 
da en los adultos, con una supervivencia media de 15 meses tras el diagnóstico. Estudios 
recientes han revelado una gran cantidad de mutaciones genéticas y alteraciones 
moleculares que dirigen el proceso de tumorogénesis de este tumor, describiéndose así 
diferentes subgrupos de la enfermedad. Además, al igual que en el MB, se ha descrito la 
existencia de las células madre de glioma (GSCs), también causantes de la resistencia a 
los tratamientos actuales y de la recurrencia del tumor. Se ha de tener en cuenta que hoy 
en día no existe un tratamiento eficaz para tratar estos tumores y que ningún paciente 
consigue recuperarse de esta enfermedad. Estos datos revelan la importancia de la 
búsqueda de nuevos tratamientos y dianas terapéuticas, dirigidas específicamente a esta 
población de GSCs. 
ERBB4 es un receptor de membrana con actividad tirosina quinasa que se ha 
relacionado con el desarrollo embrionario del sistema nervioso, en concreto con 
procesos de migración neuronal. Además, también está implicado en procesos de 
tumorogénesis, jugando papeles contrapuestos dependiendo del tipo de tumor. En este 
trabajo, observamos que este receptor tiene una función esencial en el desarrollo del 
cerebelo, controlando la población de las células progenitoras y su proceso de migración. 
Además, demostramos que la activación de este receptor en células progenitoras del 
cerebelo, y también en células de MB, hace que éstas sean más resistentes a los estímulos 
apoptóticos. Esto sugiere que su sobreactivación podría proteger a dichas células de 
estímulos apoptóticos, proporcionándoles resistencia frente a la quimioterapia o la 
 
 
radioterapia. Por esta razón, decidimos profundizar en el estudio de la función de ERBB4 
en el desarrollo y progresión del MB. En primer lugar, mediante el análisis de datos 
disponibles en bases de datos, observamos que ERBB4 se encontraba altamente 
expresado en los MBs del subgrupo 4, el subgrupo más común. Además, encontramos 
que la alta expresión de este receptor se asociaba con una menor supervivencia de los 
pacientes, siendo esta diferencia aún más significativa entre los pacientes del subgrupo 
4. Cabe destacar que aún no ha sido descrita la vía de señalización alterada causante de 
la generación del tumor en este subgrupo, por lo que estos resultados demuestran la 
utilidad de este receptor, no solo como marcador con valor pronóstico, sino también 
como posible marcador de dicho subgrupo. Para dilucidar la función de ERBB4 en las 
células de MB, inhibimos la expresión de este receptor mediante partículas lentivirales y 
observamos una reducción en la viabilidad celular junto a una activación de la apoptosis. 
Asimismo, al inyectar estas células en ratones inmunodeprimidos comprobamos que la 
capacidad de auto-renovación, de iniciación y de progresión tumoral se reducen con el 
silenciamiento de ERBB4. Igualmente, observamos un enriquecimiento de la expresión 
de este receptor en las MBSCs y también que su silenciamiento disminuía 
significativamente la capacidad proliferativa y de auto-renovación de estas células. Así 
pues, en este trabajo revelamos que ERBB4 podría ser una nueva diana terapéutica en 
MB y proponemos su inhibición como estrategia a utilizar, en combinación con las 
terapias existentes, con el objetivo de reducir las dosis de quimio- y radioterapia 
utilizadas actualmente, para paliar, en parte, los graves efectos secundarios de las 
terapias actuales. 
Por otra parte, el factor de transcripción SOX1 tiene un papel fundamental en el 
desarrollo embrionario y el mantenimiento de las células madre en la edad adulta. Su 
papel en procesos de oncogénesis se ha descrito ampliamente, revelándose como un 
supresor tumoral en diferentes tipos de tumores. Sin embargo, al contrario de lo 
publicado hasta el momento, en este trabajo se ha demostrado el papel oncogénico de 
SOX1 tanto en GBM como en MB.  
En primer lugar, en lo que respecta al papel de SOX1 en MB, en este trabajo 
describimos, haciendo uso de datos disponibles en bases de datos públicas, que su 
expresión se encuentra elevada en los tumores del subgrupo SHH en comparación con 
los otros subgrupos. En relación a esto, observamos una mayor expresión de este factor 
de transcripción en las líneas celulares de MB pertenecientes al subgrupo SHH. Asimismo, 
comprobamos que un alto nivel de expresión de SOX1 se correlaciona con un peor 
pronóstico de los pacientes, haciéndose más notable esta diferencia en los pacientes del 
subgrupo SHH. Es más, al analizar diferentes genes de la vía de SHH en estos pacientes, 
observamos que SOX1 podría ser mejor biomarcador de dicho subgrupo, además de ser 
mejor marcador  pronóstico que cualquiera de los genes de la vía de SHH. Con el objetivo 
de esclarecer el papel de SOX1 en la progresión y el fenotipo maligno del MB, silenciamos 
su expresión mediante partículas lentivirales en células provenientes de este tipo 
tumoral, observando una disminución de la proliferación y de la viabilidad celular, así 
como de la formación y de la progresión tumoral al inyectar estas células en ratones 
inmunodeprimidos. En esta línea, observamos una expresión aumentada de SOX1 en las 
MBSCs y que su silenciamiento genético disminuye la capacidad de auto-renovación de 
dichas células. Cabe destacar que este fenotipo es más drástico al realizar los 
experimentos en células pertenecientes al subgrupo SHH, reforzando la implicación de 
SOX1 con este subgrupo de MBs. Todo ello evidencia el papel fundamental de este factor 
de transcripción en la progresión del MB, en concreto de los del tipo SHH, y sugiere que 
SOX1 podría constituir una nueva diana terapéutica en MB. Por ello, sería interesante 
buscar nuevas terapias dirigidas a inhibir dicho factor de transcripción. 
En el caso del GBM, en este trabajo demostramos que SOX1 se encuentra sobre-
expresado en GBM en comparación con el tejido sano, tanto en nuestra cohorte como 
en bases de datos accesibles. Además, y al igual que en el MB, observamos que los altos 
niveles de expresión de SOX1 están directamente asociados con un peor pronóstico de 
los pacientes, lo que sugiere su utilidad como marcador pronóstico. En lo que respecta a 
la heterogeneidad intratumoral, observamos que este factor de transcripción está 
altamente enriquecido en las GSCs, tanto en las derivadas de pacientes como en células 
cultivadas en medio selectivo para célula madre. Respecto a su regulación, demostramos 
que en GBM, SOX1 está regulado por otro miembro de su familia, SOX2, un factor de 
transcripción implicado en procesos de embriogénesis y neurogénesis. Así, al realizar 
ensayos de silenciamiento de SOX1 en células de GBM observamos una disminución 
significativa de las propiedades malignas de estas células, como son la capacidad de 
 
 
proliferación, la habilidad de auto-renovación y el potencial de diferenciación. Además, 
al inyectar las células silenciadas en ratones inmunodeprimidos, observamos una 
disminución de la capacidad de iniciación y progresión tumoral de las células de GBM. 
Todos estos resultados indican un papel importante de SOX1 en el desarrollo de este 
tumor y en el mantenimiento de la población de las GSCs, causantes de la resistencia al 
tratamiento y la recurrencia tumoral.  
En conjunto, en este trabajo hemos demostrado un papel hasta ahora no descrito 
de ERBB4 y SOX1 en MB y en GBM, en el que se han revelado como genes esenciales para 
el mantenimiento y la malignización de estos tumores. Además, en este trabajo hemos 
descrito por primera vez la función de SOX1 como un oncogén. Teniendo en cuenta las 
características de estos tumores y la necesidad de encontrar nuevas dianas y estrategias 
terapéuticas, este trabajo propone la inhibición de ERBB4 y SOX1 como una nueva 
estrategia terapéutica prometedora para combatir la resistencia a las terapias actuales e 
intentar reducir las dosis empleadas con el fin de reducir los efectos secundarios 
generados. Además de proponerse como nuevas dianas terapéuticas, en este trabajo 
hemos demostrado que ERBB4 y SOX1 podrían ser utilizados como marcadores 
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Nowadays, cancer is the non-contagious illness that generate more deaths, only 
surpassed by cardiovascular diseases. Moreover, since lifespan is increasing year after 
year, the incidence of different type of cancers is incrementing. The following data 
demonstrate this affirmation: in 2012, 14 million new cases had been diagnosed and 
more than 8 million deaths caused by cancer had been documented (Ferlay et al., 2015). 
In contrast, in 2018, there were more than 18 million  new diagnosed cancer cases, and 
9.5 million deaths caused by this disease (Ferlay et al., 2019). Moreover, both incidence 
and mortality are expected to continue to increase in the coming years. 
Cancer is caused by a malignant transformation of common cells from the body. 
This transformation process is performed through different phases, with genetic and 
epigenetic changes caused by different factors, such as environmental oness. The last 
ones create genetic, epigenetic and transcriptional modifications, and when the 
accumulation of these modifications reach a threshold, the cells undergo the malignant 
transformation. 
In 2000, Hanahan and Weinberg detailed the 6 specific abilities tumor cells 
present and that differences them from the non-malignant cells. These described abilities 
include: proliferative signaling support, growth suppressors evasion,, replicative 
immortality enabling, , invasion and metastasis activation, angiogenesis induction, , cell 
death resistance and cellular energetics’ deregulation (Hanahan and Weinberg, 
2000)[Figure I1]. 11 years later, the same authors redefine these hallmarks including 4 
new abilities that tumor cells present: immune system escape, tumor promoting 
inflammation, genome instability and mutation and deregulation of cellular energetics. 
Altogether, they conclude that different tumors may have common molecular 
mechanisms, and that finding those mechanisms may lead to the validation of new 
therapeutic targets (Hanahan and Weinberg, 2011). 




Figure I1. Representative image of the specific characteristics of tumor cells. Modified from Hanahan and 
Weinberg, 2011.  
 
Although in the last decades there have been great improvements in regards to 
tumors’ treatment, nowadays some tumor types are still incurable and present resistance 
to the applied therapies. It is the reason why tumors relapse and develop metastasis. This 
phenomenon doesn’t occur in all type of tumors, and even within the same type of 
cancers, tumors act in different manners according to their subgroups and their 
development stages. This is due to the heterogeneity of the tumors  
 
1.1. Inter- and intra-tumor heterogeinty 
Although, in general terms, a large number of tumors present some common 
alterations, significant molecular differences are presented between the same type of 
tumors from different patients. This heterogeneity is known as inter-tumor 
Introduction ½ 1. Cancer   
11 
 
heterogeneity. In fact, different tumors present a great variety of different genetic and 
epigenetic alterations, which are responsible of differences in i) the phenotypes, ii) the 
response to treatments and iii) the prognostic of patients. 
There are different reasons why this heterogeneity occurs. First, it is probably due 
to the origin of the tumor, as tumors of the same tissue could be developed from different 
type of cells (Visvader, 2011). The second reason could be tumor development itself, 
which is a random, dynamic and uncontrolled process, thus the emergence of multiple 
molecular alterations may appear in a short time. Third, these alterations are conditioned 
and could be supported by extrinsic factors in the tumor microenvironment (Tlsty and 
Coussens, 2006). Hence, all this heterogeneity causes significant differences between 
patients’ outcome and, thus, complicates the diagnosis and the selection of the 
appropriate treatment for each patient, making clear the necessity of finding new 
biomarkers for patients’ stratification and personal treatment (Nowell, 1976).  
Moreover, heterogeneity can be also found inside the same tumor (denominated 
as intra-tumor heterogeneity). This makes difficult the characterization of each tumor 
and consequently, specific treatment design. Intra tumor heterogeneity also promotes 
treatment resistance, and thus, progression and recurrence of the disease (McGranahan 
and Swanton, 2017). In addition, genome sequencing analysis has demonstrated that in 
the same tumor coexist several tumor cells clones that are genetically different with 
distinct phenotypes (Burrell et al., 2013). In line with this, genetically different subclones 
have been described in the primary tumor and metastasis of the same patient, which 
demonstrates that secondary tumors may arise from a minority of cells within the 
primary. These reduced tumor subclones could stay in dormancy for years, which 
complicates the establishment of effective new therapeutic strategies (Ding et al., 2010; 
Vignot et al., 2013). 
Different theories have emerged to explain this intra-tumor heterogeneity. The 
most known ones are the clonal evolution or stochastic model and the cancer stem cell 
or hierarchic model.  
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1.1.1. Stochastic or clonal evolution model 
The clonal evolution model postulates that all the cells of the tumor have the 
same growth and division potential, since each cell has the capacity to self-renew (giving 
rise to two daughter cells with similar characteristics to the original cell) or differentiate 
(originating two daughter cells oriented to cellular differentiation) (Nakahata et al., 1982). 
In this model, the cells do not follow an organization system, since all the cells contribute 
equally to tumor growth (Dingli et al., 2007), and the cell clones that present the most 
beneficial characteristics regarding their environment will expand and displace the other 
cell clones, at the same time experimenting new modifications that will perpetuate the 
heterogeneity (Greaves and Maley, 2012; Nowell, 1976). In this process of tumor 
evolution, the cellular plasticity constitutes a non-inheritable source of heterogeneity 
that also promotes phenotypic differences between tumor cells (Marusyk and Polyak, 
2010) and has important implications in the therapy resistance and metastatic 
dissemination (Marusyk et al., 2012).  
1.1.2. Cancer Stem Cells or hierarchical model 
The other theory or model is the cancer stem cell or hierarchic model. In almost 
all tumors a subpopulation of tumor cells with stem cell characteristics has been found, 
named as cancer stem cells (CSCs). This discovery leads to the appearance of the model 
or theory of CSCs. This theory suggests a hierarchic organization in which the tumor is 
generated from a CSC, which by symmetric divisions auto-renews its population, 
generating cells with the same stemness capacity than the mother cell, and by 
asymmetric divisions generates more differentiated daughter cells, with properties of 
limited proliferation that constitute the bulk of the tumor (Reya et al., 2001) [Figure I2]. 
This hierarchy, however, is not unidirectional, since it does not go only from a 
dedifferentiated state to a more specialized one. Thanks to Takahashi and Yamanaka, 
evidences that differentiated cells could revert their state and go back to stem cell 
characteristics under determined conditions or in presence of certain factors had 
emerged (Takahashi and Yamanaka, 2006). In cancer, this process of dedifferentiation 
towards CSCs would also be feasible, which would allow and increase the adaptability of 
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different types of cancer to antitumor therapies (Chaffer et al., 2011; Heddleston et al., 
2011).  
The hierarchical model or the CSCs model does not invalidate the concept of 
clonal evolution regarding tumor progression, but complements it by adding the concept 
of a cellular hierarchy in which CSCs are the origin of the tumor and are the source of the 
heterogeneity, due to their indefinite self-renewal capacity and elevated plasticity 
(Peitzsch et al., 2013). For this reason, CSCs can produce cells with different grades of 
differentiation and can also experiment transdifferentiating processes giving rise (in 
cancer context) to highly invasive cells with mesenchymal phenotype (Liu et al., 2013; 
Ricci-Vitiani et al., 2008) or even stromal cells like pericytes or endothelial cells (Cheng et 
al., 2013).  
 
 
Figure I2. Principal models or theories of tumor heterogeneity. (A) In accordance with the clonal evolution 
theory, the somatic alterations that affect the cell of origin give place to multiple clones, with different 
sensitivity to the therapies and capacity to proliferate and survive. These cellular clones of the tumor are 
genetically instable, suffer genetic alterations and the clones with the most aggressive phenotype will be 
the ones will survive to the therapies. All the cells of the tumor have the capacity to maintain and expand 
the tumor. (B) The model or theory of the stem cells defends that only a minoritarian population known as 
cancer stem cells (CSC) has the capacity of self-renewal and limitless proliferation that give rise to clones 
with very different genetic profiles. Created with BioRender.com. 
 
CSCs reside in niches, which are anatomically distinct regions within the tumor 
microenvironment. These niches are responsible for maintaining the principle properties 
of CSCs, such as plasticity preservation, protection from immune system and metastasis 
facilitation (Plaks et al., 2015).   
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Besides cancer cells, tumors also contain other cell types such as the immune 
system cells, the endothelial cells of the surrounding blood vessels and the stroma cells 
(fibroblasts and pericytes). All of them form the denominated tumor microenvironment, 
a complex system in which tumor cells and non-tumor cells communicate and influence 
each other (Junttila and de Sauvage, 2013). Nowadays, it is well described that the 
influence of the tumor microenvironment is very important for the progression of the 
tumor. A clear example of this premise is the induction of angiogenesis that tumor cells 
promote and that allows them to achieve nutrients and oxygen, in addition to 
disseminate through blood vessels (Hanahan and Weinberg, 2011). Other clear 
demonstration of the relevance of this microenvironment is the fact that some recent 
antitumor therapies that are been studied are targeting stroma cells, such as cancer 
associated fibroblasts (CAFs), which, as a result of their oncogenic context, are 
phenotypically and functionally different from the normal fibroblasts, and promote the 
proliferation and the invasive capacity of tumor cells (Calgani et al., 2016).  
Thus, taking all this information together, we can conclude that different 
mechanisms contribute to the intra-tumor heterogeneity, including genetic mutations, 
tumor microenvironment and the existence of tumor cell subpopulations with self-
renewal and multipotency ability, the subpopulation denominated as cancer stem cells 
(CSCs), which have specific characteristics that are following explained. 
1.1.2.1. Stem cells characteristics 
For understanding the biology of CSCs, first it is necessary to define the specific 
properties of an adult stem cell. A normal adult stem cell is defined by two main 
characteristics, shared with CSCs, including pluripotency and self-renewal capacity  (Lobo 
et al., 2007): 
- Pluripotency: a capacity of a non-differentiated stem cell to differentiate into 
distinct cellular linages. Depending on that capacity, there are different levels of 
“potency” (Bozdag et al., 2018): 
- Totipotency: is the ability to generate a hole organism from one cell. 
Embryonic cells within the first couple of cell divisions after fertilization 
are the only cells that are totipotent. 
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- Pluripotency: is the ability to generate cells of different linages of the 
three germinal layers (except for the placenta) from one cell.  
- Multipotency: is the ability of generating different type of cells, but all of 
them belonging to the same linage. In this level are located the adult stem 
cells. 
- Unipotency: is the ability to generate a single cell type. 
- Self-renewal capacity: It is the ability of cells to self-perpetuate using both 
symmetric and asymmetric divisions. Thanks to this process, stem cells retain their 
undifferentiated state (by symmetric division) and maintain or increase their 
number as needed (by asymmetric divisions), thus creating new, more specialized 
cells necessary for the maintenance of the organism (He et al., 2009). 
According to this classification, adult stem cells are multipotent cells, capable of 
generating different cell types, but all of them belonging to the same tissue or cell lineage. 
They are distributed throughout the adult organism, but located in very specific regions 
of the organs called stem cell niches, and are responsible for the formation of new cells 
in order to replace those eliminated by apoptosis, necrosis or senescence processes. They 
are cells, therefore, essential for the maintenance of homeostasis of the organism and 
tissue regeneration (Blanpain and Fuchs, 2014). These cells are predominantly in a 
quiescent state (in G0 phase), non-dividing, but they are able to exit this state in response 
to a stress stimulus, thus, entering in the cell cycle, expanding and differentiating (Arai et 
al., 2004).  
Among other characteristics of the stem cells, it has been observed that these 
cells are smaller (Li et al., 2015a) and present lower metabolism activity, aspects that are 
related with their quiescent state. Moreover, they present high expression levels of 
aldehyde dehydrogenase enzyme (ALDH) (Dolle et al., 2015), express specific surface 
markers and develop a high efflux of substances by ATP Binding Cassette Subfamily G 
Member (ABCG) membrane transporters, reason why they can be distinguished by a low 
accumulation of fluorescent substances like Hoechst 33342 or Rhodamine 123 (Goodell 
et al., 1996; Jones et al., 1996; Leemhuis et al., 1996). 
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The capacity for self-renewal and the potentiality of stem cells are properties that 
are shared with cancer cells, so it does not seem unreasonable to think that some type 
of stem cells, or the transformation of somatic cells into stem cells, could be involved in 
the process of tumorigenesis. 
1.1.2.2. CSCs’ characteristics 
As well as normal stem cells, CSCs also present distinctive characteristics of size, 
markers, metabolism and substances’ efflux (Bleau et al., 2009; Li et al., 2015a). It has 
been demonstrated that CSCs are specifically resistant to conventional treatments. 
Several factors or mechanisms participate in this resistance, such as DNA damage 
reparation mechanisms, alteration of the cell cycle control, drug expulsion processes, 
certain signaling pathways activation and tumor microenvironment influence (Borovski 
et al., 2011). Following, the main specific characteristics involved in treatment resistance 
of the CSCs are described. 
Self-renewal capacity: conferred by symmetric and asymmetric divisions (Al-Hajj 
and Clarke, 2004). This is guided by the activation of several signaling pathways during 
embryonic development and tissues homeostasis. Among them WNT/β-Catenin, Notch 
and Sonic Hedgehog (SHH) pathways can be found (Borah et al., 2015; Karamboulas and 
Ailles, 2013).  
Quiescence: where cells stay in G0 phase of the cell cycle, in which they don’t 
divide. However, they can exit it and reintroduce in the cell cycle in response to 
physiological stimuli. Quiescence makes CSCs resistant to conventional treatments, since 
most of the therapies target proliferating cells and thus, don’t influence the quiescent 
cells (Najafi et al., 2019). Moreover, quiescence could also explain the tumor recurrence 
and metastasis, since CSCs could be maintained quiescent for long periods and wake up 
inducing tumor progression in the same place or disseminating (Recasens and Munoz, 
2019).  
Highly active DNA damage reparation: this process has been related to CSCs’ 
resistance to radio- and chemotherapy, since these cells have the ability to activate 
rapidly the machinery to repair DNA damage and, thus, go ahead in the cell cycle 
(Abdullah and Chow, 2013). 
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Cellular plasticity: is part of normal biology in development and adult homeostasis 
to respond to stimuli and overcome cellular stress. In cancer cells, this ability confers 
chemoresistance (Deheeger et al., 2014). Using this plasticity, CSCs can perform a 
transition between a more proliferative state, with an epithelial nature, and a more 
quiescent and invasive one, with a mesenchymal nature. This process of epithelial-
mesenchymal transition (EMT), or its reverse mesenchymal-epithelial (MET), have been 
studied in the context of cancer biology and their relation with CSCs and metastasis (Mani 
et al., 2008; Morel et al., 2008; Nieto et al., 2016). This plasticity is a challenge for 
therapies, since EMT increases the invasion and dissemination capacity of cells, while 
decreases the proliferation, thus, conferring resistance to chemotherapy (Singh and 
Settleman, 2010). Moreover, reversion to an epithelial phenotype by MET allows cells to 
resume the proliferation that is required for tumor growth in distant organs, thus 
inducing metastasis (Korpal et al., 2011; Ocana et al., 2012; Tsai et al., 2012).  
Moreover, the following characteristics are also present in CSCs: ABC 
transporters’ increment (Di and Zhao, 2015; Fletcher et al., 2010), low ROS levels (Singer 
et al., 2015), high ALDH activity (Deng et al., 2010; Huang et al., 2009; Ma and Allan, 2011; 
Marcato et al., 2011) and apoptosis protection (Capper et al., 2009; Maji et al., 2018; Qi 
et al., 2015; Steinbichler et al., 2018). 
Apart from these characteristics that confer treatment resistance to CSCs, the 
expression of some markers could be used to identify and isolate them. On the one hand, 
they express specific surface markers, such as CD34 (Bonnet and Dick, 1997; Lapidot et 
al., 1994), CD133 (Hemmati et al., 2003; Singh et al., 2004b), CD44 and CD15 (Ajani et al., 
2015; Al-Hajj and Clarke, 2004; Read et al., 2009). However, in many cancers there is no 
consensus regarding the value and specificity of the different surface markers, since their 
expression can vary during tumor growth and may be heterogeneous between patients 
and even in the same tumor (Medema, 2013). 
On the other hand, CSCs also express higher levels of stem cell markers. OCT4, 
SOX2 and NANOG transcription factors and components of WNT/B-Catenin, Notch and 
SHH signaling pathways have been related to the phenotype of these stem cells 
(Hadjimichael et al., 2015; Liu et al., 2013).  
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All these CSCs’ characteristics are highly relevant, since they make them 
responsible for tumor progression and therapy resistance. So, taking this into account, 
CSCs could become the specific targets of new therapies, and once they are eliminated, 
it would be enough to use conventional therapies to eliminate differentiated cells and 
thus reach a stable regression of the tumor (Singh et al., 2004a). Thus, new therapies 
targeting CSCs should be used in combination with classical therapies to reach an optimal 
result. 
1.1.2.3. Origin of CSCs 
Even if the specific characteristics of CSCs are well known, the identity of the 
normal cells that acquire the changes that promote the capacity of tumor initiation and 
progression is still unknown (Perez-Losada and Balmain, 2003; Visvader, 2011). In this 
respect, it is known that this process requires accumulation of alterations and is 
improbable to occur in the half-life of an adult cell. That is why it is thought that CSCs are 
derived from self-renewable normal stem cells or progenitor cells that acquire self-
renewal capacity thanks to mutations [Figure I4], which has been demonstrated in various 
types of cancers (Alcantara Llaguno et al., 2009; Blanpain, 2013).  
 




Figure I3. Cancer stem cells could originate from specific mutations in stem cells, progenitor cells, or even 
differentiated cells, due to dedifferentiation process. Moreover, CSCs can be also originated from 
dedifferentiation of differentiated tumor bulk cell. CSCs has the ability to promote tumor progression and 
to resist to chemo- and radiotherapy. This is the reason why they are responsible of tumor recurrence, 
creating a more heterogeneous tumor after treatment. Created with BioRender.com. 
 
Another hypothesis to explain CSCs origin suggests that cells in the bulk of the 
tumor are able to dedifferentiate and become CSCs [Figure I3]. Differentiation processes 
are strictly regulated by epigenetic mechanisms and are generally unidirectional and 
irreversible processes (Cantone and Fisher, 2013). However, the capacity of 
reprograming completely differentiated somatic adult cells into the denominated 
induced pluripotent stem cells (iPSC) by ectopic introduction of OCT3/4, SOX2, KLF4 and 
c-MYC factors (Takahashi and Yamanaka, 2006) indicates that dedifferentiation is a 
feasible process. In the case of the dedifferentiation of differentiated tumor cells to CSCs, 
this process has been demonstrated to occur at least in gliomas (de la Rocha et al., 2014; 
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Friedmann-Morvinski et al., 2012; Lee et al., 2008; Moon et al., 2011). Moreover, 
embryonic stem cell (ESC) markers have been identified in CSCs, postulating that these 
cells could originate from ESCs as a consequence of mutations in the first developmental 
stages (Schoenhals et al., 2009).  
Altogether, the identification of these crucial cell populations may allow earlier 
detection of malignancies and better prediction of tumor behavior, and ultimately may 
lead to preventive therapies for individuals at high risk of developing cancer (Visvader, 
2011)




2. Central Nervous system tumors 
Central nervous system (CNS) tumors constitute a heterogeneous group of 
neoplasms that, even if they are rare, share a considerable morbidity and mortality rate, 
especially in children and young adults, constituting respectively 30 % and 20 % of cancer 
deaths (McNeill, 2016).  
CNS tumors include brain tumors, which could be very heterogeneous regarding 
they aggressiveness and mortality rate. More than 120 brain tumor types have been 
described by the National Brain Tumors Society, and they are classified by the World 
Health Organization (WHO) regarding their cellular origin and aggressiveness. The most 
common CNS tumors in children are pilocytic astrocytoma, embryonal tumors and 
malignant gliomas, whereas the most common ones in adults are meningiomas, pituitary 
tumors and malignant gliomas (McNeill, 2016). 
 
2.1. Medulloblastoma 
Brain tumors are the most common solid tumors in children, and among them 
medulloblastoma (MB) is the most frequent one, representing around the 20 % of the 
CNS tumors in childhood (Bartlett et al., 2013). These tumors form a heterogeneous 
group of embryonal tumors of the cerebellum. In fact, 4 different MB molecular 
subgroups have been described (WNT, SHH, Group 3 and Group 4), which will be 
addressed later (Taylor et al. 2012). All subtypes of MBs are classified by the WHO as 
grade IV lesions, the highest grade of malignancy according to this classification (Louis et 
al., 2016). MB arises in the cerebellum due to an abnormal development of this brain 
structure, this is the reason why these tumors are named as embryonal tumors. It is 
suspected to originate from the dysregulation of various discrete neuronal stem or 
progenitor cell populations during early development (Northcott et al., 2019). 
This tumor affects around 5 children per 1 million individuals (Ostrom et al., 2018) 
and the most common age of appearance is between 6 and 8 years, although some MBs 
Juncal Aldaregia Fernandez ½ PhD Thesis ½ 2020    
22 
 
can occur during the first years of life or during adulthood (Northcott et al., 2019). The 
diagnosis of this tumor is based on clinical symptoms, imaging by magnetic resonance 
imaging MRI (both of the brain and total spine, in order to assess primary tumor and to 
screen for macroscopic metastases), cerebrospinal fluid (CSF) cytology (in order to detect 
microscopic metastases) and an integrated histopathological and molecular analysis 
(Northcott et al., 2019).  
Standard therapy is based on surgical resection, in order to remove the tumor, 
followed by cytotoxic chemotherapy and, in non-infants (defined as patients younger 
than 3 years of age), radiation. The most widely used chemotherapeutic agents are 
cisplatin, carboplatin, vincristine, cyclophosphamide and lomustine. Owing the 
propensity of MBs to metastasize within the CNS, the most successful radiation therapy 
is the irradiation of the entire cranio-spinal axis, being the most common one the cranio-
spinal irradiation (CSI) with a focal boost on the primary tumor (Northcott et al., 2019). 
However, treatment outcome depends on the age of the patient and the histological and 
molecular features of the tumor. Moreover, current therapy, principally CSI, causes 
severe, widespread side effects, such as permanent neurocognitive disability, 
neuroendocrine dysfunction, psychological deficits and secondary malignancies among 
others (Musial-Bright et al., 2011; Saury and Emanuelson, 2011). Thus, the goal of both 
chemo- and radiotherapy is to deliver the minimum required dose to reach the maximal 
disease control using the least toxic agents, in this way trying to avoid the severe side 
effects. However, 30 % of surviving patients relapse after the initial treatment (Kadota et 
al., 2008; Musial-Bright et al., 2011). 
Furthermore, almost 30 % of patients with MB present disseminated tumor in the 
moment of the diagnostic (Park et al., 1983). MBs normally spread from the CSF, and the 
most common dissemination is leptomeningeal. However, metastases outside the CSF 
can occur, even if are rare. They normally appear in the bone, in the lymph nodes or in 
the lung (Rochkind et al., 1991). 
The therapeutic approach used nowadays has improved the survival rate of 
patients up to a 70-90 %, but it can vary depending on the age of the patient and the type 
of tumor (Coluccia et al., 2016). The overall survival for patients older than 3, with a gross 
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total resection of their tumor and non-metastatic at the moment of the diagnosis is 
between 70 and 85 % (Gajjar et al., 2006; Oyharcabal-Bourden et al., 2005; Packer et al., 
2006). However, for patients younger than 3, with a subtotal resection and/or metastatic 
at the moment of the diagnosis (which are considered as high-risk patients), the overall 
survival is lower that 70 % (Gajjar et al., 2006; Gandola et al., 2009; Jakacki et al., 2012), 
since they cannot receive CSI because of the risk of promoting a second neoplasia (Kumar 
et al., 2017).  
2.1.1. Cerebellum development  
As mentioned before, MB originates due to an aberrant cerebellum development. 
The cerebellum is located inferior to the cerebrum and posterior to the brainstem 
(Iulianella et al., 2019). Even if it has been thought to be important to control only motor 
functions, recent studies have suggested that alterations in this brain structure may be 
related to non-motor diseases, such as autism spectrum (Ito, 2008; Schmahmann, 2004; 
Schmahmann and Caplan, 2006; Strick et al., 2009; Timmann et al., 2010).  
The cerebellum is organized in four dense layers: an internal granule cell layer 
(IGL), the Purkinje cell layer (PL), the molecular layer (ML, comprised by interneurons), 
and the external granule cell layer (EGL) [Figure I4]. The complete development of the 
cerebellum structure occurs postnatally, taking place in the first 2 years of live in humans, 
that correlates with the first 21 days in mouse (Butts et al., 2014a).  
 
 




Figure I4. Cerebellar structure and CGNPs migration. Cerebellum outer layer is composed by 4 main layers, 
i) the external granule layer (EGL), also composed by two layers, the outer (oEGL) and inner (iEGL) layers ii) 
the molecular layer iii) the Purkinje cell layer and iv) the internal granule layer (IGL). At birth, CGNPs are 
located in the EGL, the ones in the oEGL are more proliferative, whereas the ones in the iEGL has stopped 
proliferating to start migrating to the IGL through the Bergman glia fibers (located in the molecular layer) 
and finally differentiated into neurons in the IGL. Orange arrow represents the direction of CGNPs’ 
migration. Created with BioRender.com. 
 
To make a long story short, cerebellum development needs a well-regulated rate 
of proliferation and differentiation of the cerebellar granule neuron progenitor cells 
(CGNPs). In the first stages these cells undergo a rapid expansion in the EGL, and 
afterwards, they exit the cell cycle and migrate internally through Bergmann radial fibers 
to the IGL, where they differentiate into interneurons (Mainwaring and Kenney, 2011; 
Rakic, 1971), resulting in a completely developed cerebellum.   
In more detail, CGNPs derive from the rhombic lip (RL) (Wingate and Hatten, 
1999), whose development is completely dependent on the function of Atoh1/Math1, 
which is induced by bone morphogenetic protein (BMP) signals (Alder et al., 1999). As 
development of the cerebellum progresses, the retreat of fibroblast growth factor (FGF) 
signaling depresses BMP signals, and consequently promotes the formation of the first 
migratory populations derived from Atoh1 expressing RL progenitors, which give rise to 
both cerebellar neurons and extra-cerebellar nuclei in ventral hindbrain (Green et al., 
2014). In the embryonic day 13 in mouse, these precursor cells generate migratory CGNPs 
Introduction ½ 2. Central Nervous System Tumors    
25 
 
(Machold and Fishell, 2005), leave the RL and migrate tangentially forming a proliferative 
layer in the surface of the cerebellum, the EGL. This is a layer in which the CGNPs are in 
a proliferative state. Here they begin a variable number of rounds of amplification by 
symmetric divisions in order to generate a wide number of progenitor cells (Espinosa and 
Luo, 2008). For this stage onwards, the EGL splits into two layers, an upper or outer one 
containing dividing CGNPs (oEGL) and a lower or inner EGL layer containing newly 
generated CGNPs (iEGL) [Figure I4] (Chedotal, 2010). Subsequently, cells located in the 
iEGL stop proliferating and give rise to inwardly, radially migrating post-mitotic CGNPs 
that switch their migration pattern from tangential to radial and translocate along the 
fibers of the Bergmann glia to the forming IGL, where they will differentiate into neurons 
(Komuro and Rakic, 1998; Kuhar et al., 1993). However, how CGNPs switch from a 
proliferative state in the oEGL to differentiation in the iEGL is still poorly understood.  
Even if it is thought that CGNPs only originate from RL, Wojcinski et al. 
demonstrate that there is a second source of these cells that is only mobilized under 
specific conditions. They demonstrated that Nestin-positive glial cells, which 
embryonically originate in the cerebellar ventricular zone, act as a progenitor reservoir in 
the adult cerebellum to supply newborn CGNPs upon cerebellar damage, such as the one 
caused after irradiation (Wojcinski et al., 2017). This finding gives us hope for the 
regenerative properties of the cerebellum after therapies against cancer, such as 
chemotherapy or radiation.  
The whole process of proliferation, migration and differentiation of CGNPs is well-
regulated by several signaling pathways. SHH-Patched (PTCH1) and WNT signaling 
pathways are key regulators of this process. On the one hand, Shh is secreted by the 
Purkinje cells and acts directly on the proliferation of CGNPs in the oEGL, and indirectly 
influences the differentiation of Bergmann or radial glia, which consequently stimulates 
CGNPs differentiation and migration to the IGL (Dahmane and Ruiz i Altaba, 1999). In the 
absence of this protein, PTCH1 (Shh receptor) inhibits Smoothened (SMO)-GLI signaling 
pathway, but in the presence of Shh, PTCH1 releases the negative regulation that is 
exerting to SMO, thus activating the signaling pathway and promoting cell proliferation 
of the CGNPs [Figure I5] (Wechsler-Reya and Scott, 2001). On the other hand, WNT 
signaling pathway presents a similar mechanism of action, since in the absence of WNT, 
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the multiprotein complex formed by Axin, Glycogen synthase kinase 3 beta (GSK3b) and 
Adenomatous polyposis coli (APC) phosphorylates cytoplasmic b-Catenin, promoting its 
degradation. However, in the presence of WNT, its binding to Frizzled receptor inhibits 
the GSK3b, in turn inhibiting the function of the multiprotein complex. That way, b-
Catenin will accumulate and translocate to the nucleus, promoting cell cycle progression 
of the CGNPs [Figure I5] (Haegele et al., 2003). Moreover, NeuroD1 seems to be also 
important for the exit of the CGNPs from the cell cycle in the EGL, since it downregulates 
Atoh1 expression, thereby promoting the migration of these cells to the IGL (Butts et al., 
2014b).  
 
Figure I5. SHH/PTCH1 and WNT signaling pathways. (A) The SHH ligand inactivates the PTCH1 receptor 
allowing SMO to become active. Red cross represents the release of the inhibition exerted by PTCH1 on 
SMO when SHH is present. SMO activates GLI proteins, a family of transcription factors that turn on the 
expression of different target genes, giving rise to cell proliferation and tumorigenesis. (B) The binding of 
WNT to Frizzled receptor activates a cascade of downstream events, resulting in the activation of b-Catenin 
destruction complex. The red cross represents the release of the inhibition exerted by b-Catenin 
destruction complex on b-Catenin. As a consequence, b-Catenin activates and promotes the transcription 
of genes that promote cell proliferation and tumorigenesis. Adapted from (Aldaregia et al., 2018). Created 
with BioRender.com. 
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2.1.2. Origin of medulloblastoma 
When a dysregulation of the cerebellar development process occurs and the 
transition between proliferation and differentiation of the cells from the EGL is disrupted, 
medulloblastoma progression may occur due to the incapacity of the cells to exit from a 
proliferative state and enter in a differentiation process (Grimmer and Weiss, 2006). As a 
consequence of this excessive proliferation, cells will continue proliferating and will form 
the tumor (Marino, 2005). The loss of equilibrium between proliferation and 
differentiation may be caused by an alteration of the signaling pathways mentioned 
above, for example, due to an excessive activation of both WNT or SHH-PTCH1 signaling 
pathways, proof of it are the WNT and SHH medulloblastoma mice models (Dey et al., 
2012; Gibson et al., 2010; Goodrich et al., 1997).  
Kadin et al. first proposed that the origin of medulloblastoma is the CGNPs for the 
EGL of the cerebellum (Kadin et al., 1970). Even if now it is clear that SHH MBs arise from 
this group (Schuller et al., 2008; Yang et al., 2008), recent findings have demonstrated 
that other medulloblastomas originate from different cell localizations. First, some years 
ago, Gibson et al. demonstrated that subgroups of medulloblastoma have different 
developmental origins, discovering that some WNT medulloblastomas were arisen from 
the dorsal brainstem cells (Gibson et al., 2010). Later, Grammel et al. discovered that 
some SHH medulloblastomas were arising from the granule neuron precursors of the 
cochlear nuclei of the brainstem (Grammel et al., 2012). Moreover, two independent 
studies also reported a different cell of origin for Group 3 MBs, as this subgroup MBs are 
characterized by high levels of MYC, they appear to derive from cerebellar stem cells 
(Kawauchi et al., 2012; Pei et al., 2012). Finally, in the case of Group 4 MBs, the most 
prevalent group, their origin is not clear, even if it has been demonstrated that several 
cell types can give rise to this type of tumor (Kumar et al., 2017). Even though it has been 
described that different subgroups of medulloblastoma have distinct cells of origin, it is 
interesting to note that all these cells have in common stem cell properties, and that in 
medulloblastomas the majority of the cells have stem-like appearance (Kumar et al., 
2017). 
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2.1.3. Medulloblastoma classification 
Until some years ago, MBs were classified based on their histopathological features. 
Specifically, they were classified in three main subgroups: the classic, the desmoplastic-
nodular and the large cell anaplastic (LCA) MBs. In 2007, the classification performed by 
the WHO defined four distinct histological subgroups: desmoplastic-nodular, large cell, 
anaplastic and MB with extensive nodularity (MBEN), being the first one the one with the 
best prognosis (Louis et al., 2007). This classification changed completely in 2011, when 
Northcott and colleagues, using a bioinformatic analysis of transcriptional data from two 
cohorts of Toronto and Moscow, discovered the existence of four distinct molecular 
variants of MB, which they denominated as WNT, SHH, Group C and Group D (Northcott 
et al., 2011). These findings, together with additional studies, gave rise to a conference 
in Boston in 2010, where the discussant reached a consensus of the existence of four MB 
subgroups, that they named WNT, SHH, Group 3 and Group 4 (Taylor et al., 2012). Finally, 
in a more recent study, where 763 MB samples were analyzed using the similarity 
network fusion approach, Cavalli and colleagues identified new subtypes within the 
previously described four MB subgroups. The results they obtained suggest 12 subtypes, 
two within WNT MBs, four within SHH MBs, three within Group 3 MBs and three within 
Group 4 MBs (Cavalli et al., 2017). Main features of these subtypes and the relationship 
between the different classifications are summarized in Figure I6. 
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Figure I6. Image summarizing the main clinical and molecular characteristics of the different subtypes 
according to Cavalli classification. Modified from(Taylor et al., 2012).   
 
2.1.3.1. WNT subgroup 
The main characteristic of this subgroup MBs is the aberrant activation of the 
WNT/b-Catenin signaling pathway (Clifford et al., 2006). The patients belonging to this 
subgroup present the best prognosis; however, it is the less common one. In the last 
classification conducted by Cavalli and colleagues, two subtypes within the WNT 
subgroup were identified: WNT a and WNT b. The main molecular difference between 
these two subtypes is that WNT a tumors present monosomy of chromosome 6, a 
chromosome where b-Catenin encoding gene is located, whereas WNT b tumors are 
normally diploid for this chromosome [Figure I6].  Moreover, the other main difference 
of these two subtypes is presented in the age of appearance of the tumor. While WNT a 
tumors are commonly presented in children and adolescents, WNT b tumors appear in 
adolescents and adults [Figure I6] (Cavalli et al., 2017). 
2.1.3.2.  SHH subgroup 
The tumors belonging to this subgroup are characterized by the aberrant 
activation of SHH signaling pathway. Different genes that participate in this pathway 
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Regarding the clinical features, patients diagnosed with SHH MBs present an 
intermediate prognosis, with the exception of infants, who have a good prognosis.  
In the last classification four different subtypes within the SHH subgroup have 
been defined: SHH a, SHH b, SHH c and SHH d [Figure I6] (Cavalli et al., 2017). The SHH 
a subtype mainly affects to children and adolescents and its particular characteristic is 
that it is the only one presenting TP53 mutations (Cavalli et al., 2017). Furthermore, this 
subtype tumors present enrichment of genes involved in DNA repair and cell cycle 
progression. Regarding to SHH b and SHH c, these subtypes affect mainly to infants, but 
the survival rate varies between both of them. As it is shown in Figure I6, SHH b tumors 
are characterized by phosphatase and tensin homolog (PTEN) loss and they present the 
lowest survival rate within all SHH MBs, presenting a 67.3 % of survival at 5 years [Figure 
I6]. Moreover, Cavalli and colleagues identified enrichment in the developmental 
signaling pathways in SHH b and SHH c subtypes. Finally, SHH d subtype MBs present as 
a main characteristic enrichment in mutations of Telomerase reverse transcriptase (TERT) 
promoter (Cavalli et al., 2017) [Figure I6]. 
2.1.3.3. Group 3 subgroup 
Among all MB subgroups, this is the one that shows the worst overall survival, 
presenting a median survival rate of 66.7 ± 76.6 % at 2 years (Jiang et al., 2017). To date, 
a specific altered signaling pathway that is responsible of originating the disease has not 
been identified. In the last classification three different subtypes has been described 
within this subgroup: Group 3a, 3b and 3c. Regarding chromosomic alterations, the first 
one is characterized by the loss of chromosome 8q, chromosome that is encoding v-myc 
avian myelocytomatosis viral oncogene homolog (MYC). However, tumors belonging to 
the Group 3b subtype are characterized by the activation of the GFI1 and GFI1B 
oncogenes, amplification of OTX2, and loss of DEAD-box helicase 31 (DDX31) on 
chromosome 9. Finally, tumors of subtype Group 3c present amplification of MYC as a 
consequence of a gain of the chromosome 8q [Figure I6] (Cavalli et al., 2017).  
In this last classification the signaling pathways implicated in each subtype has 
been also characterized. In this regard, it has been described that Group 3a tumors 
present an enrichment of photoreceptor, muscle contraction and primary cilium-related 
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genes, while Group 3b and 3c present enrichment in protein translation pathways. 
Moreover, Group 3c also presents enrichment in genes related to telomere maintenance 
[Figure I6] (Cavalli et al., 2017). 
2.1.3.4. Group 4 subgroup 
The Group 4 MBs are the most common subgroup, representing the 40 % of all 
MBs. As happens with Group 3 MBs, in these tumors the signaling pathway that is 
originating the disease has not been identified yet. Cavalli and colleagues have identified 
three different subtypes within the Group 4 MBs: Group 4a, 4b and 4c. The main 
chromosomic characteristics of Group 4a tumors are amplification of neuroblastoma-
derived v-myc avian myelocytomatosis viral related oncogene (MYCN) and cyclin 
dependent kinase 6 (CDK6), chromosome 8p loss and chromosome 7q gain.  Regarding 
Group 4b tumors, they present duplication of synuclein alpha interacting protein (SNCAIP) 
and ubiquitous i17q. Finally, Group 4c tumors are characterized by the amplification of 
CDK6, loss of chromosome 8p and gain of chromosome 7q, as present also Group 4a 
MBs, but in this case with the absence of MYCN amplification [Figure I6] (Cavalli et al., 
2017). 
In regard to the data obtained by Cavalli and colleagues about the differentially 
expressed signaling pathways, they identified an activation of migration related pathways 
in Group 4a, and an activation of mitogen activated kinase-like protein (MAPK) and 
fibroblast growth factor receptor 1 (FGFR1) signaling pathways in Group 4b. Finally, in 
Group 4c tumors phosphoinositide-3-kinase/protein kinase B (PI3K-AKT) and ERBB2 
receptor tyrosine kinase 4 (ERBB4)-mediated nuclear signaling pathways activation has 
been identified [Figure I6] (Cavalli et al., 2017). 
2.1.4. MBSCs theory 
In the last decades the increasing interest to understand the molecular 
mechanism underlying the formation, progression and recurrence of MB has revealed an 
important role of CSCs as a principal driver of MB initiation and relapse (Azzarelli et al., 
2018). As it has been previously mentioned, several tumors present intratumor 
heterogeneity in which a small fraction of tumor cells called CSCs present stem properties 
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and the ability to proliferate and maintain the tumor growth (Clarke et al., 2006). Briefly, 
these cells are characterized by having self-renewal (a key property to regulate the 
oncogenic potential) and differentiation capacities (Manoranjan et al., 2012). In the last 
years CSCs has been described in several solid and hematopoietic tumors (Batlle and 
Clevers, 2017), including MB (Singh et al., 2003). These CSCs seem to reside in a 
perivascular niche, in a microenvironment composed of supportive cells, extracellular 
matrix and factors needed to maintain cancer stemness (Calabrese et al., 2007). These 
MB stem cells (MBSCs) present neural stem and progenitor features as they are 
characterized by CD133, SOX2, Musashi1, NES, CD15 and BMI1 expression (Ahmad et al., 
2015; Hemmati et al., 2003; Read et al., 2009). All these genes are also expressed in 
neural stem cell (NSC) (Cai et al., 2002; Kaneko et al., 2000; Lessard and Sauvageau, 2003; 
Park et al., 2003; Uchida et al., 2000; Zappone et al., 2000).  
In addition to present high expression of some NSC markers, several signaling 
pathways and most relevantly CD133, WNT, SHH, Notch, PI3K/AKT and MYC, have been 
demonstrated to control CSCs cell cycle and growth. (Cordeiro et al., 2014; Guessous et 
al., 2008).  
CD133. Physiologically, CD133 induces WNT/b-Catenin signaling (Mak et al., 2012) 
and has also been described as an important regulator of PI3K-AKT signaling pathway in 
CSCs (Wei et al., 2013). The first MBSCs that had been isolated from human tissue were 
CD133 and Nestin positive and had shown an improved proliferation, self-renewal and 
differentiation capacity, since they had the ability to grow forming clusters similar to 
neurospheres in vitro and were able to produce tumors in vivo (expressing NSC markers 
such as Nestin) when they were transplanted into immunocompromised mice forebrains 
(Singh et al., 2003). Moreover, when injecting a small number of CD133 + cells (100 cells) 
into immunocompromised mice, MB formation was confirmed, whereas when injecting 
the same amount of CD133– cells, tumor formation failed (Singh et al., 2004b). These 
results demonstrate the importance of this gene expression in tumor initiation process. 
Moreover, CD133 has also been related to apoptosis as well as radiotherapy and 
chemotherapy resistance (Blazek et al., 2007; Dean et al., 2005). 
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SHH pathway. This signaling pathway is activated by hedgehog ligands that bind 
to the PTCH1 receptor and maintain tumor growth and cell stemness (Enguita-German 
et al., 2010). 
Notch pathway. This signaling pathway is required for controlling growth and 
proliferation of neural stem/progenitor cells, but also embryonal tumors (Pierfelice et al., 
2008), including MB (Fan and Eberhart, 2008)(Wang et al., 2017b). 
PI3K-AKT pathway. This signaling pathway has been demonstrated to play an 
important role in embryonic stem cells renewal (Wang et al., 2017a) and in the 
maintenance of CSCs in solid tumors (Dubrovska et al., 2009; Zhou et al., 2007), including 
MB (Frasson et al., 2015; Hambardzumyan et al., 2008). 
MYC family. MYC proteins have been associated with MBs and more specifically 
with Group 3 MBs, while MYCN amplification is a characteristic of SHH and Group 4 MBs 
[Figure I6]. It has been also demonstrated that spheres cultured from MYCN-driven mice 
MBs express neuronal markers (such as Neurogenin-1 (Ngn1), Synaptophysin (Syp), 
Oligodendrocyte transcription factor 2 (Olig2) and Sox9) and when transplanted 
orthotopically into mice, spheres were able to form massive tumors which mimic human 
MBs (Swartling et al., 2012).  
As mentioned when explaining CSC theory, these cells are able to survive chemo- 
and radiotherapy, thus contributing to failure of treatment with multiple drugs, since they 
have characteristics such as quiescence, activation of pro-survival/anti-apoptosis 
pathways and interaction with microenvironmental factors (Cojoc et al., 2015). MBSCs 
are also considered to be the responsible of common events as therapy resistance and 
tumor recurrence (Kumar et al., 2017). Moreover, CSCs has been also associated with 
tumor dissemination through EMT (Mani et al., 2008). Therefore, it is necessary to find 
new therapeutic strategies targeting this type of cells in order to avoid both therapy 
resistance and tumor recurrence.  
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2.2. Glioblastoma  
In adults, the most common brain tumors are gliomas. These tumors are derived 
from glial cells, which are cells of a neuroepithelial origin that are responsible for the 
protection and maintenance of neurons. Gliomas constitute the 50 % of all brain and CNS 
tumors. Both from clinical and histological aspects, they are very heterogeneous tumors, 
and range from low proliferative to very aggressive tumors. Histologically, gliomas are 
classified into 4 groups: Grade I, II, III and IV, named as pilocytic astrocytoma, diffuse 
astrocytoma, anaplastic astrocytoma and glioblastoma, respectively (Louis et al., 2007).  
Based on this classification, glioblastoma (GBM) is considered the type of glioma 
with the highest grade according to the WHO, which has classified the tumors according 
to histopathological and clinical criteria (Louis et al., 2007). Even if it is one of the 4 groups 
of gliomas, its incidence is very high, representing 12-15 % of the brain tumors and almost 
50 % of all gliomas (Ostrom et al., 2014). It is considered the most aggressive and malign 
brain tumor, with an incidence ranging between 1-5 cases per 100,000 individuals per 
year (Ostrom et al., 2014). It could appear in any age, but it is preferably presented in 
adults, demonstrating its peak of apparition between 45 and 65 years of age. GBM is one 
of the tumors with worst prognosis, presenting an average survival of the patients that 
does not exceed 15 months of live and an associated 5-year survival of less than 5 % 
(Stupp et al., 2009).  
As mentioned before, almost all of these tumors arise from glia cells. The GBM 
are mainly localized in both brain hemispheres, although they can originate in any 
location of the brain or the spinal cord. Their main characteristic is that they are very 
infiltrating tumors inside the brain, even if it is not common that they spread to other 
parts of the body, since this tumor cells do not intravasate into blood vessels (Bernstein 
and Woodard, 1995). GBM are characterized by a widely cellular spread within the brain, 
a diffuse distribution pattern in the tissue, an uncontrolled proliferation, a high genetic 
instability, apoptosis resistance, and by the presence of highly vascularized areas and 
necrotic areas (Furnari et al., 2007). Moreover, these tumors show a remarkable inter 
and intra-tumor heterogeneity in different levels: cellular, genetic, molecular, clinic and 
Introduction ½ 2. Central Nervous System Tumors    
35 
 
histopathological among others. Moreover, they present cellular hierarchy in regard to 
their morphology.  
GBM are diagnosed through both neuroimaging techniques, such as MRI or 
computer tomography (CT) scans, and tissue samples, even if they have some limitations 
(Shankar et al., 2017). Regarding the symptomatology, patients commonly suffer of 
headache, convulsions, loss of memory and behavioral changes, which are due to the 
increased intracranial pressure because of the presence of the tumor. Furthermore, they 
can also present other indicatives of the disease, such as loss of movement, instability, 
language disfunction and other cognitive disorders (Yamanaka, 2008).  
These tumors are treated by a combination of therapies that could vary 
depending if the GBM is of new diagnostic or recurrent. For new diagnosed GBM, first, 
the resection of the tumor is needed, which frequently is not complete, due to its 
infiltration and localization near vital structures of the brain. Surgery allows reducing the 
symptoms. Next, the patients are given a combination of focal radiation therapy and 
chemotherapy for 6 weeks (Stupp et al., 2005). More precisely, the chemotherapeutic 
agent that is used to treat GBM tumors is the alkylating agent Temozolomide (TMZ), due 
to its ability to cross the blood brain barrier (Brada et al., 1999; Ostermann et al., 2004). 
After this first approach, treatment continues with adjuvant TMZ for 5 days a month 
during 6 months (Stupp et al., 2002; Stupp et al., 2009). However, despite the fact that 
this treatment has been partially effective (2.5 months survival improvement) (Stupp et 
al., 2005), tumors usually reappear in the same location and with a more aggressive 
character. 
For recurrent tumors, the most used treatment is chemotherapy. The election of 
the chemotherapeutic agents depends on different factors, but if any has been used 
before, normally a different chemotherapeutic agent is administered in order to avoid 
the resistance mechanisms (Hou et al., 2006). The main treatment for recurrent tumors 
is the bevacizumab (Agha et al., 2010; Norden et al., 2008), a monoclonal anti-angiogenic 
antibody against the vascular endothelial growth factor.  
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2.2.1. GBM classification 
From the clinical point of view, GBM are classified in two main groups: primaries 
and secondaries. The primaries, or also known as de novo, appear without clinical 
evidences of any malignant precursor and are the most common ones, representing the 
90 %. The secondaries, however, come from the low-grade gliomas’ progression (Ohgaki 
and Kleihues, 2013).  
GBM can be also classified following their specific molecular alterations. Recent 
high-throughput molecular analyses have allowed conducting this molecular 
classification and have highlighted the high inter-tumor heterogeneity that GBM present 
(Brennan et al., 2013; Cancer Genome Atlas Research, 2008). Based on the results 
published by The Cancer Genome Atlas (TCGA), the different alterations present in GBM 
have been determined, which affect mainly to three signaling pathways: tyrosine-kinase 
(TK) type receptors’ signaling pathways, p53 signaling pathway and retinoblastoma (Rb) 
signaling pathway (Brennan et al., 2013; Cancer Genome Atlas Research, 2008). 
Moreover, according to the TCGA, GBM have been classified into 4 molecular subtypes 
considering genetic and epigenetic alterations, treatment response and prognosis 
(Verhaak et al., 2010). According to this classification, the following GBM subtypes have 
been described: proneural, neural, classic and mesenchymal [Figure I7].  
2.2.1.1. Proneural subtype 
Generally, tumors belonging to this subtype are secondary GBM and are 
associated with an earlier appearance. They are also characterized for presenting a longer 
overall survival.  
Regarding the alterations presented in these tumors, the most frequent ones that 
are characteristic of this subtype of GBM are the overexpression platelet derived growth 
factor receptor alpha (PDGFRA) and the mutations in isocitrate dehydrogenase 1 (IDH1) 
and phosphoinositide-3-kinase/phosphatidylinositol 3-kinase regulatory subunit alpha 
(PI3K/PIK3R1). However, they can also present several alterations, such as, loss or 
mutations in TP53, cyclin dependent kinase inhibitor 2A (CDKN2A) and PTEN, expression 
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of proneural and oligodendrocyte markers and activation of hypoxia inducible factor 
(HIF), PI3K and PDGFR signaling pathways.  
2.2.1.2. Neural subtype 
Their genetic expression pattern is the most similar to a healthy brain and the 
tumor cells appear to have a differentiated phenotype, since they express neuron, 
astrocyte and oligodendrocyte markers, such as neurofilament light (NEFL), gamma-
aminobutyric acid type A receptor subunit alpha 1 (GABRA1), synaptotagmin 1 (SYT1) and 
solute carrier family 12 member 5 (SLC12A5). They also present amplification or 
overexpression of epidermal growth factor receptor (EGFR).  
2.2.1.3. Classic subtype 
This subtype GBMs are mainly characterized by mutations, amplifications and/or 
overexpression of EGFR. Moreover, they also present loss or mutation of PTEN, loss of 
CDKN2A, overexpression of NES and activation of the Notch and SHH signaling pathways.   
2.2.1.4. Mesenchymal subtype 
This subtype tumors are the ones that present the most necrotic areas, together 
with the expression of genes associated to inflammation, such as tumor necrosis factor 
(TNF) and nuclear factor kappa (NF-kB). Moreover, other alterations like loss or mutation 
of neurofibromin 1 (NF1), TP53 and PTEN and overexpression of MET, chitinase 3 like 1 
(CHI3L1), CD44 and MER proto-oncogene tyrosine kinase (MERTK) can be found in this 
subtype tumors. 
 
Figure I7. GBM classification according to their main alterations. Modified from (Van Meir et al., 2010). 
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The importance of this classification resides in the prediction of the patients’ 
survival and their response to the conventional treatments, enabling the application of 
personalized therapy. For example, in the classic and mesenchymal subtypes the therapy 
is going to be more effective than in the other subtypes (Phillips et al., 2006). However, 
recently, and based on the information obtained due to the advanced molecular analyses 
conducted in the last years, this classification has been updated by the WHO in order to 
improve and make more precise the diagnosis of these tumors. This new classification 
[Table I1] considers both molecular and histological characteristics, reason why it 
integrates the genotypic and phenotypic parameters and classifies the GBM within 
astrocytic and oligodendrocytic tumors based on the isocitrate dehydrogenase IDH 
mutation. The following ones are the groups described by this classification: IDH wild 
type, IDH mutant and a third group as GBM NOS, in which the diagnosis is reserved due 
to the impossibility of fully evaluating IDH (Louis et al., 2016). Nowadays, IDH mutational 
status, rather than subtypes described by Verhaak and colleagues, is the routine 
diagnostic molecular marker to differentiate among GBM tumors (Louis et al., 2007). 
Table I1. GBM subtypes based on WHO current classification that integrates both molecular and 
histological parameters. Adapted from (Louis et al., 2016). 
Characteristics GBM IDH-wild type GBM IDH-mutant 
Precursor lesion Primary GBM, de novo 
Secondary GBM, generated 
from diffuse or anaplastic 
astrocytoma 
Frequency 90 % 10 % 
Average age at diagnosis 62 years 44 years 
Average survival after treatment 15 months 31 months 
Major mutations (proportion) 
TERT promotor (72 %) 
TP53 (27 %) 
EGFR amplification (35 %) 
PTEN (24 %) 
TERT promotor (26 %) 
TP53 (81 %) 
ATRX (71 %) 
 
2.2.2. Glioma stem cells theory 
As mentioned before, GBM present a high intratumor heterogeneity, and as in 
other tumors, the presence of CSCs has been demonstrated, denominated as glioma 
stem cells (GSCs) (Galli et al., 2004; Singh et al., 2004b). Different origins of these cells 
have been postulated. On the one hand, it is thought that GSCs could originate from NSCs 
that are present in the adult brain, which present self-renewal and multipotency 
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capacities to generate the main differentiated cells of the CNS, including neurons, 
astrocytes and oligodendrocytes [Figure I8] (Temple, 2001). The theory that GSCs 
originate from NSCs has been demonstrated by overexpressing oncogenes or deleting 
tumor suppressor genes in embryonic and early postnatal cells, resulting in the formation 
of astrocytoma in mice (Bachoo et al., 2002; Holland et al., 2000; Huse and Holland, 2009; 
Kwon et al., 2008; Zhu et al., 2005). When analyzing these tumors, the results obtained 
demonstrated that they were localized in the subventricular zone (SVZ), one of the NSCs 
niche in the brain, (Doetsch et al., 1997) suggesting that these tumors were generated 
from NSCs.  
On the other hand, it has been also proposed that GSCs could be originated by 
the dedifferentiation of normal adult cells of the brain, like astrocytes, neurons or 
oligodendrocytes (de la Rocha et al., 2014) [Figure I8]. Several works have induced the 
dedifferentiation of astrocytes to GSCs in p53 deficient mice by Ras (Lee et al., 2008) or 
Nanog (Moon et al., 2011) oncogenes transduction. That this type of dedifferentiation 
can occur has also been demonstrated in vivo in gliomas, by the inactivation of NF1 and 
p53 in astrocytes and neurons (Friedmann-Morvinski et al., 2012). Moreover, by the 
genetic mapping of the state of the cellular chromatin, Suvà and colleagues identified 4 
transcription factors (POU class 3 homeobox 2 (POU3F2), SOX2, Spalt like transcription 
factor 2 (SALL2) and OLIG2) in proneural GBM that were able to reprogram the 
differentiated tumor cells into GSCs [Figure I8] (Suva et al., 2014). These transcription 
factors were essential to maintain the tumorigenic capacity of these cells, suggesting that 
mediators of stem cell programs could confer the oncogenic capacities to the CSCs.  





Figure I8. Origin of glioma stem cells (GSCs). GSCs could originate from neural stem or progenitor cells due 
to mutations that provoke activation of oncogenes and inhibition of tumor suppressors. Neural stem cells 
originate neural progenitors, and then they differentiate into the three main neural cells: neurons, 
astrocytes and oligodendrocytes. These three differentiated cells could also originate GSCs, due to a 
process of dedifferentiation. Finally, GSCs are the responsible of tumor origination. Created with 
BioRender.com. 
 
GSCs have been characterized by mRNA analysis, differentiating proneural and 
mesenchymal GSCs, while they demonstrate a correspondence with proneural and 
mesenchymal high-grade gliomas respectively (Bhat et al., 2013; Mao et al., 2013). 
Proneural GSCs share some similarities with the fetal NSCs, while mesenchymal GSCs are 
more similar to adult NSCs (Morokoff et al., 2015; Ricci-Vitiani et al., 2008). These GSCs 
are more aggressive, invasive, angiogenic and resistant to therapies than the proneural 
ones. Moreover, the mesenchymal GSCs are mostly derived from primary or de novo 
GBM, whereas the proneurals have been also found in secondary GBM and in grade III 
gliomas (Mao et al., 2013; Nakano, 2015). 
GSCs present specific characteristics, among them they are characterized for 
expressing several markers, such as CD133, CD15, A2B5 and NES. Moreover, they present 
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some characteristics that are usual in CSCs: ALDH1 activity, low proteasome activity and 
high ABC transporters activity (Ludwig and Kornblum, 2017). 
As the theory of the CSCs decamines, GSCs have also been related to therapy 
resistance. Even if treatments for GBM have improved in the last decades, these continue 
to be ineffective. Although they initially regress, these tumors end up recurring. Since 
conventional therapies directly target proliferative cells, the undifferentiated and 
quiescent GSCs population can lead to therapy resistance and frequently to tumor 
recurrence (Ajani et al., 2015; Carrasco-Garcia et al., 2013). Moreover, GSCs resistance 
to both chemotherapeutic agents and radiotherapy has been demonstrated (Bao et al., 
2006; Liu et al., 2006). Indeed, several studies have related the DNA-damage repair 
activity to radiotherapy resistance (Bao et al., 2006; Cheng et al., 2011; King et al., 2017; 
Short et al., 2011). Regarding chemotherapy resistance, it has been described that the 
expression of the O-6-methylguanine-DNA methyltransferase enzyme (MGMT), 
responsible for eliminating the methyl groups of the DNA, contributes to GSCs resistance 
to TMZ (Qiu et al., 2014). 
Other studies have demonstrated that GSCs present a higher activation of ATM, 
checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2) kinases, and a slowdown of 
the cell cycle in front of radiation, thus, these cells achieve an efficient DNA repair which 
results in radio-resistance (Bao et al., 2006; Ropolo et al., 2009). It has been also 
demonstrated that GSCs express higher levels of anti-apoptotic proteins such as BCL-2 
than differentiated tumor cells (Tagscherer et al., 2008). Moreover, the high expression 
of ABCG2 cellular transporters, which play an important role in the drug efflux, have been 
related to the chemo-resistance of GSCs (An and Ongkeko, 2009).   
Furthermore, it has been shown that GSCs overexpress genes that take part in 
NOTCH and SHH signaling pathways, and that their pharmacological inhibition using 
gamma-secretase and cyclopamine, respectively, induce the sensitization of GSCs to 
treatments such as TMZ (Ulasov et al., 2011).  
Related to therapy resistance, cellular plasticity has been described to be a 
phenomenon that occurs in several tumors, where differentiated cells could turn into 
CSCs in response to the pressure induced by chemo or radiotherapy. First of all, it has 
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been observed that GSCs from cell lines and patient derived cells augmented in response 
to TMZ treatment both in vitro and in vivo, and that these cells came from the conversion 
of differentiated tumor cells into GSCs, which expressed stem cell markers such as CD133, 
SOX2, OCT4 and NES and presented a high tumorigenic phenotype (Auffinger et al., 
2014). This conversion from differentiated tumor cells to GSCs in response to treatment 
has also been demonstrated when the application of TMZ induces an overexpression of 
HIF and cells become into GSCs, showing elevated expression levels of CD133 (Lee et al., 
2016). In concordance with this affirmation, it has been also demonstrated the 
dedifferentiation of differentiated tumor cells toward GSCs in response to stress such as 
hypoxia (Safa et al., 2015). Furthermore, it has been determined that other treatments 
such as irradiation could regulate the dedifferentiation of GBM cells in a process that 
implicates to survivin dependent signaling pathway (Dahan et al., 2014).  
In summary, the evidences presented indicate that GSCs are the responsible not 
only for tumor formation and maintenance (de la Rocha et al., 2014), but also for 
treatment resistance (Carrasco-Garcia et al., 2013; Liu et al., 2006).  
Overall, GBM’s high heterogeneity hinders diagnosis and adequate therapeutic 
intervention, emphasizing the need to identify biomarkers that allow a correct patient 
stratification and tailored therapy. Moreover, the dismal prognosis of GBM highlights the 
need to unravel the critical molecular mechanisms underlaying its progression to develop 
novel personalized therapeutic strategies. 




3. ERBB receptors 
ERBB receptors are a family of tyrosine kinase growth factor receptors. This family 
is composed by 4 members: the epidermal growth factor receptor ERBB1, best known as 
EGFR, ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). As they are membrane receptors, 
they need the binding of a ligand for their activation. These receptors can be stimulated 
by at least six different epidermal growth factor (EGF) family hormones, including EGF, 
transforming growth factor-α (TGF-α), amphiregulin (AR), betacellulin (BTC), heparin-
binding EGF-like growth factor (HBEGF), epiregulin and epigen, and the family of 
neuregulins (NRG), composed by 4 members (NRG1-4) [Figure I9] (Buonanno and 
Fischbach, 2001; Segers et al., 2020; Wang, 2017). When the ligand binds to the receptor, 
the dimerization of the receptor happens, allowing both its homodimerization and 
heterodimerization with another member of the family. Homodimers are normally 
formed by ERBB1 and ERBB4, while heterodimers can be formed by ERBB1 and ERBB2, 
ERBB3 and ERBB2, and ERBB4 and ERBB2 (Vermeulen et al., 2016). The binding of the 
ligand to the receptors activates different intracellular signaling pathways, such as 
RAS/MAP-Kinase and PI3K/AKT ones, thus regulating cell migration, proliferation, survival 
and differentiation (Roskoski, 2014). 
3.1. ERBB4 
ERBB4 is a 180 kDa protein and, as the other members of the family, is composed 
by an extracellular ligand binding domain, a single transmembrane domain and an 
intracellular domain (ICD). In the case of ERBB4, the ICD contains a functional tyrosine 
kinase enzyme and a C-terminal tale (Veikkolainen et al., 2011). This receptor has several 
ligands that can activate it: betacellulin (Riese et al., 1996a), epiregulin (Komurasaki et al., 
1997), HBEGF (Elenius et al., 1997b) and the four members of NRG (NRG1-4) (Carraway 
et al., 1997; Harari et al., 1999; Plowman et al., 1993; Zhang et al., 1997). The only ligands 
specific for ERBB4 are NRG3 and NRG4 [Figure I9]. 
ERBB4 is the unique receptor of the family that undergoes alternative splicing, 
having at least two different isoforms expressed at the same time. As a result of 
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alternative splicing, different ERBB4 variants are produced, differing in the extracellular 
juxtamembrane (JM) (Elenius et al., 1997a) and intracellular cytoplasmic (CYT) (Elenius et 
al., 1999) domains. Regarding the variants differing in the JM domain, there is one lacking 
the exon 16 (JM-b) (Elenius et al., 1997a) and other one having this exon (JM-a) 
(Gilbertson et al., 2001). In this exon is encoded the tumor necrosis factor-α converting 
enzyme (TACE), one of the enzymes responsible for the regulated intramembrane 
proteolysis (Rio et al., 2000). Thus, the isoforms having the exon 16 could be cleaved and, 
consequently, the activated intracellular kinase domain could be moved into the cell and 
translocate to the nucleus acting as a transcription factor [Figure I9] (Ni et al., 2001; Ni et 
al., 2003; Vidal et al., 2005). Additionally, there are two different isoforms that differ in 
the CYT domain: CYT-1 and CYT-2, the first one contains the exon 26 while the second 
one does not [Figure I9] (Elenius et al., 1999). This exon encodes the domain that can 
mediate specific coupling to SH2 and WW domain-containing proteins, such as PI3K 
(Elenius et al., 1999) and ubiquitin ligases (Sundvall et al., 2008). The isoforms produced 
by the alternative splicing have different functions and activate different cell processes, 
such as cell growth, survival and apoptosis (Veikkolainen et al., 2011).  
 
ERBB4 is linked to two main intracellular signaling pathways: RAS-MAPK-ERK and 
PI3K-AKT pathways [Figure I9]. When ERBB4 is activated, and thus phosphorylated, it 
induces a sustained activation of RAS-MAPK-ERK pathway, and in consequence activates 
cell-cycle cessation and differentiation (Iwakura and Nawa, 2013; Ortega et al., 2012). In 
the case of CYT-1 isoform, the phosphorylation of the Y1056 residue results in p85 
adaptor recruitment to activate PI3K-AKT signaling, inducing both chemotaxis and 
survival (Kainulainen et al., 2000), whereas CYT2 isoform has not the ability to activate 
the PI3K-AKT signaling pathway. Regarding JM-a isoform, it is susceptible to proteolytic 
cleavage by TACE and c-secretase, which releases an 80 kDa ERBB4 fragment, named 
ERBB4-ICD. This fragment will be released to the cytoplasm and will interact with the 
transcription factor signal transducer and activator of transcription 5A (STAT5A), 
subsequently translocating to the nucleus to act as a transcription factor (Sundvall et al., 
2010; Vidal et al., 2005).  





Figure I9. ERBB receptors, their ligands and ERBB4 receptor isoforms and their intracellular signaling. On 
the top left the 4 ERBB receptors are presented, showing the different ligands that can activate them. On 
the top right the alternative splicing of ERBB4 is represented, showing the different isoforms generated as 
a consequence of the splicing in the JM and the CYT domain. JM-a isoform can be cleaved and release to 
the cytoplasm, whereas JM-b isoform cannot. Moreover, CYT-1 isoform has the ability to activate PI3K, 
whereas CYT-2 has not. Different combinations of these variations create the 4 isoforms. Down is 
represented the intracellular signaling of ERBB4. ERBB4 acts mainly through ERK and Akt signaling 
pathways, regulating cell differentiation, survival and protein synthesis. ERBB4 JM-a isoform can be cleaved 
by TACE and c-secretase resulting in an 80 kDa ERBB4-ICD protein, which will dimerize with STAT5A, 
resulting in a nuclear translocation. Adapted from(Segers et al., 2020; Wang, 2017)and(Veikkolainen et al., 
2011.)Created with BioRender.com. 
 
3.1.1. Implication of ERBB4 in CNS and cerebellum development 
ERBB4 receptor plays an important role in the development, ranging from 
embryogenesis to the development of heart, skin and CNS (Segers et al., 2020; Tidcombe 
et al., 2003), where is specifically involved in the development of the neural crest, 
myelination and neuronal migration and pathfinding (Birchmeier, 2009). Moreover, 
activated ERBB4 promotes neurogenesis and neuronal differentiation and survival 
(Gerecke et al., 2004; Ghashghaei et al., 2006; Min et al., 2011). In fact, knockout mice 
for the ERBB4 present defects in the hindbrain (Golding et al., 2000).  
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Regarding cerebellum, ERBB4 is expressed in CGNPs and it is involved in cerebellar 
development (Pinkas-Kramarski et al., 1997; Vullhorst et al., 2009), since ERBB4 knockout 
mice present deficits in neuronal migration, cerebellar heterotopias, alterations in 
number and distribution of specific subpopulations of interneurons, deficiencies in the 
astrocytic and oligodendrocytic lineages, and additional insults in major brain structures 
(Perez-Garcia, 2015). In fact, it has been demonstrated that this receptor is expressed in 
the cerebellum during its development, and that ERBB4-mediated signaling in the glia is 
essential for the movement of the CGNPs along the radial glial fibers (Elenius et al., 1997a; 
Rio et al., 1997).  
Furthermore, ERBB4 ligands are also implicated in CNS and cerebellum 
development (Opanashuk et al., 1999). For instance, HBEGF has been identified to be 
expressed during cerebellum development both in the EGL and the IGL, and also in 
cerebellar Purkinje cells (Hayase et al., 1998; Kornblum et al., 1999; Nakagawa et al., 
1998; Piao et al., 2005). Moreover, NRG have been demonstrated to be expressed in the 
cerebellum and participate in neuronal migration (Gilbertson et al., 1998; Rio et al., 
1997). 
3.1.2. ERBB4 in cancer and MB 
Overexpression and activation of ERBB receptors is often associated with poor 
patient outcomes and advanced tumor states and has been proven as therapeutically 
relevant in breast, colon and other tumors (Muraoka-Cook et al., 2008). Whereas the 
other members of the ERBB family have been related to aggressive forms of different 
tumor types (Hyman et al., 2018; Hynes and Lane, 2005; Vermeulen et al., 2016), ERBB4 
presents growth inhibiting properties and it is downregulated in aggressive tumors, 
suchas breast cancer (Muraoka-Cook et al., 2008; Naresh et al., 2006). However, several 
controversies about the anti- or pro-oncogenic role of ERBB4 appeared in the last years. 
This could be explained by the multiple ligands that can activate ERBB4, its numerous 
intracellular phosphorylation sites, the presence of alternative splice variants, the 
different intracellular signaling pathways affected, and the different downstream 
responses in different cell types and disease stages (Segers et al., 2020).  
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In more detail, the vast majority of published studies indicate that ERBB4 inhibits 
or has no effect on tumor growth, including breast and hepatocellular cancer (Liu et al., 
2017; Muraoka-Cook et al., 2006). However, a limited number of studies indicate that 
ERBB4 may have a growth stimulating effect on certain tumor cells such as in colorectal 
cancer, gastric cancer, and melanoma (Prickett et al., 2009; Williams et al., 2015; Xu et 
al., 2018). These data demonstrate the dual role of this receptor, which is dependent of 
the tumor type. 
Few evidences have been published regarding the role of ERBB4 in MB. On the 
one hand, it has been shown that human tumor samples express higher levels of this 
receptor than the healthy cerebellum (Zeng et al., 2009). Moreover, its high expression 
has been correlated with a poor prognosis (Bal et al., 2006; Gilbertson et al., 1997). It has 
been also demonstrated that ERBB4 isoforms are differentially expressed in MB (Ferretti 
et al., 2006; Gilbertson et al., 2001). Finally, a recent study has reported an oncogenic 
role for aberrant ERBB4-mediated signaling in MB, specifically in Group 4 patients, 
through a proteomic and phosphoproteomic approach (Forget et al., 2018). 
 




4. SOX transcription factors 
SOX (sex-determining region Y (SRY)-box) genes are a family of transcription 
factors distinguished by a conserved high-mobility group (HMG) DNA-binding domain. 
This family is composed by 20 members, and these are classified into 8 groups based on 
their HMG sequence identity (Schepers et al., 2002). Members within the same group 
may have overlapping expression patterns, share biochemical properties, and perform 
synergistic or distinct functions. These transcription factors play an essential role in 
embryonic and postnatal development, and in stem cells regulation and maintenance, 
especially in the CNS (Pevny and Placzek, 2005; Sarkar and Hochedlinger, 2013).  
The activity and expression of SOX proteins are regulated at multiple levels. They 
interact with other factors to carry out their function. However, the expression of SOX 
factors is regulated by themselves or by other members of the family. Their expression is 
also regulated both post-transcriptionally, by miRNAs, and post-translationally, by 
modifications such as phosphorylation, sumoylation, acetylation, methylation and 
glycosylation, which affect their activity, stability and intracellular localization (Kamachi 
and Kondoh, 2013). Their activity is also modulated by the protein-protein interactions. 
Specifically, SOX proteins recognize and bind to components of SHH and WNT signaling 
pathways, in which SOX-GLI and SOX-b-Catenin interactions, respectively, are involved in 
their activity (Bernard and Harley, 2010; Malki et al., 2010; Oosterveen et al., 2012).  
As mentioned before, SOX factors play an important role in the embryonic 
development during early gastrulation, sex determination, hematopoiesis and 
neurogenesis. During these processes, their function is necessary for the maintenance of 
stem cell pool and also to determine the commitment of certain cell populations in the 
development of differentiated tissues, highlighting the prominent role they play in the 
CNS. Historically these genes have been defined as crucial genes in embryonic 
development. However, recent studies demonstrate that their activity is not exclusive of 
development period, but also they are expressed in adult stem cells (Sarkar and 
Hochedlinger, 2013).  
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There is a growing body of evidence indicating that mutations and dysfunction of 
SOX factors are involved in several human diseases, including a variety of cancers. In fact, 
it has been thought that the genes implicated in tumor progression could coincide with 
genes involved in embryonic development, due to their activity in stem cells and the 
nexus between these cells and cancer. In general, some of the members of these 
transcription factors family act as oncogenes while the others are tumor suppressors 
(Castillo and Sanchez-Cespedes, 2012). Example of this affirmation are SOX2, SOX4, SOX9 
and SOX10, which display an oncogenic role in different type of tumors, such as lung and 
esophageal squamous cell carcinomas, small cell lung cancer, colorectal cancer, 
melanoma and GBM (Bass et al., 2009; Carrasco-Garcia et al., 2016; Castillo et al., 2012; 
Garros-Regulez et al., 2016a; Matheu et al., 2012; Sun et al., 2014). Besides, SOX17 and 
SOX11 present a tumor suppressor function in some other tumor types, such as 
gastrointestinal tumors, mantle cell lymphomas, colorectal cancers, cholangiocarcinomas 
and GBM (de la Rocha et al., 2014; Du et al., 2009; Kuo et al., 2015; Li et al., 2015b; 
Merino-Azpitarte et al., 2017). 
4.1. SOX1 
SOX1 (SRY-box 1) is a member of SOXB1 subgroup, a group also comprising SOX2 
(SRY-box 2) and SOX3 (SRY-box 3). It has been less studied than the other members of the 
group, but its important role in promoting neurogenesis has been already described (Kan 
et al., 2004).  
4.1.1. Implication of SOX1 in CNS and cerebellum development 
During development, SOX1B subgroup members show different expression 
patterns. While SOX1 is the earliest known neuroectoderm linage specific marker, which 
is activated during gastrulation, SOX2 and SOX3 show broader expression patterns that 
turn on at the pre-implantation and epiblast stages, respectively (Wood and Episkopou, 
1999)(Venere et al., 2012). SOX1 is expressed in telencephalic neurons of the ventral 
striatum throughout development (Ekonomou et al., 2005). In the absence of SOX1, the 
early differentiation of these neurons appears normal but migration to the proper 
location is affected (Ekonomou et al., 2005). Thus, SOX1 has been described as a key 
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regulator of neural progenitor identity and neural cell fate determination, since it 
maintains the ability of proliferation and differentiation of these progenitors from early 
development to adult stages (Aubert et al., 2003; Kan et al., 2004; Pevny et al., 1998; 
Venere et al., 2012). Moreover, SOXB1 group members are co-expressed in the neural 
stem cell population and show certain degree of functional redundancy (Bylund et al., 
2003; Pevny and Placzek, 2005).  
Interestingly, SOX1 plays an important role in cerebellar development, since it has 
been described to be expressed in the Bergmann glia progenitors (Alcock and Sottile, 
2009; Sottile et al., 2006). These cells are essential for the development and correct 
arborization of Purkinje cells, and consequently the correct migration of CGNPs to the 
IGL, thus forming a correct cerebellum. 
4.1.2. SOX1 in cancer 
To date, SOX1 has been described to play a tumor suppressor role in several tumor 
types, such as ovarian, hepatocellular, cervical and nasopharyngeal cancers, where its 
expression appears silenced by hypermethylation of its promoter (Guan et al., 2014; Lin 
et al., 2013; Su et al., 2009; Tsao et al., 2012), since hypermethylation of tumor 
suppressors contributes to carcinogenesis (Dawson and Kouzarides, 2012). 
Mechanistically, SOX1 acts as a tumor suppressor via the interaction with β -Catenin, 
consequently inhibiting WNT signaling pathway (Guan et al., 2014; Tsao et al., 2012).  
Regarding the activity of SOXB1 members in GBM, the oncogenic function and 
clinical relevance of SOX2 are well established, most of its roles being linked to GSC 
regulation (Alonso et al., 2011; Gangemi et al., 2009; Garros-Regulez et al., 2016a; Garros-
Regulez et al., 2016b; Ikushima et al., 2009). In contrast, little is known about the 
expression or function of SOX1 and SOX3. Interestingly, microarray analysis in SOX2 
knock-down glioma cells identified SOX1 and SOX18 among the almost 500 genes whose 
expression was altered (Fang et al., 2011). 
Moreover, even if SOX2 and SOX3 have been described as oncogenes in 
medulloblastoma (Ahlfeld et al., 2013; Gong et al., 2018; Treisman et al., 2019; Vanner et 










































ERBB4 and SOX1 play an important role in brain development and stem cell 
maintenance, as well as in the pathogenesis of different tumors. However, little is known 
about a potential role of SOX1 in brain tumors such as GBM and, specially, MB, despite 
its key role in neural embryonic development and its previous implication as a tumor 
suppressor in different tumor types has been described. In addition, ERBB4 role in MB is 
not clear, mainly due to the complex molecular network associated with its signaling 
function. Taking this background into account, we intended to go deeper into the 
function of both proteins in adult and pediatric brain tumors.  
We hypothesize that ERBB4 and SOX1 play a role in MB pathogenesis, and that 
SOX1 is also involved in the carcinogenesis of GBM, through regulating CSCs proliferation 
and self-renewal capacity, which might be contributing to the therapy resistance showed 













































1. To characterize the role of ERBB4 in MB. 
a. To characterize the function of ERBB4 in cerebellum development and 
in CGNPs. 
b. To analyze the expression of ERBB4 among MB subgroups and to 
determine its impact in patients’ survival. 
c. To study the effect of ERBB4 silencing in medulloblastoma cell lines 
and MBSCs, both in vitro and in vivo. 
2. To characterize the role of SOX1 in MB. 
a. To analyze the expression of SOX1 among MB subgroups and to 
evaluate its impact in patients’ survival.  
b. To investigate the effect of SOX1 silencing in medulloblastoma cell 
lines and MBSCs, both in vitro and in vivo. 
c. To study the main downstream signaling pathways following SOX1 
silencing. 
3. To characterize the role of SOX1 in GBM. 
a. To analyze the expression of SOX1 in healthy and GBM samples and to 
assess its impact in patients’ survival.   
b. To investigate the effect of SOX1 silencing in GBM cell lines and GSCs, 
both in vitro and in vivo. 





































1. Human samples 
Human glioblastoma samples were provided by the Basque Biobank for Research-
OEHUN (http://www.biobancovasco.org). Data for GBM and LGG was downloaded using 
TCGAAssembler. The methods and experimental protocols in human samples were 
carried out in accordance with relevant guidelines, and all study participants signed the 
informed consent form. The study was approved by the ethic committee of Biodonostia 
Health Research Institute and Hospital University Donostia. 
2. Experimental animals 
With the aim of addressing the hypothesis of this work we took advantage of 
several mice strains. The mice strains used, as well as their main description and 
reference, are summarized in Table M1.  
Mice were housed in specific pathogen-free barrier areas of the Biodonostia 
Health Research Institute and the Neuroscience Research Center at University of North 
Carolina (UNC), and handled in compliance with the animal research regulations specified 
in the European Union Directive [2010/63/EU] and in the University of North Carolina 
Institutional Animal Care and Use Committee approved protocol 16-099. All studies were 
approved by Biodonostia Health Research Institute and the University of North Carolina 
Animal Care and Use Committees. Mice were maintained in ventilated racks under 
controlled humidity, light cycle, temperature, food and water, always fulfilling the criteria 
established for this species. Whenever possible, all experiments were performed in age-
matched or littermates’ mice and blind to the experimental condition of the animals. For 
brain and cerebellum extraction and for tumor extraction, animals were anesthetized 
with isoflurane (880393HO, Abbvie), and sacrificed using CO2 or decapitation, depending 









Table M1. Different mice used in the studies. 
Name Complete strain name Description Reference 
Foxn1nu/ Foxn1nu 
Hsd: Athymic Nude-
Foxn1 nu (Athymic 
Nude) 
Athymic and hairless 









Absence of functional T 














results in the 
constitutive expression 
of the Smo/EYFP fusion 








(Mao et al., 2006) 
Conditional ErbB4 KO ErbB4loxP/loxP 
ErbB4 gene flanked by 
two loxP sites to make 
a conditional ErbB4 KO 
when crossing them 
with Cre mice 
(Golub et al., 2004) 
hGFAP-Cre hGFAP-Cre Mice expressing Cre in 
hGFAP positive cells 
(Zhuo et al., 2001) 
 
To examine the expression of ErbB4 in cerebellum development, as no genetic 
alterations were required, C57BL/6J mice strain was used. To determine the role of ErbB4 
in cerebellar development and apoptotic resistance of CGNPs, conditional ErbB4 KO mice 
were crossed with hGFAP-Cre mice to generate ErbB4 KO or Het mice, lacking one copy 
or both of ErbB4 gene respectively, and specifically in CGNPs. In order to clarify the 
implication of ErbB4 in MBs’ apoptotic resistance, conditional ErbB4 KO mice, SmoM2 
mice and hGFAP-Cre mice were crossed, generating hGFAP-Cre; SmoM2;ErbB4KO or 
hGFAP-Cre;SmoM2; ErbB4Het mice, thus generating mice with constitutive expression of 
Smo signaling pathway and lacking both copies or one copy of ErbB4 gene respectively. 
Because of Smo signaling constitutive activation, these mice formed MB spontaneously 
within 15-17 days after birth. To assess tumor formation and progression and to avoid 
the rejection of the injection of human cells, immunocompromised nude mice, Foxn1nu/ 
Foxn1nu mice, were used.  




3. Cell culture 
The summary of the media used in the culture of cells isolated from mice and of 
human cell lines is represented in Table M4.  
3.1. CGNPs isolation and culture 
Plates were first treated with Poly-L-Lysine (P4832, Sigma-Aldrich) for one hour at 
room temperature (RT). Depending on the plate size, different volumes of Poly-L-Lysine 
was used in order to cover the entire plate surface. Once the incubation was completed, 
the plate was washed 3 times with Hank's Balanced Salt Solution (HBSS, 14175-095, 
Gibco) supplemented with 6 g/L glucose (G8769, Sigma-Aldrich). Once the plate was 
washed, half of the appropriate final volume of Dulbecco's Modified Eagle Medium 
Nutrient Mixture F-12 (DMEM/F12, 11330-032, Gibco) supplemented with 100 U/mL 
penicillin and 100 µg/mL streptomycin (15140122, Gibco), 1 % N2 (17502048, Gibco), 1 
% KCl 2.5 M and 10 % foetal bovine serum (FBS, 10270106, Gibco) was added. Then, the 
plate was incubated at 37 ºC until the cells were seeded. Needed treatments, were added 
to this media if required. The concentrations used for each treatment are specified in 
Table M2. 
For CGNP isolation, pups were sacrificed at postnatal day 5-7 (p5-7) by 
decapitation; their cerebella were removed and collected in tubes containing HBSS + 
Glucose. Then, HBSS + Glucose was removed and cerebella were dissociated with 0.25 % 
Trypsin (T4424, Sigma) by incubating them at 37 ºC for 5 minutes. In order to inactivate 
the trypsin, 1 mL CGNP-DMEM/F12 + 10 % FBS media was added to the tubes containing 
the tissue. Next, to remove the media and trypsin, the tubes were placed in ice until the 
precipitation of the dissociated tissue. Afterwards, mechanic dissociation was performed 
using 1 mL of HBSS + Glucose. Then, the tubes were placed in ice for 2 minutes and the 
supernatant was collected in a new tube. The precipitated tissue was mechanically 
dissociated again repeating the same steps and mixing the first supernatant with the one 
collected in the second dissociation. Finally, the collected supernatants were 
centrifugated at 100 g for 1.5 minutes 3 times, supernatant was discarded and the cell 
pellets were resuspended in the appropriate volume of CGNP-DMEM/F12 + 10 % FBS to 
seed them in the previously treated plate. Cells were incubated for 4 hours at 37 ºC, at 




95 % of humidity, 21 % of O2 and 5 % of CO2. Then, the media was removed and CGNP-
DMEM/F12 media without FBS was added. Then the cells were incubated in the same 
conditions for 24 h. Lastly, these cells were collected for further experiments. 
Table M2. Concentrations, timing and references of the treatments used with CGNPs. 
Drug Concentration Time of treatment Reference Manufacturer 
Shh 0.5 µg/mL 24 hours 464-SH R&D technologies 
hNRG1 100 nM 24 hours 4730-10 BioVision 
HBEGF 100 nM 24 hours 4267-10 BioVision 
Dexamethasone 200 µM 24 hours D4902 Sigma 
 
3.2. Human cell lines 
All characteristics and detailed information of the cell lines used in this work are 
summarized in Table M3.  
D283Med, D341Med, CHLA-01-Med and CHLA-01R-Med MB cell lines and 
U87MG (U87), U373MG (U373), U251MG (U251), A172 and T98G glioma cell lines were 
obtained from the American Type Culture Collection (ATCC). DAOY and UW228 MB cell 
lines were kindly provided by Dr. Castresana (Universidad de Navarra, Unav,(de la Rosa 
et al., 2016). All glioma cell lines and DAOY, UW228 and D283Med MB cell lines were 
grown as adherent cell lines in Dulbecco's Modified Eagle Medium (DMEM, 41966029, 
Gibco) supplemented with 10 % FBS (10270106, Gibco), 2 mM L-Glutamine (25030024, 
Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (15140122, Gibco). In order to 
detach the adherent cells, 0.05 % trypsin/EDTA (25300054, Gibco) was used, incubating 
the cells in contact with it for 5 minutes at 37 ºC.   
D341Med cell line was grown as spheres in suspension in DMEM supplemented 
with 20 % FBS; 2 mM L-Glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. 
CHLA-01-Med and CHLA-01R-Med cell lines were grown in suspension in 
DMEM/F12 (11514436, Thermo Fisher) supplemented with 2 mM L-Glutamine, 100 U/mL 
penicillin, 100 µg/mL streptomycin, 2 % B27 (11514436, Thermo Fisher), 20 ng/mL 
epidermal growth factor (EGF, A15E9644, Sigma-Aldrich) and 20 ng/mL basic fibroblast 
growth factor (bFGF, PHG0023, Gibco).  




Glioma Neural Stem 166 (GNS166) and 179 (GNS179) cell lines were kindly 
provided by Dr. Steve Pollar (MRC Centre for Regenerative Medicine and Edinburgh 
Cancer Research Centre, University of Edinburgh) and GB1 and GB2 cell lines were 
established in Dr. Ander Matheu’s laboratory. These cell lines were grown in DMEM/F12 
media, supplemented with 1.34 % D-(+)-Glucose solution 45 % (G8769, Sigma-Aldrich), 2 
mM L-Glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin, 1 % of N2 and 2 % 
B27, 20 ng/mL EGF and 20 ng/mL bFGF. To get an adherent culture, 1:500 of laminin at 1 
mg/ml (L2020, Sigma-Aldrich) was added to the media. In order to detach these cells, 
accutase (A1110501, Gibco) was used, incubating the cells in contact with this enzyme 
for 5 minutes at 37 ºC. 
Table M3. Cell lines characteristics used in this work.  
Cell line Type of cell Origin Culture media Come from 
A172 Glioma GBM 
DMEM + 10 % 
FBS ATCC (CRL-1620) 
T98G Glioma GBM DMEM + 10 % 
FBS 
ATCC (CRL-1690) 
U87MG Glioma Astrocytoma DMEM + 10 % 
FBS 
ATCC (HTB-14) 
U251MG Glioma GBM DMEM + 10 % FBS ATCC 
U373MG Glioma GBM 
DMEM + % 10 
FBS ATCC (HTB-17) 
GNS166 Glioma Stem Cell GBM DMEM/F12 Dr. Steve Pollard (MRC) 
GNS179 Glioma Stem Cell GBM DMEM/F12 Dr. Steve Pollard (MRC) 
GB1 Glioma Stem Cell GBM DMEM/F12 
Donostia University 
Hospital’s patient 
GB2 Glioma Stem Cell GBM DMEM/F12 Donostia University 
Hospital’s patient 
DAOY MB MB DMEM + 10 % 
FBS 
Dr. Castresana (Unav) 
UW228 MB MB DMEM + 10 % FBS Dr. Castresana (Unav) 
D283 Med MB MB 
DMEM + 10 % 
FBS ATCC (HTB-185) 
D341 Med MB MB 
DMEM + 20 % 
FBS ATCC (HTB-187) 
CHLA-01-Med MB MB CHLA-DMEM/F12 ATCC (CRL-3021) 
CHLA-01R-
Med 
MB metastasis Pleural fluid CHLA-DMEM/F12 ATCC (CRL-3034) 









All cell lines were maintained in standard conditions at 37 ºC of temperature, 95 
% of humidity, 21 % of O2 and under 5 % of CO2 pressure. All the cell culture procedures 
have been performed under laminar flow hoods of class II security (Class II Biohazard 
Safety Cabinets, ESCO). Cell lines were regularly tested for mycoplasma. 
Table M4. Cell specific culture medias and components used in this work.  
Name of the media Media’s components Cells 
DMEM + 10 % FBS 
DMEM + 10 % FBS + 2 mM L-Glutamine + 100 
U/mL penicillin + 100 µg/mL streptomycin 
DAOY, UW228, D283Med, 
U87MG, U373M, U251MG, 
A172, T98G and HEK 293T 
DMEM + 20 % FBS DMEM + 20 % FBS + 2 mM L-Glutamine + 100 
U/mL penicillin + 100 µg/mL streptomycin D341Med 
DMEM/F12 
DMEM/F12 + 1.34 % D-(+)-Glucose solution 
45 % + 2 mM L-Glutamine + 100 U/mL 
penicillin + 100 µg/mL streptomycin + 1 % N2 
+ 2 % B27 + 20 ng/mL EGF + 20 ng/mL bFGF 
GNS166, GNS179, GB1, GB2 
and CSC oncospheres 
CHLA-DMEM/F12 
DMEM/F12 + 2 mM L-Glutamine + 100 U/mL 
penicillin + 100 µg/mL streptomycin + 2 % 




DMEM/F12 + 100 U/mL penicillin + 100 
µg/mL streptomycin + 1 % N2 + 1 % KCl 2.5 
M (+ 10 % FBS) 
CGNPs 
 
3.3. Genetic expression modulation by lentiviral infections 
For lentiviral infections, the following constructs have been used: lentiviruses 
harboring plKO.1 puro (8453, Addgene) and pWXL-GFP (122257, Addgene) plasmids as 
control (empty vector), plKO.1 shSOX1.1 and plKO.1 shSOX1.5 plasmids (NM_005986, 
Sigma) for SOX1 expression silencing, SOX1 plasmid (kindly provided by Dr. Stevanovic) 
for SOX1 overexpression, and plKO.1 shERBB4.2 and plKO.1 shERBB4.3 (NM_005235, 
Sigma) for ERBB4 silencing. Prior to lentivirus generation, all the plasmids were verified 
by enzymatic digestions, selecting the appropriate enzyme for each plasmid. Restriction 
enzymes were selected by uploading the full plasmid sequence to the Restriction Mapper 
version 3 (Blaiklock, 2018). The buffers and amount of enzyme were used according 
manufacturer instructions. In all cases, the mix without enzyme was used as control. 
Products migration was performed in an agarose (8067, Condalab) gel for band size 
determination and analysis.   
 




Lentiviruses were generated at the Viral Vector Unit of Centro Nacional de 
Investigaciones Cardiovasculares. 200 x 103 cells were lentivirally transduced with 
different plasmids. Lentiviral infections were performed with a multicity of infection 
(MOI) of 10 for 6 h in each cell line appropriate media and in the presence of 2 µg/mL 
polybrene (H9268, Sigma-Aldrich). The efficiency of these transductions was certified 
after 48 h by observing cells fluorescence under the microscope Nikon Eclipse TS-100 or 
by adding 2 µg/mL puromycin (P8833, Sigma-Aldrich) to the media. 
4. Functional assays 
4.1. Proliferation assay 
For each experiment cells were seeded in duplicate in 6-well-plates (P6, 3506, 
CorningTM). 2.5 x 104 cells were cultured in each well in a final 2 mL volume media. At 
days 1, 3 and 5 post-culture, cells were detached with trypsin and then counted. The 
obtained results were represented graphically, showing the total number of cells per 
experimental condition in each time point.    
4.2. Measurement of CSCs proliferation and self-renewal 
capacity  
For CSC proliferation assays, cells were plated at a density of 10 x 103 cell per well 
in triplicate (for each experimental condition) in tissuenon-treated P6. CSCs were 
incubated in DMEM/F12 media containing EGF and bFGF. 300 µL of fresh media were 
added twice a week. To analyze the proliferation capacity, the number of formed primary 
(1ry) oncospheres was counted after 10 days culture. After, oncospheres were 
mechanically and enzymatically disaggregated with accutase for 5 min to obtain a single-
cell suspension and re-plated at the same cell concentration to form secondary (2ry) 
oncospheres. To analyze the self-renewal capacity of this oncospheres, 2ry oncospheres 
were counted after 10 days culture. 
4.3. Colony formation assay 
For each experimental condition, 0.5 x 103 cells were seeded in 3 wells of a P6, in 
a final volume of 2 mL. Cells were maintained in culture for 10 days and the media was 




renewed 5 days later. At day 10 after seeding, cells were fixed adding 0.5 mL of 37 % 
paraformaldehyde (PFA) to the culture media and incubated for 30 min at RT in agitation. 
Next, media and PFA were removed and fixed cells were stained with 5 % Giemsa 
(1.09204.0500, Merck) diluted in phosphate buffer saline (PBS, 14190094, Gibco). Cells 
were again incubated for 30 minutes at RT in agitation. Finally, Giemsa was removed and 
the wells were washed with distilled H2O (dH2O) and dried. Lastly, formed colonies were 
counted. 
4.4. Cell viability assay (MTT) 
In order to measure cell viability, a colorimetric assay based on the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) metabolism was 
performed. This assay assesses the purple crystals of the formazan formed due to the 
reduction of the MTT reactive by the succinate-dehydrogenase enzyme present in the 
viable cells.     
4.4.1. DAOY and UW288 cell lines 
To perform this assay, 0.5 x 103 cells per well were cultured in sextuplicate (per 
experimental condition) in 96-well plates (P96, 3585, CorningTM). After 96 hours of 
incubation at 37 ºC and 5 % CO2, 0.44 mg/mL MTT (M2128, Sigma-Aldrich) was added. 
After additional 3.5 h incubation at 37 ºC and 5 % CO2, the well contents were removed 
and formed purple crystals in each well were resuspended in 150 µL DMSO (D2650, 
Sigma-Aldrich). In order to dissolve the crystals, the plate was incubated shaking at RT for 
15 min. Afterwards, the absorbance of each well was measured at 570 nm by the 
Multiskan Ascent plate reader (Thermo Scientific).  
4.4.2. D283Med cell line 
In this case, 5 x 103 cells per well were seeded in P96 plates , in sextuplicate (per 
experimental condition). After 96 hours of incubation at 37 ºC and 5 % CO2, 0.44 mg/mL 
MTT (M2128, Sigma-Aldrich) was added. After additional 3.5 h incubation at 37 ºC and 5 
% CO2, 100 µL of isopropanol (I9516, Sigma-Aldrich) + 0.01 M HCl were added per well to 
the culture media, and the purple crystals were resuspended by pipetting. Finally, the 




absorbance of each well was measured at 570 nm by the Multiskan Ascent microplate 
reader (Thermo Scientific).   
4.5. Migration assay 
To assess the cells migration capacity, 24 h before seeding the cells for the 
experiment, the FBS was removed, changing the media to FBS free media. To perform 
these experiments, 6.5 mm Transwell® chambers with 8.0 µm pore polycarbonate 
membrane inserts (3422, Corning) were used. Before culturing the cells in these inserts, 
they were humidified with FBS free media by incubating them for 1 h at 37 ºC and 5 % 
CO2. Then, 2.5 x 104 cells were seeded in each insert, using FBS free media, in a total 
volume of 100 µL. As a chemoattractant to make the cells migrate through the 
polycarbonate membrane media with FBS was used. So, inserts were placed in 24-well 
plates (P24, 3527, CorningTM) and 500 µL of media with FBS was added in the wells below 
the inserts, allowing the contact of the FBS-media with the polycarbonate membrane. 
Cells were then incubated for 48 h at 37 ºC and 5 % CO2.  
Next, cells that had migrated were stained adding 300 µL of Cell Stain (90144, 
Millipore) solution in a P24 well, placing the inserts in the wells and incubating them 
stirring for 20 min at RT. Afterwards, the inserts were washed with dH2O and dried. 
Pictures of the migrated cells were taken with an Eclipse TS100 (Nikon) microscope. For 
the migrated cells quantification, polycarbonate membranes were unstained with 200 µL 
of Straction Buffer (90145, Millipore), adding this volume to P24 plate well, placing the 
insert above and incubating them stirring for 15 min at RT. Finally, 100 µL of the Straction 
Buffer were placed into a P96 plate well. The absorbance was measured at 570 nm in a 
MultiSkan Ascent microplate reader (Thermo Scientific) using the Ascent software.  
4.6. Cytometry assays 
4.6.1. Cell cycle assay 
Cell cycle assay was used in order to quantify the percentage of the cultured cells 
in each phase of the cell cycle. To perform this assay 1 x 106 cells were collected and 
washed once with 1X PBS. Next, they were resuspended in 300 µL of 1X PBS and fixed by 
adding 700 µL 100 % cold ethanol (EtOH, ET00111000, Scharlab) drop wise and by 




vortexing. The cells were fixed in a final 70 % ethanol and incubated overnight (O/N) at -
20 ºC. After, these cells were washed once, centrifuging them at 1,000 g for 5 min at RT. 
The supernatant was discarded and 1 mL of 1X PBS was added, centrifugation and 
discarding the supernatant again. Once the cells were washed, they were stained in 500 
µL of 1X PBS, 0.1 mg/mL RNAse A (R4875, Sigma-Aldrich) and 0.05 µM TO-PRO-3 (T3605, 
LifeTech) and incubated for 30 min at 37 ºC in the dark. Cells were then passed through 
a SH800S (Sony) cytometer and TO-PRO-3 emission was measured using the 638 nm laser 
and 665/30 nm filter. Cell droplets were discarded and results were analyzed using the 
SH800S Cell Sorter Software.  
4.6.2. Cell apoptosis assay 
Cell apoptosis rate in the cultures was measured by Annexin-V staining. For this, 
Annexin-V Alexa Fluor 488 conjugate apoptosis detection kit (A13201, Thermo Fisher) 
was used according to the manufacturer instructions. First, around 1 x 106 cells were 
harvested and washed once in PBS. Next, the cells’ pellet was resuspended in 1 mL of 
annexin-binding buffer (10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl2, at pH 7.4). 
Afterwards, 5 µL of annexin V conjugate was added per 100 µL of cell suspension, as well 
the SYTOX Blue, in order to stain dead cells. Then, the samples were incubated at RT for 
15 min. After this incubation period, 400 µL of annexin-binding buffer were added, mixed 
gently and the samples were kept on ice until they were analyzed using a flow cytometer 
(Beckman Coulter Gallios). The number of positive cells was calculated as the percentage 
of the total cells relative to the control experimental condition. 
4.7. In vivo carcinogenesis assay 
4.7.1. Subcutaneous tumors’ formation  
Subcutaneous tumor formation assays were performed using 6-8-week-old 
immunocompromised Foxn1nu/ Foxn1nu mice. These mice present a mutation in the 
FOXn1 gene, an essential gene in thymus and hair development, so they lack mature T 
cells (www.jax.org/strain/007850). Subcutaneous injection was performed in these mice, 
in the inferior two flanks. To complete these injections, cells were collected and washed 
with 1X PBS and finally were resuspended in the appropriate concentration in 1X PBS. 




100 µL of this suspension were injected in each mice flank, then mice were examined 
twice a week, by measuring the size of the formed tumors with a caliber until the end 
point of the experiment (until tumors reached the maximum length of 15 mm). Tumors’ 
volumes were calculated using V = (L x W2 x 0.5) equation, where L represents the biggest 
length of the tumor and W represents the shortest one. 
Tumor initiation assay was also performed. On this aim, different cell dilutions 
were injected. The minimum number of cells necessary to initiate tumor formation can 
be calculated thanks to the Extreme Limiting Dilution Analysis (ELDA, Hu and Smyth, 
2009) platform.  
4.7.2. Stereotaxic brain tumors´ formation 
Brain tumors’ formation experiments were performed in 6-8-week-old NOD-SCID 
mice, which lack B and T lymphocytes. Considering that this strain allows both xenogeneic 
and halogenic transplantation, it is considered the perfect mouse model to perform 
human cell transferences and xenografts (www.jax.org/strain/001303). Injected cells, 
being stem like GNS166 cells, were detached from the plate using accutase enzyme, then 
washed with 1X PBS and resuspended at the desired volume and concentration in 1X PBS.  
For each mouse, 1 x 105 cells were injected in a total volume of 1 µL using a 75 
RN, 26s ga 2’’ Hamilton syringe (HA-87930, Teknokroma Analítica) in the right hemisphere 
of the striatum. The injections were performed using a stereotaxic instrument (Kopf 
Instruments) [Figure M1] in the following coordinates: Bregma: + 1.00 mm posterior, -2 
mm left side and -2.5 mm depth, following the protocol established by Dr. Pollard (Pollard 
et al., 2009), with a constant flow of 0.05 µL/min. 
After the injection, mice were examined twice a week in order to detect tumor 
appearance signals as weight and functional abilities’ loss or other deterioration signals. 
When there was any evidence of tumor appearance, mouse brains were extracted and 
fixed in 4 % PFA (158127-5006, Sigma-Aldrich) in order to investigate them later.  
During the experiments, to detect weight loss, mice were weighed once a week 
using a weighing scale (TE15025, Sartorious). 






Figure M1. Representative images of stereotaxic instrument (Kopf Instruments) and injection.  
 
5. Protein analyses 
5.1. Protein extraction and quantification 
Cells were collected, centrifuged for 5 min at 8000 g (microcentrifuge 22R, 
Beckman Coulter) to discard the supernatant and washed once with 1X PBS.  The 
obtained cell pellets were lysate in 80-120 µL (depending the number of cells in each 
pellet) of Lysis Buffer (1 % NP-40, 150 mM NaCl, 5 mM EDTA, 50 mM NaF, 30 mM 
Na4P2O7, 1 mM Na3VO4, 50 mM Tris-HCl pH 7.4), supplemented with a different protease 
inhibitors mix (P8340, Sigma-Aldrich), phosphatase inhibitors cocktail (P5726, Sigma-
Aldrich) and the inhibitor of serine proteases phenylmethanesulfonyl fluoride (PMSF, 
P7626, Sigma-Aldrich) at a 100 µM concentration. Pellets were maintained for 30 min on 
ice and then centrifuged at 13000 g for 10 min at 4 °C for cellular debris precipitation. 
Supernatants containing whole cell protein extracts were collected and protein 
concentration was quantified by the colorimetric bicinchoninic acid assay (BCA) using a 
calibration line performed with 5 different concentrations of bovine serum albumin (BSA) 




(Pierce BCA assay kit 23227, Thermo Scientific). Absorbance was measured at 570 nm in 
a MultiSkan Ascent spectrophotometer (Thermo Scientific).                
5.2. Western Blot 
For Western Blot (WB) technic, one fifth of loading buffer 5X (312.5 mM Tris pH 
6.8, 10 % sodium dodecyl sulfate (SDS), 50 % glycerol, 0.5 % bromophenol blue and 5 % 
β-mercaptoethanol) was added to the desired amount of protein (ideally between 20-30 
µg). Samples were then incubated at 95 ºC for 5 min in order to denaturalize them and 
were separated by molecular weight by sodium dodecyl sulphate-polyacrilamide gel 
electrophoresis (SDS-PAGE).  
1.5 mm thick polyacrylamide gels were used, composed by stacking gel (4.5 % 
polyacrylamide) and separating gel (10 % for proteins of 100-300 kDa and 15 % for 
proteins between 15-99 kDa). When necessary, fror proteins size separation, commercial 
polyacrylamide gels (4561085, BioRad) were used, with a gradient of 4 % to 15 % 
polyacrylamide. Electrophoresis was performed using an electrophoresis buffer (Tris 20 
mM, glycine 0.2 M, SDS 0.1 % and pH 8.3) and the power supply BioRad HC Power Pac for 
60-90 min (depending on the protein size) at 120 V. Proteins were transferred to a 
nitrocellulose membrane (Amersham Protran 0.2 μm NC; 10600001, GE Healthcare Life 
Science). Transfer was performed with a transfer buffer (Tris 25 mM, 192 mM glycine, 20 
% methanol, pH 8.6) for 90 min at 220 mA. To avoid the unspecific reactivity of primary 
antibodies the membrane was blocked with Tris Buffered Saline 0.01 % Tween 20 (TBS-T, 
8221840500, Merck Millipore) and 5 % skim milk powder (70166, Sigma-Aldrich) for 1 h 
at RT. The nitrocellulose membranes were incubated for 15-18 h at 4 °C with different 
primary antibodies, see Table M5, following the manufacturer recommendations. 
After the incubation with primary antibodies, membranes were washed 3 times 
for 5 min with TBS-T and incubated with the corresponding horseradish peroxidase (HRP)-
conjugated secondary antibody [Table M5] for 1 h at RT. Finally, membranes were 
washed 3 times with TBS-T. Protein detection was performed by chemiluminescence 
using NOVEL ECL Chemi Substrate (WP20005, Thermo Fisher) for highly expressed 
proteins and Luminata Crescendo Western HRP Substrate (WBLUR0100, Millipore) and 




SuperSignal West Femto Maximun Sensitive Substrate (#34096, ThermoFisher) for low 
expression proteins. Light signal was recorded by iBrightFL1000 (Invitrogen). 
Table M5. Primary and secondary antibodies used in the WB technique. 
    
5.3. Cell immunofluorescence  
Cells were seeded in 8-well immunofluorescence plates (154534, LabTek Thermo) 
and when they got the ideal confluence, cells were fixed with 4 % PFA for 10 min at RT. 
Next, cells were washed 3 times with 1X PBS and were blocked and permeabilized with 
1X PBS 5 % FBS and 0.3 % Triton X-100 (T8787, SigmaAldrich) for 1 h at RT. Fixed cells 
were incubated for 15-18 h at 4 ºC with the appropriate primary antibody for each 
experiment [Table M6]. After this incubation, cells were washed 3 times with 1X PBS and 
were incubated with the correspondent secondary antibody [Table M6] for 1 h at RT in 
darkness. Then, after washing the secondary antibody 3 times, cell chromatin was stained 
for 2 min with HOESCTH (33342, Sigma-Aldrich) at 1 µg/mL and slides were mounted 
using Fluoro-Gel mounting media (17985-10, Aname) or cell chromatin was stained and 






Diluted in Produced 
in 
Supplier Reference 
SOX1 1:250 TBS-T 5 % milk Rabbit Cell 
Signaling 
4194 
SOX2 1:500 TBS-T 5 % milk Rabbit Millipore AB5603 
ERBB4 1:250 TBS-T 5 % milk Rabbit Cell Signaling 4795S 






1:300 TBS-T 0.5 % milk Rabbit Cell Signaling 9664S 
CD133 1:300 TBS-T 5 % milk Rabbit Abcam ab16518 
SOX9 1:500 TBS-T 5 % milk Rabbit Millipore AB5535 
P27KIP 1:500 TBS-T 5 % BSA Rabbit BD 
Bioscience 
BD610241 




Antibody Used dilution Produced in Supplier Reference 
Goat anti-






1:1,000 Goat Santa 
Cruz 
sc-2005 




phenylindole (DAPI) counterstain (H1500, Vector Laboratories). Cell immunofluorescence 
(IF) was evaluated with Eclipse 80i microscope and processed with NIS Element Advances 
Research (Nikon) software. 
Table M6. Primary and secondary antibodies used for cell IF.  
Primary antibodies 




1:2,000 Mouse Abcam ab14955 
ß-Catenin 1:250 Mouse BD Bioscience 610153 
Cleaved-caspase-3 
(cC3) 1:500 Rabbit R&D systems AF835 
Secondary antibodies 
Antibody Used dilution Produced in Supplier Reference 




1:500 Goat Invitrogen A11034 




1:500 Goat Invitrogen A21422 
 




1:500 Goat Invitrogen A21244 
  
5.4. Tissue immunofluorescence 
After dissecting the tissue, brains were fixed in 4 % PFA for at least 48 h. Tissue 
was processed and embedded in paraffin at the UNC Center for Gastrointestinal Biology 
and Disease Histology core. Sections were deparaffinized, and antigen retrieval was 
performed using a low-pH citric acid-based buffer. Staining was performed with 
assistance from the UNC Translational Pathology Laboratory. Slides were scanned using 
the Leica Biosystems Aperio ImageScope software (12.3.3). The primary and secondary 
antibodies used to perform the immunofluorescences are summarized in Table M7. The 
primary antibodies used are the following: anti-phospho-ERBB4 (P-ERBB4, PA5-38501, 
ThermoFisher, Waltham, MA, USA), anti-HBEGF (1:500, sc-365182, SantaCruz, Dallas, TX, 
USA), NeuN (MAB377, Millipore, Burlington, MA, USA), GAD1, and GFAP (Z0334, Dako, 




Santa Clara, CA, USA). Where indicated, nuclei were counterstained with DAPI (catalog 
number D1306; Life Sciences, St. Petersburg, FL, USA). 
Table M7. Primary and secondary antibodies used for tissue IF.  
Primary antibodies 
Antigen Produced in Supplier Reference 
p-ERBB4 Rabbit Thermo Fisher PA5-38501 
Hbegf Mouse Santa Cruz sc-365182 
NeuN Mouse Millipore MAB377 
GAD1 Rabbit Invitrogen PA5-21397 
GFAP Rabbit Dako Z0334 
Secondary antibodies 
Antibody Produced in Supplier Reference 
Alexa Fluor® 488 Goat 
Anti-Rabbit IgG (H+L) 
Antibody 
Goat Invitrogen A11034 
Alexa Fluor® 488 
Donkey Anti-Mouse 
IgG (H+L) Antibody 
Donkey Invitrogen A21202 
Alexa Fluor® 555 Goat 
Anti-Mouse IgG (H+L) 
Antibody 
Goat Invitrogen A21422  
Alexa Fluor® 555 
Donkey Anti-Rabbit 
IgG (H+L) Antibody 
Donkey Invitrogen A31572 
 
5.5. Tissue immunohistochemistry  
Immunohistochemistry (IHC) was performed to identify the expression of the 
proteins of interest in the brains and subcutaneous tumors generated in animal models.  
Tumors and brains were extracted and fixed in 4 % PFA for at least 48 h at RT. 
Afterwards, tissues were embedded in paraffin and cut in 4 μm thick sections using a 
microtome. Then, the slides were deparaffined, rehydrated by successive baths in 
decreasing alcohols percentages and incubated in boiling citrate buffer for 10 min for 
antigenic recovery. Endogenous peroxidase was blocked in 5 % hydrogen peroxidase in 
methanol for 15 min. Next, samples were incubated in blocking solution (PBS, 0.3 % Triton 
X-100 and 5 % FBS) supplemented with the corresponding primary antibody [Table M8] 




at 37 ºC for 2 h. After incubation with the primary antibody, the slides were washed and 
incubated with the appropriate secondary antibodies [Table M8]. Following, samples 
were incubated for 10 min at RT with 3,3’Diaminobenzidine (DAB, SPR-DAB-060, Spring 
Bioscience), getting as a product of the reaction oxidized DAB, a brown precipitate in the 
tissue. The nuclei were stained by incubating the samples for 19 min at RT with 
hematoxylin (6765004, Shandon). Finally, the stained slides were observed with an 
Eclipse 80i microscope and processed by the NIS Elements Advances Research (Nikon) 
software or were digitally acquired using an Aperio ScanScope XT (Aperio). 
Table M8. Primary and secondary antibodies used for tissue IHC.  
Primary antibodies 
Antigen Produced in Supplier Reference 
SOX1 Rabbit Cell Signaling 4194 
SOX2 Rabbit Millipore AB5603 
PML Rabbit Bethyl Laboratories A301-167A 
Nrg1 Mouse Thermo Fisher MA5-12896 
KI67 Rabbit Abcam ab15580 
Cleaved-caspase-3 
(cC3) Rabbit R&D systems AF835 
Secondary antibodies 
Antibody Produced in Supplier Reference 
MACH 3 Rabbit HRP-
Polymer 
Rabbit BioCare Medical M3R531 
MACH 3 Mouse HRP-
Polymer 
Mouse BioCare Medical M3M530 
 
For hematoxylin/eosin staining, fixed and paraffinized brain slides were subjected 
to hematoxylin and eosin staining using a Varistain Gemini ES (A78000014, Thermo 
Fisher) following the manufacturers instructions. Briefly, the slides were deparaffinized 
and rehydrated by successive baths in decreasing alcohols percentages. Next, they were 
submerged in hematoxylin for 2 min. After washing the slides with hot water, they were 
finally stained with eosin (6766008, Shandon) for 1 s.  




6. Gene expression analysis 
6.1. Ribonucleic acid extraction 
Total ribonucleic acid (RNA) was extracted from cell lysates and from fresh tissue. 
Regarding the tissues, samples were homogenized in a tissue-lyser (Quiagen Retsch 
MM300) before adding TRI Reagent Solution (AM9738, Life Technologies). Cells were 
directly lysed with TRI Reagent Solution. The same procedure was used for cell pellet and 
tissue RNA extraction. After the complete disaggregation, 200 µL chloroform were added 
(C2432, Sigma-Aldrich) and gently mixed. After an incubation of 10 min at RT, samples 
were centrifuged at 13,000 g at 4 ºC for 10 min. The aqueous phase formed in the 
centrifugation was transferred into a diethyl pyrocarbonate (DEPC, 159220, Sigma-
Aldrich) treated 1.5 mL microcentrifuge tube. Next, 500 µL of 2-propanol (I9516, Sigma 
Aldrich) and 1 µL of glycogen (at 5 µg/µL) (AM9510, Ambion) were added to each sample. 
After 10 min incubation at RT, samples were centrifuged at 13,000 g at 4 ºC for 22 min. 
Supernatant was discarded and the pellet was washed twice with 75 % EtOH by 
centrifugation. The remaining RNA pellet was dried and eluted in RNAse free water 
(10977-035, Invitrogen). Finally, RNA concentration was measured by 
spectrophotometry at 260 and 280 nm with a Nanodrop-1000 (Thermo Scientific). 
6.2. Reverse transcription 
For retro-transcription experiments, Maxima First Strand complementary DNA 
(cDNA) Synthesis Kit for real time quantitative polymerase chain reaction (RT-qPCR) with 
dsDNase Kit (K1671, Thermo Scientific) was used. cDNA synthesis was performed starting 
from a total RNA amount of 2 µg. Samples were incubated at different temperatures 
following the manufacturer instruction in a BioRad C1000 Thermal Cycler. Specifically, 
this retro-transcription protocol is based on an incubation phase of 10 min at 25 ºC, 
followed by 30 min at 50 ºC and 5 min at 85 ºC. The obtained cDNA was diluted in RNase 
free water up to a concentration of 4 ng/µL. 




6.3. Real Time Quantitative Polymerase Chain Reaction (RT-
qPCR) 
Gene expression determination via messenger RNA (mRNA) was performed by RT-
qPCR, starting with 20 ng of cDNA. The reaction was performed using the reaction mix 
Absolute SYBR Green mix (4368706, Applied Biosystem) or KiCqStart SYBR Green 
ReadyMix (KCQS01, Sigma-Aldrich) and 0.01 µM of primers (forward and reverse) specific 
for the target gene. The sequences of the primers in this work are summarized in Table 
M9. 
RT-qPCR reactions were performed in two different ways depending on the 
reaction mix used. When using Absolute SYBR Green mix, the reactions were performed 
in the Light Cycler 96 (Roche) thermocycler following the temperature cycles defined by 
the manufacturer. Briefly, the program consists in 1 cycle of 120 s at 50 °C, 1 cycle of 600 
s at 95 °C, 41 cycles of 15 s at 95 °C, 60 s at 60 °C and a last cycle of 10 s at 95 °C followed 
by 60 s at 60 °C and 1 s at 97 °C. When using the KiCqStart SYBR Green ReadyMix, the 
reactions were performed in the CFX984 real-time thermal cycler (BioRad) following the 
temperature cycles defined by the manufacturer. Briefly, the program consists in a cycle 
of 120 s at 50 ºC, a cycle of 600 s at 95 ºC, 40 cycles of 15 s at 95 ºC and 60 s at 60 ºC, 
dissociation of 5 s at 65 ºC, and then heat until 95 ºC gradually at 0.5 ºC/s. To correct the 
possible differences of the loaded sample amount, β-actin and Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH) were used for the mice and human samples 
normalization, respectively. Relative quantification was calculated using 2-ΔΔCt method, in 
which the normalized gene expression of the sample is calculated taking as reference a 










Table M9. Primers sequences used in RT-qPCR reactions.  
Gene Sense/Forward sequence (5’ à 3’) Antisense/Reverse sequence (5’ à 3’) 
Human 
ANKRD1 TGAGTATAAACGGACAGCTC TATCACGGAATTCGATCTGG 
BOC CAAGGTCACAAATTCCTCTG CATCTCCACTTCATACAAGC 
CCND1 AGGAAGAGCCCCAGCCATG GTTCCTCGCAGACCTCCAG 
CD133 (Chapter 1 and 2) AAGCATTGGCATCTTCTATG TTTGCTCTGGAGTTTCATTC 
CD133 (Chapter 3) GCTCAGACTGGTAAATCCCC GACTCGTTGCTGGTGAATTG 
CEACAM1 CCACCTAACAAGATGAATGAAG GAATCTCCTAGTGATGAGGG 
CNPase AAGAGCTGGGGAACCACAAG GAGCCTTCCCGTAGTCACAA 
CTNNB1 AGGGCTTACTGGCCATCTTT AAACGCACTGCCATTTTAGC 
ERBB4 AGGGTGATGATCGTATGAAG TCTTGCTCTGGAAGTATAGATG 
FUT4 ACAAAATCATCTGTTGGGAC AGCAGATAAGCACTTTCAAC 
GFAP GGAAGATTGAGTCGCTGGAG ATACTGCGTGCGGATCTCTT 
GAPDH (Chapter 1 and 2) ACAGTTGCCATGTAGACC TTGAGCACAGGGTACTTTA 
GAPDH (Chapter 3) ATGGGGAAGGTGAAGGTCGG GACGGTGCCATGGAATTTGC 
HBEGF GCTTATATACCTATGACCACAC GTACCTAAACATGAGAAGCC 
IGFBP3 AATCATCATCAAGAAAGGGC GAACTTCAGGTGATTCAGTG 
IL6 GCAGAAAAAGGCAAAGAATC CTACATTTGCCGAAGAGC 
MYC GGCTCCTGGCAAAAGGTCA CTGCGTAGTTGTGCTGATGT 
NESTIN (Chapter 1 and 2) ATGGAGACGTCGCTG ACAGCCAGCTGGAAC 
NESTIN (Chapter 3) AGACTTCCCTCAGTTTAGG CAGGTGTCTCAAGGGTAGCAG 
NRG1 GTGGAATCAAACGCTACATC AAAGGTCTTTCACCATGAAG 
OCT4 TTCAGCCAAACGACCATC CAGGTTGCCTCTCACTCG 
p27KIP GCAACCGACGATTCTTCTAC  CTTCTGAGGCCAGGCTTCTT  
PML (Chapter 1 and 2) AGAGGATGAAGTGCTACG TACAGCTGCATCTTTCCC 
PML (Chapter 3) CATCACCCAGGGGAAAGA CATCACCCAGGGGAAAGA 
POSTN ATACTCTCCAGTGTTCTGAG TTGGCAGAATCAGGAATTAG 
PTHLH GCTATTATTTCAGAGGAAGCG CTCGGGACTTATTTAGCAAC 
SEMA5A CTATAAAGAAATTGGCCCCTG ACAACAAGTTCTTTCTGTCC 
SOD2 ATCATACCCTAATGATCCCAG AGGACCTTATAGGGTTTTCAG 
SOX1 (Chapter 1 and 2) TGCTTGTTCTGTTAACTCAC AAAGAACCTCAGAGAGAGTC 
SOX1 (Chapter 3) AGACCTAGATGCCAACAATTGG GCACCACTACGACTTAGTCCG 
SOX2 (Chapter 1 and 2) ATAATAACAATCATCGGCGG AAAAAGAGAGAGGCAAACTG 
SOX2 (Chapter 3) TACAGCATGTCCTACTCGCAG GAGGAAGAGGTAACCACAGGG 
SOX9 AGCGAACGCACATCAAGAC CTGTAGGCGATCTGTTGGGG 
THBS1 GTGACTGAAGAGAACAAAGAG CAGCTATCAACAGTCCATTC 
TP63 CAGCCTATATGTTCAGTTCAG CAGTCCATGCTAATCTCAATC 
VCAM1 ACTTGATGTTCAAGGAAGAG TCCAGTTGAACATATCAAGC 
Mouse 
ErbB4 GGCAATCTCATCTTTCTTGT GACTGTATGTTCAGGAAACC 
Hbegf GAGCTATAGGAACCTTCAGAG ATCGGAAATGAATGAAGACG 
Nrg1 TAGTCACAGCTGGAGTAATG CTGAGGAAGCTGTTACATTC 
 
6.4. Microarray performing and analysis 
The microarray analysis of gene expression was performed starting from 0.5 µg of 
the MB cells mRNA, both controls (plKO) and ERBB4 or SOX1 silencing (shERBB4 or 
shSOX1) cells, using Clariom S Human (902926, Thermo Fisher) microarray chips. The 




microarray procedure was performed by Biodonostia Genomics Facility. The analysis of 
differential expression was performed using Transcriptome Analysis Console (TAC 4.0, 
Thermo Fisher), where the genes differentially expressed compared to the distinct 
experimental conditions were selected according to their p-value significance (lower than 
0.05 and a fold-change higher than 2).  Finally, the altered pathways identification with 
ERBB4 or SOX1 silencing and genes contributing in these pathways were obtained using 
the GSEA software (Broad Institute), program that integrates the selected genes in 
pathways depending on their most significant biological relationship according to the 
bibliography.   
6.5. RNAscope In Situ Hybridization analysis 
RNAscope was performed by the UNC Translational Pathology Laboratory with the 
RNAscope 2.5 Duplex Assay (ACD Bio-Systems) according to the ACD protocol for fresh-
frozen tissue, in order to detect RNA expression directly in the tissue. ERBB4 (Cat No. 
311,801) probe was used in this work.  
7. Statistical analysis 
Results of the present work are represented with the standard error of the mean 
(SEM), also indicating the number of experiments (n). Each experiment was repeated at 
least 3 times in an independent manner. If not otherwise indicated, all statistical analyses 
were calculated using the statistical Student's t-test for normal distributions. Two-tail 
statistical significance is represented as: *p≤0.05; ** p≤0.01; *** p≤0.001, one-tail as ≠ 
and ns as non-significant. Correlations and survival curves data was analyzed with 
GraphPad Prism 5 software (GraphPad Software, Inc. CA, USA). For genes correlation 
assessment, Spearman analysis was used.  For the evaluation of the survival curves 






































































ERBB4 is required for cerebellar development and 
malignant phenotype of medulloblastoma 
ERBB4 is expressed in the inner part of the external germinal 
layer during cerebellum development 
First, we investigated the expression of ErbB4 in the cerebellum in wt mice. For 
this aim, we measured its mRNA levels in the whole developing cerebellum at different 
time points (postnatal day 7 (p7), p14, and p18). We observed that ErbB4 levels were 
similar at the different stages of the cerebellum development [Figure R1-1.A]. Next, in 
order to assess the topography of this receptor expression, we performed an RNAscope 
analysis and immunofluorescence assays in p7 mice cerebellum. These experiments 
revealed that ErbB4 is expressed in the inner part of the EGL [Figure R1-1.B], whereas the 
expression of the active form of ErbB4 (P-ErbB4) is observed in the whole EGL [Figure R1-
1.C]. This layer, where ErbB4 appears to be expressed, constitutes the proliferative layer 
of the developing cerebellum. Specifically, the external part of the EGL is very 
proliferative, whilst the inner part is the more differentiated side.  
 




Figure R1-1. ErbB4 is expressed in the EGL during cerebellar development. (A) ErbB4 mRNA expression in 
mice cerebellum at postnatal day 7 (p7), p14, and p18. (B) Representative RNAscope images of ErbB4 mRNA 
expression in p7 mouse cerebellum (n ≥ 3). Scale bars: left image = 199.8 µm and right image = 49.91 µm. 
(C) Representative immunofluorescence images of P-ErbB4 protein expression in p7 mouse cerebellum (n 
≥ 3). Scale bars: left image = 600 µm and right image = 200 µm. 
 
Regarding ErbB4 receptor activation, different ligands exist. Among them, Hbegf 
and Nrg1 are the most relevant ones. Hbegf is expressed in developing cerebellum by 
Purkinje cells and it seems to be the dominant ligand in this brain structure (Kornblum et 
al., 1999). Besides, Nrg1 expression has been observed in the cerebellum EGL (Gilbertson 
et al., 1998). In this work, the expression of both ligands was measured at p7, p14, and 
p18 stages of cerebellum development by RT-qPCR. The results showed that the 
expression of Hbegf increases from p7 to p18 in a regular manner, whilst Nrg1 expression 
remains constant during this period of time [Figure R1-2.A]. Moreover, with the aim of 
investigating their localization in vivo, Hbegf and Nrg1 expression was assessed by 
immunofluorescence and immunohistochemistry assays. The results showed that Hbegf 
is expressed in the outer part of the IGL [Figure R1-2.B], where cells differentiated to 
neurons. However, Nrg1 expression was very low or undetectable [Figure R1-2.C]. 
Altogether, these results revealed the different pattern of expression of ErbB4 ligands 
during cerebellar development in vivo. 





Figure R1-2. ErbB4 ligands present different expression pattern during cerebellar development. (A) Hbegf 
and Nrg1 mRNA expression in mice cerebellum at p7, p14 and, p18. (B) Representative 
immunofluorescence images of Hbegf protein expression in p7 mouse cerebellum (n ≥ 3). Scale bars: left 
image = 500 µm and right image = 300 µm. (C) Representative immunohistochemistry images of Nrg1 
protein expression in p7 mouse cerebellum. Scale bars: left image = 400 µm and right image = 200 µm.  
 
ERBB4 is essential for normal CGNP migration during 
cerebellar development 
To assess the role of ERBB4 in CGNPs in vivo, we took advantage of ErbB4 mutant 
or knock out (KO) mice (Gassmann et al., 1995). First, we analyzed and compared the 
cerebella of p20 control and ErbB4 KO mice by Hematoxylin and Eosin and 
immunofluorescence staining. At this time point, all the CGNPs should have migrated to 
the IGL and should have differentiated into neurons in this layer. However, the 
Hematoxylin and Eosin staining images of the ErbB4 KO mice showed that CGNPs were 
still located in the EGL at p20 [Figure R1-3]. These results confirm that ErbB4 is essential 
in CGNPs migration during cerebellar development. 
Furthermore, we investigated different cell type markers in order to determine 
the localization of each cell type in both control and ErbB4 KO mice cerebella. In the 
images obtained, we could detect NeuN positive stained cells that remain in the EGL in 
the mutant mice cerebella. These results suggest that the neuronal differentiation 
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process of the CGNPs was not disrupted by the lack of ErbB4 [Figure R1-3]. On the 
contrary, immunofluorescence performed for the Purkinje cell Glutamate decarboxylase 
1 (Gad1) marker (Kirsch et al., 2012) showed disorganization in the Purkinje cells in ErbB4 
KO mice [Figure R1-3], since they did not form the straight layer that can be observed in 
the images of wt mice cerebella. Moreover, when analyzing glial fibrillary acidic protein 
(Gfap) astrocyte marker, immunofluorescence images of ErbB4 mutant mice cerebella 
also demonstrated disorganization of these cells [Figure R1-3], which form the radial glia 
from where CGNPs migrate through to get to the IGL.  
All the results obtained demonstrate that ErbB4 has an essential role in the 
organization and normal development of the cerebellum and that its deficit causes 
aberrant migration and differentiation of the CGNPs. 
 
Figure R1-3. ErbB4 deletion impairs migration during cerebellar development. Representative 
immunofluorescence images of the indicated proteins in p20 wt and ErbB4 KO mouse cerebella.  
 
ERBB4 is expressed in cultured CGNPs, and its activation 
protects cells from an apoptotic stimulus in vitro and in vivo 
To further investigate the role of ErbB4 when it is activated in CGNP cells 
population, p5 mice cerebella were isolated and these cells were cultured in vitro. 
Afterwards, CGNPs were treated with exogenous Shh, with the aim of maintaining them 
in a proliferative status, and with exogenous Hbegf and human NRG1 (hNRG1), in order 
to activate the ErbB4 receptor. In the performed experiments, the treatment with 




exogenous Hbegf obtained a low activation of ErbB4 [Figure R1-4.A], since differences in 
P-ErbB4 levels when performing Western Blot analysis were very low when comparing 
treated and untreated CGNPs. However, when treating the cells with exogenous hNRG1, 
a strong activation of ErbB4 could be observed, as there was a significant increase in P-
ErbB4 levels [Figure R1-4.A]. These results show that there is a different response of 
ErbB4 to both ligands in vivo and in vitro. 
Next, CGNPs from wt and ErbB4 mutant mice cerebella were cultured and treated 
again with exogenous Shh, hNRG1, and dexamethasone (a cell apoptosis activator). The 
results in wt mouse cultures showed that when ErbB4 is activated with hNRG1, cells are 
less sensitive to dexamethasone apoptosis activation. In fact, Western Blot analysis of 
cleaved-Caspase-3 (cC3) expression showed lower expression levels of this apoptosis 
marker in wt mouse cultures [Figure R1-4.B]. However, when the same experiments were 
repeated with ErbB4 KO mice cultured cells, the results show an augmented cC3 levels 
even when cells were treated with exogenous hNRG1 [Figure R1-4.B]. These results 
demonstrate that specifically ErbB4 receptor, and no other members of the family, is the 
responsible of apoptotic protection in CGNP cells.  
To characterize the role of ErbB4 not only in normal development, but also in 
tumorigenesis process, ErbB4loxP/loxP mice were crossed with hGFAPcre; SmoM2 mice. The 
last ones’ special characteristic is that they develop MB spontaneously within 15–17 days 
after birth (Mao et al., 2006). First, we analyzed the tumors obtained in the pups acquired 
after this breeding. When we compared ErbB4 Het mice, with one copy of the ErbB4 gene 
in Gfap expressing cells, with KO mice, which totally lack ErbB4 expression in Gfap 
expressing cells, the results obtained by Western Blot analysis showed an increment in 
cC3 levels in p15 KO mice tumors compared with tumors obtained from p15 Het mice 
[Figure R1-4.C]. These phenotypes were replicated in p17 KO and Het mice tumors [Figure 
R1-4.D]. All these results demonstrate that ErbB4 confers resistance to apoptosis not only 
in healthy CGNPs in vitro, but also in tumor cells in vivo, thus suggesting the inhibition of 
ErbB4 as a possible therapeutic approach to activate apoptosis in MB cells. 




Figure R1-4. ErbB4 activation protects CGNPs and MB tumor cells from apoptosis. (A) Western Blot analysis 
of P-ErbB4, ErbB4 and b-Actin of CGNPs from p5 wt mice treated with the indicated compounds (n ≥ 3). (B) 
Western Blot analysis of P-ErbB4, cC3 and b-Actin of CGNPs from wt and ErbB4 KO p5 mice treated with 
the appropriate compounds (n ≥ 3). Western Blot analysis of P-ErbB4, cC3 and b-Actin obtained from (C) 
p15 and (D) p17 cerebellum from SmoM2; ErbB4 Het or KO mice (n ≥ 3). 
 
The higher expression that ERBB4 presents in Group 4 
medulloblastomas is associated with poor clinical outcome 
To investigate the ERBB4 impact on human MB progression, we analyzed the 
expression of ERBB4 in different databases of human clinical biopsies from MB tumors. 
First, we investigated the expression of ERBB4 in the four different established MB 
groups. The results obtained show that Group 4 MBs were the ones presenting the 
highest expression of ERBB4 in all the analyzed databases [Figure R1-5.A–D and Table R1-
1.A-D]. Moreover, we studied the expression of ERBB4 in various human MB cell lines, 
detecting higher expression levels of this receptor in cells belonging to Group 4 
(D283Med, D341Med, CHLA-01-Med, and CHLA-01R-Med) compared to DAOY and 
UW228 cell lines belonging to SHH subgroup [Figure R1-6].  





Figure R1-5. Group 4 MBs present high levels of ERBB4. Boxplot of the log2 of ERBB4 expression in the 
indicated MB subgroups in (A) Northcott et al. (2012) cohort (n = 1087), (B) Robinson et al. (2012) cohort 
(n = 76), (C) Remke et al. (2011) cohort (n = 64), and (D) Cavalli et al. (2017) cohort (n = 612).   
 
Table R1-1. p-values of the differences of ERBB4 expression between the different MB subgroups in 
Northcott PA et al. 2012 cohort (n = 1087), Robinson G et al. 2012 cohort (n = 76), Remke M et al. 2011 
cohort (n = 64) and Cavalli FMG et al. 2017 cohort (n = 612).  
Northcott PA et al. 2012 (n = 1087) 
T test WNT Group 3 Group 4 
SHH - N/S 1.67 x 10-6 
Group 3 N/S - 8.76 x 10-5 
Group 4 1.67 x 10-6 8.76 x 10-5 - 
Robinson G et al. 2012 (n = 76) 
T test WNT SHH Group 4 
WNT - 0.0135 3.73 x 10-8 
SHH 0.0135 - 0.0017 
Group 4 3.73 x 10-8 0.0017 - 
Remke M et al. 2011 (n = 64) 
T test WNT SHH Group 4 
WNT - N/S 9.84 x 10-5 
SHH N/S - 0.00017 
Group 4 9.84 x 10-5 0.00017 - 
Cavalli FMG et al. 2017 (n = 612) 
T test WNT SHH Group 3 Group 4 
WNT - 9.5 x 10-17 1.7 x 10-34 3.4 x 10-57 
SHH 9.5 x 10-17 - 8.0 x 10-15 4.2 x 10-35 
Group 3 1.7 x 10-34 8.0 x 10-15 - 9.8 x 10-3 
Group 4 3.4 x 10-57 4.2 x 10-35 9.8 x 10-3 - 





Figure R1-6. MB cell lines belonging to Group 4 express higher ERBB4 levels. ERBB4 mRNA expression levels 
in the indicated MB cell lines (n ≥ 3). 
 
Furthermore, we investigated the correlation between ERBB4 expression levels 
and clinical characteristics of the patients in publicly available datasets of the Cavalli 
cohort. Strikingly, high ERBB4 expression levels were associated with shorter overall 
survival in Group 4 MBs (p-value = 1.8 × 10−3) [Figure R1-7.A]. Furthermore, high ERBB4 
expression levels were also associated with shorter overall survival when analyzing all the 
patients (p-value = 0.012) [Figure R1-7.B]. Taken all together, these results show that 
ERBB4 expression correlates with poor prognosis in all MBs. Moreover, its expression is 
especially elevated in Group 4 samples, where its high levels could be a promising 
prognostic biomarker. 





Figure R1-7. High ERBB4 levels are associated with poor clinical outcome. Kaplan-Meier curves for the 
Cavalli et al (2017) cohort’s (A) Group 4 patients’ and (B) all patients’ overall survival rates based on ERBB4 
expression obtained from hgserver1. 
 
ERBB4 knock-down decreases cell viability and activates 
apoptosis in human medulloblastoma cells in vitro and in vivo 
Next, we investigated whether ERBB4 plays a role in MB progression. To reach this 
goal, we knocked-down ERBB4 expression in two human MB cell lines (DAOY and 
D283Med) with two independent short hairpin RNAs (shRNAs). First, we verified the 
effective inhibition of ERBB4 by Western Blot and RT-qPCR analysis when using both 
shERBB4 constructs (sh2 and sh3) [Figure R1-8.A-B]. Functionally, this silencing promoted 
a significant decrease of more than 2-fold in cell growth rates in both MB cell lines 
measured by cell counting at different time points [Figure R1-8.C-E].  




Figure R1-8. ERBB4 knock-down impairs MB cell growth in vitro. (A) Representative image and 
quantification of Western Blot analysis of ERBB4 in control (plKO) and shERBB4 (sh2 and sh3) D283Med 
cells (n = 4). (B) ERBB4 mRNA expression in control (plKO) and shERBB4 (sh2 and sh3) cells (n ≥ 9). (C) 
Relative cell growth at day 5 comparing plKO with sh2 and sh3 cells (n ≥ 3). plKO, sh2 and sh3 (D) DAOY and 
(E) D283Med cells number at day 1, 3 and 5 after seeding (n ≥ 3).  
 
To assess if the reduction observed in the cell number was related to an inhibition 
of proliferation or to a reduction of cell viability, we carried out MTT studies to assess cell 
viability and immunofluorescence assays to detect proliferative cells. In line with our 
previous results, MTT studies showed a diminished cell viability rate in ERBB4 silenced 
DAOY and D283Med cells [Figure R1-9.A]. Nevertheless, these phenotypes did not seem 
to correlate with a reduction in proliferation, considering that the number of cells positive 
for the proliferative marker phospho-histone H3 (PHH3) was similar between the three 
conditions in DAOY cells [Figure R1-9.B]. Thus, we can conclude that ERBB4 silencing 
impairs cell viability, but it does not stop cell cycle, and consequently cell proliferation. 





Figure R1-9. ERBB4 knock-down impairs MB cell viability in vitro. (A) Cell viability assessment by MTT in sh2 
and sh3 relative to plKO cells (n ≥ 6). (B) Representative images and quantification of PHH3 positive cells in 
sh2 and sh3 relative to plKO DAOY cells (n ≥ 3). 
 
To clarify the origin of the decreased cell viability but not of cell proliferation, we 
performed a cell cycle assay. This assay is based on quantifying the cells’ number in each 
cell cycle phase, thus providing the information about the cell cycle status in each 
experimental condition. The results showed an increase in subG0/G1 in ERBB4 knock-
down cells comparing to control cells [Figure R1-10.A-B], suggesting an increased cell 
death of these MB cells when knocking-down ERBB4. We confirmed this increase in the 
apoptosis by quantifying the number of cells positive for both cC3 and Annexin-V 
apoptotic markers. We found an elevated number of positive cells for the both markers 
in DAOY and D283Med sh2 and sh3 cells comparing to plKO experimental condition 
[Figure R1-10.C-E].  
Finally, we also investigated the role of ERBB4 in the MB cell migration ability. We 
observed that ERBB4 knock-down resulted in a significant decrease in the migration 
potential of DAOY MB cells [Figure R1-10.D].  
Altogether, these results further highlight the relevance of ERBB4 in maintaining 
critical cellular phenotypes, mainly apoptosis and migration, during homeostasis and 
pathological conditions.  




Figure R1-10. ERBB4 knock-down increases apoptosis of MB cells in vitro. Cell cycle assay measuring the 
number of cells in each cell cycle phase in plKO, sh2 and sh3 (A) D283Med and (B) DAOY cells (n ≥ 3). (C) 
Percentage of Annexin-V positive cells in plKO, sh2 and sh3 DAOY and D283Med cells (n ≥ 3). (D) 
Immunofluorescence quantification of cC3 positive cells in sh2 and sh3 relative to plKO DAOY and D283Med 
cells (n ≥ 4). (E) Representative immunofluorescence images of cC3 positive cells in plKO, sh2 and sh3 DAOY 
and D283Med cells (n ≥ 4). (F) Representative images and quantification of the migration assay in DAOY 
cells (n ≥ 3). 
 
Next, we wanted to extend the results obtained in vitro to determine whether 
ERBB4 could regulate tumor growth in vivo. For this aim, we injected sh2 and sh3 DAOY 
and D283Med cells subcutaneously in immunocompromised mice. Interestingly, we 
observed a significant decrease of shERBB4 DAOY and D283Med cells tumor growth of 
over 70 %, especially with sh3 experimental condition, which did not form tumors in 
D283Med cells [Figure R1-11.A-B]. To validate these results, the weight of generated 




tumors was measured, showing a lower weight for tumors generated from knocked-
down cells than for tumors generated from control cells [Figure R1-11.A-C]. Moreover, 
tumors molecular analysis by immunohistochemistry revealed increased apoptosis, 
characterized by higher cC3 positive cells, and decreased proliferation, since they 
presented lower KI67 positive cells, in sh2 DAOY and D283Med cells [Figure R1-11.D-E]. 
Taken together, all these results showed that ERBB4 is required for MB cell survival and, 
thus, tumor progression. 
 
Figure R1-11. ERBB4 knock-down reduces tumor progression in vivo. Volume of tumors generated after 
subcutaneous injection of (A) DAOY and (B) D283Med plKO, sh2 and sh3 cells (n ≥ 8) at the indicated time 
points. (C) Quantification of tumors’ weight generated after subcutaneous injection of DAOY and D283Med 
pLKO and sh2 cells (n = 8). Representative images of the immunohistochemical staining of cC3 and KI67 in 
tumors generated after subcutaneous injection of (D) DAOY and (E) D283Med pLKO and sh2 cells (n ≥ 3).  
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ERBB4 is highly expressed in MBSCs and its knock-down 
inhibits stem cells activity 
With the aim of investigating the role of ERBB4 in MBSCs, we cultured DAOY and 
UW228 MB cell lines (with low endogenous levels of ERBB4) and D283Med and D341Med 
cell lines (with high expression of ERBB4) in the presence of serum and in stem cell 
specific media to induce oncospheres formation. First, we verified whether the stem cell 
specific culture condition increased the expression of some of the well-established MBSC 
markers: CD133, Fucosyltransferase 4 (FUT4), SOX2 and NESTIN (Read et al., 2009; Singh 
et al., 2003; Vanner et al., 2014). RT-qPCR and Western Blot analysis demonstrated that 
in all cell lines, the cells cultured as oncospheres presented higher levels of these MBSC 
markers compared to the expression of MB cell lines cultured in the presence of serum 
[Figure R1-12.A-C]. Interestingly, we observed that oncospheres formed from DAOY and 
UW228 cell lines showed higher expression levels of ERBB4 than cells cultured in the 
presence of serum [Figure R1-12.C-D].  
To further analyze the relation between ERBB4 and MBSC markers expression, we 
performed a correlation analysis of ERBB4 gene expression with CD133 and FUT4 genes 
expression in all human MB cell lines. The results showed a positive correlation between 
ERBB4 and both MBSC markers’ expression [Figure R1-12.E-F], thereby linking ERBB4 high 
levels expression to MBSCs activity. 





Figure R1-12. ERBB4 is overexpressed in MBSCs. (A) mRNA levels of the indicated stem cell markers of DAOY 
and UW228 cells grown in serum or in stem cell media as oncospheres (n ≥ 3). (B) mRNA levels of the 
indicated stem cell markers of D283Med or D341Med cells grown in serum or in stem cell media as spheres 
(n ≥ 3). (C) Western Blot analysis of the indicated proteins in protein extracts of cells grown in serum 
(D283Med or D341Med) or in stem cell media as oncospheres (n ≥ 3). (D) ERBB4 mRNA expression levels 
of DAOY and UW228 cells grown in serum and stem cell media (n ≥ 3). Correlation between (E) CD133 and 
(F) FUT4 expression levels with ERBB4 expression levels in different MB cell lines (DAOY, UW228, D283Med, 
D341Med, CHLA-01-Med, and CHLA-01R-Med) (n ≥ 3). 
 
To directly explore the role of ERBB4 in the MBSCs activity, we cultured DAOY and 
D283Med cells with ERBB4 knock-down in stem cell specific media allowing them to form 
oncospheres, and then we quantified the number of oncospheres formed. The results 
showed a marked decrease in the ability of the cells with ERBB4 knocked-down to form 
oncospheres, both in DAOY and D283Med cells [Figure R1-13.A]. Moreover, we measured 
the ability to form secondary oncospheres, by disaggregating the primary oncospheres 
and seeding them again. We found that the ability to form secondary oncospheres was 
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also significantly impaired in sh2 and sh3 DAOY MB cells [Figure R1-13.B]. In line with 
these results, ERBB4 silencing significantly decreased the ability of colony formation 
[Figure R1-13.C]. Altogether, these results suggest that ERBB4 has an important role in 
the maintenance of MBSCs. 
 
Figure R1-13. ERBB4 expression regulates MB stem cell (MBSC) activity in vitro. (A) Representative images 
and quantification of the oncospheres’ number formed from the indicated conditions in DAOY and 
D283Med cells (n ≥ 4). (B) Quantification of the number of 1ry and 2ry oncospheres formed from plKO, sh2 
and sh3 DAOY cells (n ≥ 3). (C) Representative images and quantification of the colonies’ number formed 
from the indicated conditions in DAOY cells (n ≥ 3). 
 
With the objective to further characterize the impact of ERBB4 in MBSCs activity, 
we moved to in vivo experiments. We injected limited dilution concentrations of knocked-
down ERBB4 DAOY and D283Med cells subcutaneously in immunocompromised mice. 
Strikingly, the frequency of tumor initiation in DAOY cells was 1 in 475,710 and 1 in 
946,994 in sh2 and sh3 cells, respectively, compared to 1 in 99,524 in the control cells 
[Figure R1-14.A,C]. Moreover, the tumor initiation in D283Med cells was 1 in 1,649,864 
and infinite in sh2 and sh3 cells, respectively, compared to 1 in 441,838 in the empty 
vector harboring cells [Figure R1-14.B,D]. These differences in stem cell frequenciy 




between the tested experimental conditions were all statistically significant. These results 
confirm that ERBB4 inhibition limits tumor initiation and reveal its essential role in MBSCs 
activity. 
 
Figure R1-14. ERBB4 expression regulates MBSC activity in vivo. (A) Frequency of tumor initiation after 
subcutaneous injection of 1 x 106, 1 x 105 and 5 x 104 DAOY cells transduced with plKO, sh2 and sh3 in nude 
mice. (B) Frequency of tumor initiation after subcutaneous injection of 1 x 106 and 1 x 105 D283Med cells 
transduced with plKO, sh2 and sh3 in nude mice. The incidence of tumor initiation was measured using 
ELDA platform (black line represents plKO condition, red line represents sh2, and green line represents 
sh3). Number of stem cells needed to initiate a tumor in the indicated conditions with (C) DAOY and (D) 
D283Med cells.  
ERBB4 knock-down alters multiple processes and pathways in 
medulloblastoma cells 
Finally, we wanted to investigate the pathways from which ERBB4 is acting in MB 
cells to promote a tumorigenic activity. In order to identify the pathways altered when 
knocking-down ERBB4 expression, we carried out a transcriptomic analysis of plKO, sh2, 
and sh3 DAOY cells. We found that in sh2 DAOY cells, 293 genes were upregulated 
whereas 395 genes were downregulated. Regarding sh3 DAOY cells, 724 genes appeared 
upregulated whereas 997 genes were downregulated. All the identified genes presented 
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a p-value lower than 0.05 and a fold-change higher than 2. After identifying the altered 
genes in each shERBB4, we sorted out the common genes for both shRNAs, and found 
179 genes upregulated and 297 downregulated. These common genes were further 
selected and used to perform a gene enrichment analysis with the Gene Ontology (GO) 
gene sets, considering biological processes. The results obtained in this gene enrichment 
analysis were consistent with our functional studies previously performed, since 
processes such as cell motility, morphogenesis, development, cell growth and 
proliferation, and cell signaling were downregulated when knocking-down ERBB4 [Figure 
R1-15.A]. On the contrary, cell death and response to stimulus processes were increased 
[Figure R1-15.B].  
Among the identified common genes, lower expression levels of stem cell markers 
such as CD133, Doublecortin like kinase 1 (DCLK1), LIN7, SRY-box 4 (SOX4), SERPINE3, or 
Tumor protein P63 (TP63); genes involved in motility-related pathways such as Paired 
related homeobox 1 (PRRX1), Matrix metallopeptidase 7 (MMP7), or Claudin; genes 
related to cell signaling as FOS or JUN; or cancer-related genes such as K-RAS were 
detected in shERBB4 cells compared to plKO cells. On the other hand, genes related to 
cell differentiation (Fibroblast growth factor 5; FGF5), cell apoptosis (Amyloid beta 
precursor protein binding family B member 2 (APBB2), Ankyrin repeat domain 1 (ANKRD1), 
Placenta associated 8 (PLAC8)), response to stress (H2A histone family member X 
(H2AFX), SERPINE1, Cadherin 13 (CDH13), Vascular endothelial growth factor A (VEGFA)) 
and cell cycle and division (CDK6, Cyclin dependent kinase 15 (CDK15), Cyclin D1 (CCND1), 
E2F transcription factor 7 (E2F7), Cell division cycle 25A (CDC25a)) displayed a higher 
expression in knocked-down cells.  





Figure R1-15. ERBB4 knock-down alters multiple pathways of MB cells. (A) Downregulated and (B) 
upregulated pathways in sh2 and sh3 DAOY cells compared with plKO cells when performing a GO gene set 
biological processes analysis from Clariom S microarray results. The p-value and the percentage of genes 
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Moreover, we also performed a gene enrichment analysis but, in this case, based 
on hallmark gene sets. The results showed alterations in genes’ expression related to cell 
cycle or stress response, thus finding a good correlation between both datasets that 
reinforce the GO gene sets analyses’ results. Furthermore, the data also revealed 
dysregulation in inflammation- or metabolism-related pathways [Figure R1-16.A-B]. 
Indeed, we observed a decreased expression of genes or inflammation markers such as 
Signal transducer and activator of transcription 3 (STAT3), Oncostatin M receptor (OSMR), 
Interleukin 1 receptor type 1 (IL1R1), Interleukin 18 receptor 1 (IL18R1), C-X-C motif 
chemokine ligand 16 (CXCL16), Interferon induced transmembrane protein 1 (IFITM1), 
Suppresor of cytokine signaling 2 (SOCS2), and Matrix gla protein (MGP), whilst we found 
an elevated expression of Interleukin 1 alpha (IL1α), Interleukin 7 receptor (IL7R) and 
Signal transducer and activator of transcription 5B (STAT5B) among others, or 









Figure R1-16. ERBB4 knock-down alters multiple pathways of MB cells. (A) Downregulated and (B) 
upregulated pathways in sh2 and sh3 DAOY cells compared with plKO cells when performing a hallmark 
gene set analysis from Clariom S microarray results. The p-value and the percentage of genes deregulated 
in each pathway are represented in the figures.  
 
Next, based on the literature, we moved our attention to genes that had been 
already related to MB. We validated in DAOY and D283Med cells some of the 
downregulated genes, such as Periostin (POSTN) (Zhu et al., 2019), BOC (Mille et al., 
2014), Vascular cell adhesion molecule 1 (VCAM1) (Liang et al., 2015), and TP63 (Forster 
et al., 2014) as well as some of the upregulated ones, such as ANKRD1 (Jimenez et al., 
2017), Thrombospondin 1 (THBS1) (Zhou et al., 2010), NRG1 (Gilbertson et al., 1998), 
PTHLH (Katoh and Katoh, 2009), and HBEGF [Figure R1-17.A-C]. Altogether, these 
analyses revealed the underlying molecular mechanisms of ERBB4 activity in MB cells. 
Others


































































































































Figure R1-17. ERBB4 knock-down alters multiple pathways of MB cells. mRNA levels of (A) downregulated 
and (B) upregulated genes in control (plKO) and shERBB4 (sh2 and sh3) DAOY cells (n ≥ 3). (C) mRNA levels 
of downregulated and upregulated genes in plKO and sh3 D283Med cells (n ≥ 3).  
 
To characterize the impact of the identified pathways and genes in MB and their 
relation with ERBB4, we moved to clinical samples. First, we completed a correlation 
study between the expression of ERBB4 and the validated genes, taking advantage of the 
publicly available Cavalli FMG et al. (2017) cohort. We considered only Group 4 patients’ 
data. The results showed a statistically significant positive correlation between ERBB4 and 
two genes (BOC and TP63) found to be downregulated when knocking-down ERBB4 
[Figure R1-18.A]. We found also a statistically significant negative correlation between 
ERBB4 and all of the genes that shown to be upregulated when ERBB4 was knocked-
down. Three of them (THBS1, NRG1, and PTHLH) showed statistically significance [Figure 
R1-18.B].  





Figure R1-18. Correlation between ERBB4 and ERBB4 downstream genes’ expression in human samples of 
Group 4 MBs. Correlation analysis of (A) downregulated (POSTN p-value = 0.079, BOC p-value = 2.38 x 10-
5, VCAM1 p-value = 0.835, and TP63 p-value = 0.027) and (B) upregulated (ANKRD1 p-value = 0.955, THBS1 
p-value = 1.48 x 10-14, NRG1 p-value = 5.17 x 10-3, PTHLH p-value = 6.91 x 10-6, and HBEGF p-value = 0.482) 
genes with ERBB4 expression for Cavalli cohort Group 4 patients’ (n = 326) data. All results were obtained 
from hgserver1. 
 
Afterwards, we performed the same analysis, but in this case, considering all 
patients’ data from the same cohort. The results were not as consistent as the ones 
acquired when analyzing only the data of the patients belonging to the Group 4 [Figure 
R1-19.A-B]. Thus, these results reinforce the relation between these genes and ERBB4 
expression, especially in the Group 4 MBs.  
 
 




Figure R1-19. Correlation between ERBB4 and ERBB4 downstream genes’ expression in human samples of 
MB. Correlation analysis of (A) downregulated (POSTN p-value = 2.91 x 10-3, BOC p-value = 2.08 x 10-33, 
VCAM1 p-value = 0.121, and TP63 p-value = 9.54 x 10-7) and (B) upregulated (ANKRD1 p-value = 0.013, 
THBS1 p-value = 6.78 x 10-3, NRG1 p-value = 1.07 x 10-5, PTHLH p-value = 7.95 x 10-6, and HBEGF p-value = 
3.95 x 10-8) genes with ERBB4 expression for Cavalli FMG et al. 2017 cohort’s all patients’ (n = 612) data. All 
results were obtained from hgserver1. 
 
After these two studies, we analyzed the expression of the selected genes in the 
different subgroups using the information of all patients from the same cohort. We found 
that three of the downregulated genes (BOC, VCAM1, and TP63) followed the same 
pattern as ERBB4 and showed a higher expression in Group 4 MBs [Figure R1-20.A-B].  
 
 





Figure R1-20. Expression of ERBB4 downstream genes in human samples of MB. Boxplot of the log2 of (A) 
downregulated and (B) upregulated genes in the indicated MB subgroups in Cavalli cohort (n = 612). All 
results were obtained from hgserver1. 
 
Finally, we performed a correlation analysis between the expression of the genes 
selected from the microarray and patient outcome. We found that altered VCAM1, TP63, 
ANKRD1, THBS1, and PTHLH expression levels significantly correlated with lower patient 
survival in Group 4 MB samples [Figure R1-21.A-B]. Moreover, we carried out the same 
analysis in all MB subgroups. The results showed an elevated ANKRD1 and NRG1 
expression that correlated with lower patient survival [Figure R1-22.A-B].  
 




Figure R1-21. Clinical impact of ERBB4 downstream genes in MB human samples. Kaplan-Meier curves for 
the Cavalli cohort Group 4 patients’ overall survival rates based on (A) downregulated and (B) upregulated 
expression (p-values are indicated in each graph). All results were obtained from hgserver1. 
 
 
Figure R1-22. Clinical impact of ERBB4 downstream genes in Group 4 MB human samples.  Kaplan–Meier 
curves for the Cavalli cohort’s all patients’ overall survival rates based on (A) downregulated and (B) 
upregulated genes (p-values are indicated in each graph). All results were obtained from hgserver1. 
 
All these results further extend the findings obtained in vitro to clinical samples in 
vivo, and reveal various promising genes and pathways that seem to be related to ERBB4 
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CHAPTER 2  
High SOX1 expression is a hallmark of SHH 
medulloblastomas and its inhibition depletes tumor 
malignancy 
High SOX1 expression levels are associated with poor clinical 
outcome in medulloblastoma 
First in this section, we wanted to analyze the function and impact of SOX1 
transcription factor in MB. For this aim, we analyzed SOX1 expression in publicly available 
databases of human MB clinical biopsies (Cavalli et al., 2017; Northcott et al., 2017). First, 
we compared the SOX1 expression levels in the different groups of MB. We found that 
SHH MBs present the highest SOX1 expression levels in the two analyzed cohorts [Figure 
R2-1.A-D]. We also investigated SOX1 protein levels in the different MB cell lines available 
in the laboratory, finding that cells belonging to SHH subgroup MBs presented higher 
levels of SOX1 than cells belonging to Group 3 or 4 [Figure R2-1.E].  




Figure R2-1. High levels of SOX1 are found in SHH MBs. Boxplot of the log2 of SOX1 in the indicated MB 
subgroups (A) Cavalli FMG et al. 2017 cohort (n = 612) and (B) Northcott PA et al. 2017 cohort (n = 223). P-
values of the differences in SOX1 expression in the indicated MB subgroups of (C) Cavalli FMG et al. 2017 
cohort (n = 612) and (D) Northcott PA et al. 2017 cohort (n = 223). (E) Western Blot analysis of SOX1 protein 
in SHH subgroup cell lines (DAOY and UW228) and in Group 3 or 4 cell lines (D283Med, D341Med, CHLA-
01-Med and CHLA-01R-Med). 
 
Second, we investigated the correlation of patients’ survival with SOX1 expression 
levels in the Cavalli cohort, by considering all MB patients’ and SHH group MBs data. 
Interestingly, we found that high SOX1 expression levels were associated with a worse 
clinical outcome in SHH MBs (p-value = 0.018) [Figure R2-2.A], but this correlation was 
not maintained when analyzing all MB groups together (p-value = 0.352) [Figure R2-2.B]. 
Thus, these results show that SOX1 expression is specifically elevated in SHH MBs, where 
its high levels could be a promising prognostic biomarker.  




Figure R2-2. High levels of SOX1 are associated with shorter overall survival. Kaplan-Meier curves for the 
Cavalli FMG et al. 2017 cohort´s (A) SHH group patients’ and (B) all patients’ overall survival rates based on 
SOX1 expression obtained from hgserver1. 
 
SOX1 expression seems to be a better biomarker of prognosis 
in SHH subgroup medulloblastomas than SHH signaling pathway-
related genes  
To further analyze the potential of SOX1 expression as both subgroup and 
prognostic biomarker, we first analyzed the correlation between its expression and those 
of the genes implicated in SHH signaling pathway (SHH, SMO, PTCH1, GLI1, GLI2 and GLI3 
genes), in all MB subgroups [Figure R2-3.A] and only in SHH subgroup MBs [Figure R2-
3.B]. For this aim, we took advantage of the publicly available Cavalli FMG et al. 2017 
cohort’s patients’ data. We found that all the analyzed genes’ expression correlated 
positively and significantly with SOX1 expression when analyzing all MBs [Figure R2-3.A]. 
However, when only SHH subgroup MBs were analyzed, only SMO, GLI2 and GLI3 
expression presented a positive, significant correlation with SOX1 expression [Figure R2-
3.B]. 




Figure R2-3. SOX1 correlates positively with SHH signaling pathway genes. (A) Correlation analysis between 
SOX1 and SHH (p-value = 6.95 x 10-4), SMO (p-value = 2.74 x 10-29), PTCH1 (p-value = 3.55 x 10-51), GLI1 (p-
value = 1.19 x 10-51), GLI2 (p-value = 6.26 x 10-73) and GLI3 (1.19 x 10-56), by considering all MB subgroups 
in Cavalli FMG et al. 2017 cohort (n = 612). (B) Correlation analysis between SOX1 and SHH (p-value = 0.142), 
SMO (p-value = 0.021), PTCH1 (p-value = 0.214), GLI1 (p-value = 0.466), GLI2 (p-value = 5.71 x 10-4) and 
GLI3 (p-value = 1.91 x 10-4), by considering only SHH subgroup MBs in Cavalli FMG et al. 2017 cohort (n = 
223). All the results were obtained from hgserver1. 
 
Next, we analyzed the SHH signaling pathway genes’ expression in the different 
subgroups of MB in the same cohort. We observed that SHH, SMO and GLI3 were not 
good biomarkers of SHH MB subgroup, in contrast to PTCH1, GLI1 and GLI2, since they 
presented their highest expression levels in this subgroup of the tumor [Figure R2-4 and 
Table R2-1].  




Figure R2-4. SHH signaling pathway genes present varied expression patterns between different MB 
subgroups. Boxplot of the log2 of SHH, SMO, PTCH1, GLI1, GLI2 and GLI3 in the indicated MB subgroups in 
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Table R2-1. P-values of the differences between the indicated MB subgroups of SHH, SMO, PTCH1, GLI1, 
GLI2 and GLI3 genes’ expression in Cavalli FMG et al. 2017 cohort (n = 612). 
SHH expression 
T test WNT SHH Group 3 Group 4 
WNT - 0.56 0.20 3.0 x 10-3 
SHH 0.56 - 0.02 0.02 
Group 3 0.20 0.02 - 3.8 x 10-7 
Group 4 3.0 x 10-3 0.02 3.8 x 10-7 - 
SMO expression 
T test WNT SHH Group 3 Group 4 
WNT - 8.1 x 10-5 3.2 x 10-48 6.7 x 10-48 
SHH 8.1 x 10-5 - 4.4 x 10-58 2.1 x 1041 
Group 3 3.2 x 10-48 4.4 x 10-58 - 1.5 x 10-29 
Group 4 6.7 x 10-48 2.1 x 1041 1.5 x 10-29 - 
PTCH1 expression 
T test WNT SHH Group 3 Group 4 
WNT - 7.8 x 10-25 2.0 x 1018 3.6 x 10-17 
SHH 7.8 x 10-25 - 1.0 x 10-74 7.3 x 10-121 
Group 3 2.0 x 1018 1.0 x 10-74 - 2.3 x 10-8 
Group 4 3.6 x 10-17 7.3 x 10-121 2.3 x 10-8 - 
GLI1 expression 
T test WNT SHH Group 3 Group 4 
WNT - 9.3 x 10-50 0.23 3.9 x 10-6 
SHH 9.3 x 10-50 - 1.4 x 1091 6.0 x 10-179 
Group 3 0.23 1.4 x 1091 - 1.2 x 10-6 
Group 4 3.9 x 10-6 6.0 x 10-179 1.2 x 10-6 - 
GLI2 expression 
T test WNT SHH Group 3 Group 4 
WNT - 1.2 x 10-18 1.2 x 10-86 1.8 x 10-88 
SHH 1.2 x 10-18 - 1.4 x 10-140 2.3 x 10-201 
Group 3 1.2 x 10-86 1.4 x 10-140 - 1.6 x 10-4 
Group 4 1.8 x 10-88 2.3 x 10-201 1.6 x 10-4 - 
GLI3 expression 
T test WNT SHH Group 3 Group 4 
WNT - 0.53 1.1 x 10-50 2.3 x 10-111 
SHH 0.53 - 2.2 x 10-74 2.2 x 10-149 
Group 3 1.1 x 10-50 2.2 x 10-74 - 0.26 
Group 4 2.3 x 10-111 2.2 x 10-149 0.26 - 
 
 
By analyzing only SHH subgroup patients’ data in Cavalli FMG et al. 2017 cohort, 
we observed no statistical differences in the prognosis of MB patients between high and 
low levels of SHH, SMO and PTCH1 genes expression, with a tendency of low levels linked 
to worse prognosis [Figure R2-5]. Moreover, GLI3 gene expression did not present 
statistical significance either, but it showed the opposite tendency, since this gene’s high 
expression seem to be linked to worse prognosis [Figure R2-5]. Among the studied genes, 
only GLI1 and GLI2 showed statistical significance, but they presented opposite relations 
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with prognosis. On the one hand, GLI1 low expression levels correlated with worse 
prognosis, whilst GLI2 low expression levels correlated with better clinical outcome of the 
patients as previously observed for SOX1 [Figure R2-5].  
 
Figure R2-5. SHH signaling pathway genes correlate differentially with patients’ prognosis. Kaplan-Meier 
curves for the Cavalli FMG et al. 2017 cohort´s SHH group patients’ overall survival rates based on SHH, 
SMO, PTCH1, GLI1, GLI2 and GLI3 expressions. All results were obtained from hgserver1. 
 
Taking all these results into account, the only gene implicated in SHH signaling 
pathway that seems to be a good subgroup and prognostic biomarker is GLI2. As SOX1 
present the same expression pattern and impact on patients’ survival, it could be 
proposed as a novel prognostic and subgroup biomarker for SHH MBs.  
SOX1 seems not to be related to other SOX family members in 
MB 
As SOX1 has been described to be controlled by other SOX family members in 
GBM (Garcia et al., 2017), we wondered if SOX1 could be related to other SOX factors in 
MB. For this aim, we analyzed the correlation between SOX1 and SOX2, SOX4 and SOX9 
members, finding a statistically significant positive correlation between all of them when 
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considering all MBs [Figure R2-6.A]. However, when considering only the SHH subgroup 
(expressing higher levels of SOX1), we found that only SOX2 correlates significantly 
[Figure R2-6.B]. Furthermore, we analyzed the expression of these SOX family members 
in the different subgroups of MB, finding that SOX2 and SOX9, but not SOX4, followed the 
same pattern as SOX1 [Figure R2-6.C].  
 
Figure R2-6. SOX1 correlates positively with other SOX family members only considering all MBs. (A) 
Correlation analysis of SOX2 (p-value = 2.08 x 10-70), SOX4 (p-value = 2.71 x 10-21) and SOX9 (p-value = 2.64 
x 10-38) with SOX1 considering all MB subgroups in Cavalli FMG et al. 2017 cohort (n = 612). (B) Correlation 
analysis of SOX2 (p-value = 1.99 x 10-04), SOX4 (p-value = 0.882) and SOX9 (p-value = 0.075) with SOX1 
considering only SHH subgroup MBs in Cavalli FMG et al. 2017 cohort (n = 223). (C) Boxplot of the log2 of 
SOX2, SOX4 and SOX9 in the indicated MB subgroups in Cavalli FMG et al. 2017 cohort (n = 612). All results 
were obtained from hgserver1. 
  
 
Finally, we also investigated the role as prognostic biomarkers of the three SOX 
family members considered. First, we performed Kaplan-Meier curves considering all MB 
patients and we found that only SOX9 low levels were significantly correlated with poor 
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prognosis [Figure R2-7.A]. Moreover, when performing the same analysis only 
considering SHH MBs, none of the investigated genes presented a significant correlation 
with patients’ overall survival [Figure R2-7.B]. Thus, we concluded that SOX2, SOX4 and 
SOX9 factors seem not to be correlated with SOX1 in MB. 
 
Figure R2-7. SOX family genes correlate differentially with patients’ prognosis. (A) Kaplan-Meier curves for 
the Cavalli FMG et al. 2017 cohort patients’ overall survival rates based on SOX2, SOX4 and SOX9 
expressions. (B) Kaplan-Meier curves for the Cavalli FMG et al. 2017 cohort’s SHH subgroup patients’ overall 
survival rates based on SOX2, SOX4 and SOX9 expressions. All results were obtained from hgserver1. 
 
SOX1 knock-down inhibits cell proliferation and viability in 
vitro and tumor growth in vivo 
In order to determine the role of SOX1 in MB progression, we knocked-down SOX1 
expression in conventional DAOY, UW228 and D283Med human MB cell lines with two 
independent shRNAs. Effective inhibition of SOX1 expression was demonstrated by 
Western Blot analysis using both shSOX1 constructs (sh1 and sh5) in the three cell lines 
analyzed [Figure R2-8.A]. Functionally, to asses the proliferative capacity of MB cells, we 
performed a cell counting assay and analyzed the percentage of positivity for the PHH3 
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mitosis marker. Our results demonstrated that SOX1 silencing promotes a significant 
decrease in cell growth rates in all MB cell lines, especially for DAOY and UW228 cells 
[Figure R2-8.B]. In line with these results, PHH3 positive cell number was also diminished 
in knocked-down cells comparing with control (plKO) cells in DAOY and UW228 cell lines 
[Figure R2-8.C].  
 
Figure R2-8. SOX1 knock-down impairs MB cells proliferation in vitro. (A) Western Blot analysis of SOX1 
protein from control (plKO) and shSOX1 (sh1 and sh5) conditions in DAOY, UW228 and D283Med cells (n ≥ 
3). (B) Relative cell growth at day 5 comparing plKO with sh1 and sh5 conditions (n ≥ 3). (C) Representative 
immunofluorescence images and quantification of phospho-Histone-3 (PPH3) positive cells in sh1 and sh5 
relative to plKO DAOY and UW228 cells (n ≥ 3).   
 
Moreover, to assess cell viability, we performed an MTT assay showing a decrease 
in cell viability in DAOY, UW228 and D283Med cells with SOX1 silencing [Figure R2-9.A]. 
Furthermore, this silencing also significantly decreased the ability of colony formation in 
DAOY and UW228 cells, since we observed less formed colonies in silenced cells than in 
control (plKO) ones [Figure R2-9.B].  




Figure R2-9. SOX1 knock-down impairs MB cells’ viability and colony formation ability in vitro. (A) MTT 
studies measuring cell viability in sh1 and sh5 relative to plKO DAOY, UW228 and D283Med cells (n ≥ 3). (B) 
Representative images and quantification of formed colonies for the indicated conditions in DAOY and 
UW228 cells (n ≥ 3).  
 
Finally, we determined whether SOX1 regulates tumor growth in vivo. For this aim, 
we injected subcutaneously control and silenced cells in immunocompromised mice. 
Strikingly, a significant decrease in tumor growth in shSOX1 DAOY [Figure R2-10.A] and 
D283Med cells was observed [Figure R2-10.B]. In line with these results, the weight of 
tumors generated from SOX1 knocked-down DAOY cells was smaller than controls [Figure 
R2-10.C]. It is worth to note that SOX1 silenced D283Med cells formed very few tumors, 
demonstrating the essential role of SOX1 for tumor initiation [Figure R2-10.B]. Altogether, 
these results point out that SOX1 is required for MB progression.  




Figure R2-10. SOX1 knock-down impairs tumor initiation and progression in vivo. Tumor volumes generated 
after subcutaneous injection in nude mice of (A) DAOY and (B) D283Med plKO, sh1 and sh5 cells (n = 8) at 
the indicated time-points are represented. (C) Image and quantification of the weight of the generated 
tumors by DAOY cells. 
 
SOX1 overexpression enhances cell proliferation  
To further investigate the role of SOX1 in MB, we enhanced its expression by 
lentiviral infections in DAOY (high basal SOX1 levels) and D283Med (low basal SOX1 
levels). First, we verified the correct overexpression of this transcription factor by 
Western Blot analysis, observing higher levels in the overexpression condition (SOX1) 
than in the control one (GFP) [Figure R2-11.A]. Functionally, we performed a cell counting 
assay to analyze the proliferative capacity of these cells, observing a slight increase in cell 
proliferation in D283Med cells that was not so clear in DAOY cells [Figure R2-11.B]. 




Figure R2-11. SOX1 upregulation promotes a slight increase in MB cell proliferation. (A) Western Blot 
analysis and protein quantification of SOX1 protein form control (GFP) and SOX1 overexpression conditions 
in DAOY and D283Med cells (n ≥ 3). Cell number and relative cell growth at day 5 comparing GFP with SOX1 
condition in (B) DAOY and (C) D283Med cells (n ≥ 3).  
 
Moreover, we analyzed the positivity for PHH3 (mitosis marker) and KI67 
(proliferation marker) in our cell models. In line with the previous cell count results, these 
experiments demonstrated that SOX1 overexpression promotes a slight increase in PHH3 
and KI67 positive cell number in D283Med cells, but not in DAOY cells [Figure R2-12.A-B]. 
Thus, it seems that SOX1 overexpression is only presenting a phenotype in SOX1 low 
expressing cells (D283Med), where it may be expected the overexpression to have a 
stronger impact compared to cells presenting high basal levels of SOX1, such as in DAOY 



































































































































Figure R2-12. SOX1 overexpression promotes cell proliferation only in D283Med cells. (A) Representative 
immunofluorescence images and quantification of PPH3 positive cells in SOX1 relative to GFP DAOY and 
D283Med cells (n ≥ 3). (B) Representative immunofluorescence images and quantification of KI67 positive 
cells in SOX1 relative to GFP DAOY and D283Med cells (n ≥ 3).  
 
MBSCs express high levels of SOX1 and its knock-down inhibits 
MBSCs activity 
To directly explore the role of SOX1 in MBSCs activity, we first investigated the 
expression of NESTIN, PML, ERBB4 and CD133 stem cell markers, and p27KIP 
differentiation marker, in shSOX1 DAOY cells. RT-qPCR results showed a decrease in stem 
cell markers’ expression in SOX1 knocked-down cells [Figure R2-13.A], while Western Blot 
analysis showed an increase in the levels of p27KIP differentiation marker[Figure R2-13.B].  




Figure R2-13. SOX1 knock-down decreases stem cell markers’ expression but augments differentiation 
marker levels. (A) mRNA levels of the indicated stem cell markers in plKO, sh1 and sh5 DAOY cells (n ≥ 3). 
(B) Western Blot analysis and quantification of p27KIP protein from plKO, sh1 and sh5 DAOY cell extracts (n 
≥ 3).  
 
To further investigate the role of SOX1 in MBSCs, we cultured the two 
conventional DAOY and UW228 MB cell lines in different conditions:as adherent 
monolayer in the presence of serum or in stem cell specific media, to obtain oncospheres. 
Interestingly, the oncospheres derived from both MB cell lines expressed higher levels of 
SOX1 compared to those cultured in the presence of serum [Figure R2-14.A]. In addition, 
to investigate the role of SOX1 in MBSCs function, we counted the oncospheres formed 
after culturing SOX1 knocked-down DAOY, UW228 and D283Med cells in the presence of 
stem cell medium. This experiment showed a marked decrease in the ability of forming 
oncospheres in these three cell lines when knocking-down SOX1 [Figure R2-14.B]. 
Altogether, these results suggest that SOX1 have a role in the maintenance of MBSCs.  




Figure R2-14. SOX1 expression is upregulated in MBSCs. (A) SOX1 mRNA expression levels of DAOY and 
UW228 cells grown in serum (DAOY or UW228) or in stem cell media as oncospheres (1ry) (n ≥ 3). (B) 
Representative images and quantification of the oncospheres formed from plKO, sh1 and sh5 conditions in 
the indicated cell lines.  
 
Next, we moved to in vivo experiments in order to assess the tumor cells’ initiation 
capacity. For this aim, we injected limited dilution concentrations of knocked-down SOX1 
cells subcutaneously in immunocompromised mice and then we counted the number of 
tumors formed with DAOY [Figure R2-15.A] and D283Med [Figure R2-15.B] cells. 
Strikingly, the frequency of tumor initiating cells necessary to form the tumor was higher 
in shSOX1 cells than in controls, both in DAOY [Figure R2-15.C] and D283Med [Figure R2-
15.D] cell lines. Strikingly, the frequency of tumor initiation in DAOY cells was 1 in 475,710 
and 1 in 946,994 in sh2 and sh3 cells, respectively, compared to 1 in 99,524 in the control 
cells [Figure R1-14.A,C]. Moreover, the tumor initiation in D283Med cells was 1 in 
1,649,864 and infinite in sh2 and sh3 cells, respectively, compared to 1 in 441,838 in the 
empty vector harboring cells [Figure R1-14.B,D]. The statistical differences in stem cells 
frequencies between plKO and sh1 was p-value = 1 for DAOY and p-value = 0.000123 for 
D283Med cells, and between plKO and sh5 was p-value = 0.00074 for DAOY and p-value 
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= 0.0140 for D283Med cells. All these results confirm that SOX1 inhibition limits tumor 
initiation, revealing an essential role of this transcription factor in MBSCs activity.  
 
Figure R2-15. SOX1 regulates MBSCs activity. Number of tumors formed in the indicated conditions after 
subcutaneous injection in nude mice of (A) 1 x 106 and 1 x 105 DAOY and (B) 5 x 105 and 5 x 104 D283Med 
cells. Frequency of tumor initiation of the indicated conditions in (C) DAOY and (D) D283Med cells, 
measured using ELDA platform, is also shown.  
 
SOX1 knock-down alters cell response, motility and cellular 
morphogenesis-related pathways 
Finally, to investigate which pathways could be underlying the phenotype 
observed when knocking-down SOX1, transcriptomic analysis of plKO, sh1 and sh5 DAOY 
cells was performed. In sh1 condition, 560 upregulated and 586 downregulated genes 
were found when compared to plKO control condition. Regarding sh5 cells, 89 
upregulated and 221 downregulated genes were found after comparing with control 
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cells. All these genes presented a p-value lower than 0.05 and a fold-change higher than 
2. The gene enrichment analysis was performed with each shRNA gene list separately, 
using the GO sets and considering the biological processes. The results show a 
downregulation of genes involved in cell response and motility in both sh1 [Figure R2-
16.A] and sh5 [Figure R2-16.B] conditions. On the contrary, an increase in genes 
implicated in cellular morphogenesis was observed in sh1 [Figure R2-17.A] and sh5 
[Figure R2-17.B] cells.  




Figure R2-16. SOX1 knock-down downregulates cell response and motility pathways of DAOY cells. 
Downregulated pathways in (A) sh1 and (B) sh5 DAOY cells compared with plKO cells when performing a 
GO gene sets biological processes analysis from Clariom S microarray results. The p-value and the 
percentage of genes dysregulated in each pathway is represented in all figures.  
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Figure R2-17. SOX1 knock-down upregulates morphogenesis pathway of DAOY cells. Upregulated pathways 
in (A) sh1 and (B) sh5 DAOY cells compared with plKO cells when performing a GO gene sets biological 
processes analysis from Clariom S microarray results. The p-value and the percentage of genes dysregulated 
in each pathway is represented in all figures.  
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We validated some of the genes already linked to MB or cancer based on the 
literature, such as Interleukin 6 (IL6) (Chen et al., 2018), VCAM1 (Liang et al., 2015), CEA 
cell adhesion molecule 1 (CEACAM1) (Kelleher et al., 2019), Insulin like growth factor 
binding protein 3 (IGFBP3) (Svalina et al., 2016), Superoxide dismutase 2 (SOD2) (John et 
al., 2009) and Semaphorin 5A (SEMA5A) (Saxena et al., 2018b). We found by RT-qPCR 
analysis that all these genes diminished their expression when SOX1 was knocked-down 
[Figure R2-18].  
 
Figure R2-18. SOX1 downregulates several genes expression. mRNA levels of downregulated genes in plKO 
and shSOX1 DAOY cells (n ≥ 3).  
 
To further characterize the impact of the validated genes, we moved to clinical 
samples and completed a correlation study between SOX1 and the candidate genes’ 
expression in the Cavalli FMG et al. 2017 cohort, considering both all patients data [Figure 
R2-19.A] and SHH MB patients’ data [Figure R2-19.B]. When analyzing all MB patients, we 
found a statistically significant and positive correlation between VCAM1, CEACAM1 and 
SEMA5A, and SOX1 expression [Figure R2-19.A], reinforcing the link between SOX1 and 
these genes. However, a negative correlation between SOD2 and SOX1 expression was 
found [Figure R2-19.A]. In addition, when analyzing only the SHH group MB patients’ data, 
only VCAM1 presented a statistically significant but negative correlation with SOX1 
[Figure R2-19.B], a not expected result. Therefore, the gene expression correlation 
analyses here performed in MB patients follow a varied pattern depending on the MB 
subgroup and the particular gene considered, with no clear trends.  




Figure R2-19. Impact of validated genes identified aster transcriptomic analysis in MB clinical samples. 
Correlation analysis of the validated genes expression with SOX1 expression taking into account (A) all MBs 
data (IL6 p-value = 0.450, VCAM1 p-value = 6.77 x 10-6, CEACAM1 p-value = 5.47 x 10-7, IGFBP3 p-value = 
0.562, SOD2 p-value = 7.13 x 10-18 and SEMA5A p-value = 3.73 x 10-5) and (B) SHH MBs data (IL6 p-value = 
0.073, VCAM1 p-value = 1.56 x 10-3, CEACAM1 p-value = 0.882, IGFBP3 p-value = 0.153, SOD2 p-value = 
0.383 and SEMA5A p-value = 0.608) from Cavalli FMG et al. 2017 cohorts’ data. All results were obtained 
from hgserver1. 
 
Moreover, we analyzed the expression level of the validated genesin the different 
MB subgroups, taking advantage of the same cohort information. Our results showed 
that VCAM1, CEACAM1 and SEMA5A genes are the ones with higher expression in the 
SHH subgroup MBs compared to the other subgroups [Figure R2-20], following similar 
patterns as SOX1, PTCH1, GLI1 and GLI2 genes. Thus, VCAM1, CEACAM1 and SEMA5A 
genes might be also good SHH MBs biomarkers.  




Figure R2-20. Impact of validated genes’ expression in the MB clinical samples. Boxplot of the log2 of the 
indicated genes in the different MB subgroups in Cavalli FMG et al. 2017 cohort (n = 612). All results were 
obtained from hgserver1.  
 
Finally, we studied the validated genes’ expressions’ correlation with patients’ 
outcome, finding that IL6 and SOD2 high expression levels were significantly correlated 
with poor prognosis when analyzing all MBs [Figure R2-21.A]. When repeating the same 
analysis with SHH subgroup data, IL6 high expression levels appeared to be statistically 
correlated with poor prognosis, whereas VCAM1 high expression levels did so with a 
better prognosis status [Figure R2-21.B]. Therefore, IL6 is the only gene that follows the 
same pattern as SOX1 both in all MBs and in the SHH subgroup, which postulates IL6 gene 
expression as a prognosis biomarker candidate in MB. 
 




Figure R2-21. Impact of validated genes in MB patients’ survival. Kaplan–Meier curves for the Cavalli FMG 
et al. 2017 cohort’s (A) all patients’ and (B) SHH subgroup patients’ overall survival rates based on the levels 
of validated genes obtained in the microarray analysis (p-values are indicated in each graph). All results 
were obtained from hgserver1. 
 



















SOX1 presents an oncogenic activity in glioblastoma 
High SOX1 expression levels are associated with poor clinical 
outcome in glioblastoma 
To assess the impact of SOX1 in GBM, we analyzed its expression in human brain 
tumor biopsies. First, we compared the expression of SOX1 between human low-grade 
gliomas (LGG) and healthy brain samples. The results obtained from The Cancer Genome 
Atlas (TCGA) (Brennan et al., 2013) publicly available datasets showed no differences 
between the two groups [Figure R3-1.A]. Next, we investigated SOX1 levels in a small 
GBM cohort derived from Donostia University Hospital. SOX1 expression in the analyzed 
tumor biopsies varied between 0.12 and 133 fold change when compared to healthy or 
normal brain tissue. Interestingly, 18 out of 26 tumors (69.2 %) showed higher levels of 
SOX1 with a fold-change greater than 1.5 [Figure R3-1.B]. Afterwards, we studied SOX1 
expression in the GBM data from the TCGA cohort and found , even if SOX1 levels were 
also highly heterogeneous within the different samples, that GBM presented lower SOX1 
levels than normal brain [Figure R3-1.C]. However, when we explored the relation 
between SOX1 expression levels and clinical characteristics of the patients in the TCGA 
cohort, we found that high SOX1 expression levels were associated with patients’ shorter 
overall survival (p-value = 0.02) [Figure R3-1.D]. Altogether, these results show that SOX1 
expression levels are elevated in a subset of GBM samples and that its expression could 
be a prognostic biomarker. 




Figure R3-1. High levels of SOX1 are associated to poor clinical outcome in GBM. (A) Boxplot of the SOX1 
fragments per kilobase of exon model per million reads mapped (FPKM) log2 of LGG vs normal healthy 
brain samples in the TCGA cohort. Wilcoxon test, p-value = 0.17. (B) SOX1 mRNA expression levels in GBM 
samples and normal or healthy brain samples from Donostia University Hospital cohort. (C) Boxplot of the 
log2 of the SOX1 FPKM of GBM vs normal or healthy brain samples in TCGA cohort. The number of available 
RNAseq samples for GBM is smaller than for LGG. Wilcoxon test, p-value = 0.068. (D) Kaplan-Meier curves 
for the TCGA cohort’s patients’ overall survival rates based on SOX1 expression obtained from cbioportal. 
LogRank test, p-value = 0.02.  
 
SOX2 regulates SOX1 expression in glioblastoma 
Since SOX1 is down-regulated in SOX2-silenced LN229 glioma cells according to a 
transcriptomic study (Fang et al., 2011), and as SOX2 activity modulates proliferation and 
self-renewal in glioma stem cells (Garros-Regulez et al., 2016a), we investigated whether 
the expression of SOX1 was regulated by SOX2 in GBM. Interestingly, we found that SOX2 
silencing by an shRNA (shSOX2) in U251 glioma cells (which present high endogenous 
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levels of SOX2, Garros-Regulez et al., 2016a) displayed lower SOX1 expression than 
control cells (with normal levels of SOX2) [Figure R3-2.A-B]. In line with this, SOX2 ectopic 
overexpression in U87 glioma cells (with low endogenous SOX2 levels) led to a significant 
increase in SOX1 expression [Figure R3-2.A-B]. To further study this putative correlation 
between SOX2 and SOX1, we moved to clinical biopsies and analyzed the expression of 
both transcription factors in the GBM samples from the Donostia University Hospital 
cohort. Interestingly, the correlation analysis showed a significant association between 
SOX2 and SOX1 expression in the GBM samples [Figure R3-2.C]. Indeed, we found that 60 
% of the cohort’s biopsies presenting SOX2 overexpression also showed high levels of 
SOX1, whilst all of the biopsies presenting moderate or low SOX2 levels also had low SOX1 
levels. Altogether, these results indicate a positive relationship between SOX2 and SOX1, 
and their belonging to the same signaling pathway.  
 
 
Figure R3-2. SOX1 correlates with SOX2 in GBM. (A) Western Blot analysis of SOX2 protein expression in 
U87 cells transduced with ectopic SOX2 and U251 cells infected with shSOX2. (B) SOX1 mRNA expression 
levels in the indicated GBM cell lines relative to control cells (n ≥ 3). (C) Correlation analysis of SOX2 and 
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SOX1 is enriched in GSCs population 
With the aim of investigating the role of SOX1 in GSCs population, we cultured 
several conventional glioma cell lines as adherent monolayers in the presence of serum 
(adherent), and as oncospheres in stem cell specific media. First, we analyzed SOX1 
expression levels in the different adherent cell lines. We found high levels of SOX1 in U251 
and U373 cells, and low levels in U87, A172 and T98 cells [Figure R3-3.A]. Afterwards, we 
confirmed that the oncospheres cultured in stem cell specific media expressed higher 
levels of stem cell markers (SOX2, CD133 and OCT4) [Figure R3-3.B-D], which 
demonstrates an enrichment of stemness activity in parental cells cultured as 
oncospheres. Interestingly, oncospheres derived from all five glioma cell lines presented 
also higher levels of SOX1 comparing with the adherent cells [Figure R3-3.E]. It should be 
noted that in line with their enhanced tumor-propagating activity, these oncospheres are 
known to be associated with larger and faster-growing tumors formation (Garros-Regulez 
et al., 2016a). 




Figure R3-3. SOX1 is enriched in GSCs population. (A) SOX1 mRNA levels in the indicated glioma cell lines 
showing different expression levels among them (n ≥ 3). (B) SOX2, (C) CD133 and (D) OCT4 stem cell markers 
together with (E) SOX1 mRNA levels in the indicated glioma cells cultured in stem cell specific media 
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To further characterize SOX1 expression in GSCs, we investigated this gene in 
primary GSCs derived from human patients. These cells constitute a more similar, and 
hence relevant, model to the clinical setting. First, we studied SOX1 expression levels in 
four independent patient-derived GSC cultures. Our results demonstrated markedly 
higher SOX1 levels in GSCs compared to the conventional glioma cell lines [Figure R3-4.A]. 
Next, we investigated the difference in SOX1 expression in the GSCs population when we 
differentiated our four GSCs primary cultures by removing the EGF and b-FGF2 growth 
factors, and by adding serum. Our results showed that SOX1 levels were dramatically 
decreased, by 70 %, in all four differentiated cell lines compared with GSCs cultured in 
basal conditions [Figure R3-4.B]. Similar results were observed in SOX2, CD133 and OCT4 
stem cell markers [Figure R3-4.C-D], where their expression was significantly decreased 
when these cells were differentiated. These results demonstrate that SOX1 levels are 
highly enriched in the GSCs population and also that high SOX1 expression correlates with 
the glioma cell undifferentiated condition. 




Figure R3-4. SOX1 is enriched in GSCs population. (A) SOX1 mRNA levels in U87 and U251 glioma 
conventional cell lines, and four patient derived GSC lines. SOX1 expression is represented relative to the 
U87 cell line (n ≥ 3). (B) SOX1 mRNA levels in four GSC lines cultured in stem cell media (control) compared 
to differentiated cell lines (diff) (n ≥ 2). mRNA levels of the indicated stem cell markers grown in stem cell 
media (control) and differentiation conditions (diff) in (C) GNS and (D) GB cells (n ≥ 2).  
 
SOX1 knock-down inhibits GSC activity 
To directly and specifically explore the SOX1 role in GSCs activity, we knocked-
down SOX1 expression in a patient-derived cell line (GNS166) using two independent 
shRNAs. First, we demonstrated an effective inhibition of SOX1 when using both shRNAs 
constructs (sh1 and sh5) by RT-qPCR [Figure R3-5.A]. Functionally, the silencing of this 
transcription factor promoted a significant decrease of more than 2-fold in cell growth 
rates [Figure R3-5.B]. Afterwards, we performed MTT studies in order to analyze cell 
viability. In line with the previous results, MTT studies showed a diminished cell viability 
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rate in SOX1 silenced GNS166 cells [Figure R3-5.C]. The observed phenotypes correlated 
also with a diminishment in the number of PHH3 positive cells [Figure R3-5.D]. 
Specifically, the percentage of proliferating cells decreased in more than 70 % in the sh1 
and sh5 conditions comparing with control condition [Figure R3-5.D].  
 
Figure R3-5. SOX1 knock-down impairs GSCs proliferation and viability. (A) SOX1 mRNA levels in control 
(plKO) and shSOX1 (sh1 and sh5) GNS166 cells (n ≥ 2). (B) Relative cell growth at day 5 comparing plKO and 
shSOX1 conditions in GNS166 cells (n = 3). (C) Cell viability assessment by MTT in shSOX1 relative to plKO 
GNS166 cells (n = 3). (D) Representative images and quantification of the PHH3 positive cells in plKO and 
shSOX1 conditions in GNS166 cells (n = 3). 
 
To further determine SOX1 impact on GSCs’ self-renewal regulation ability, we 
first measured the mRNA expression of several stem cell and differentiation markers in 
our SOX1 silenced GSC model. Notably, we observed a reduction in the NESTIN, SOX2, 
SOX9 and PML stem cell markers [Figure R3-6.A]. Concomitantly, we observed an increase 
in GFAP and p27KIP expression levels, a differentiation marker and a cell cycle inhibitor, 
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respectively [Figure R3-6.B]. Altogether, these results point out that SOX1 plays a relevant 
role in GSC plasticity, by regulating the stemness-differentiation dichotomy. 
 
Figure R3-6. SOX1 knock-down reduces stemness and induces differentiation. (A) mRNA levels of the 
indicated stem cell markers in sh1 and sh5 GNS166 cells relative to control (plKO) GNS166 cells’ expression 
(n ≥ 2). (B) GFAP and p27KIP mRNA levels in the indicated experimental conditions (n ≥ 2).  
 
The gold standard method to determine the presence of GSCs is to analyze the 
capacity of the original patient’s tumor to replicate that tumor in vivo when it is 
orthotopically transplanted in immunocopromised mice(Lathia et al., 2015). Therefore, 
plKO and sh1 GNS166 cells were injected intracranially in NOD-SCID mice. Interestingly, 
SOX1 silencing significantly delayed GNS166 cells’ tumor formation capacity [Figure R3-
7]. Thus, our results demonstrated that the median survival for mice injected with plKO 
cells was lower than for the mice injected with sh1 cells [Figure R3-7]. Specifically, mice 
injected with plKO cells presented a median survival of 27 weeks, whereas mice injected 
with sh1 cells survived a median of 42 weeks (an increment of about 50 %). Taken 
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together, these results show that SOX1 regulates GSCs self-renewal and their tumorigenic 
activity. 
 
Figure R3-7. SOX1 knock-down reduces tumor growth in vivo. Kaplan-Meier curve representing survival of 
NOD-SCID mice that were xenotransplantated with plKO (n = 9) and sh1 (n = 4) GNS166 cells.  
 
SOX1 knock-down inhibits U251 glioma cells-related tumor 
initiation and progression in vitro and in vivo 
In order to determine whether the mechanism by which SOX1 regulates GBM cell 
proliferation and tumor growth is GSC-specific or broader, we knocked-down SOX1 
expression in the parental U251 cell line. Western blot analysis demonstrated an effective 
inhibition of SOX1 at protein level [Figure R3-8.A]. Tumor-initiation ability, measured by 
limiting dilution injections, and oncosphere formation assays functionally defines self-
renewal capacity of CSCs in vivo and in vitro respectively (Clevers CSCs premises). 
Therefore, we tested if SOX1 silencing could regulate tumor initiation ability in vivo by 
performing subcutaneous inoculations of serial dilutions of U251 cells transduced with 
empty vector or both shSOX1 constructs (sh1 and sh5) in immunocompromised mice. In 
addition, we performed oncosphere formation assays in order to assess self-renewal 
ability in vitro. The limited dilution assay demonstrated that the frequency of tumor 
initiation was 1/1,050,263 in sh1 and 1/6,359,439 sh5 cells compared to 1/108,183 in the 
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control cells [Figure R3-8.B]. In line with these results, SOX1 silencing markedly decreased 
the U251 cells ability to generate oncospheres [Figure R3-8.C]. Furthermore, at molecular 
level, SOX1 silencing in U251 cells decreased PML and SOX2 expression [Figure R3-8.D] 
and up-regulated p27KIP levels [Figure R3-8.D]. These results imitate the phenotype 
obtained in the GSCs performed experiments and further reinforce the robust effect that 
SOX1 silencing displays on blocking self-renewal and tumor initiation capacity of glioma 
cells. 
 
Figure R3-8. SOX1 knock-down reduces tumor initiation and self-renewal ability in U251 cells in vivo and in 
vitro. (A) Representative Western Blot image of SOX1 protein expression in U251 cells infected with plKO 
or sh1 (n = 3). (B) Tumor initiation frequency after subcutaneous injection in nude mice of 5 x 104 and 5 x 
104 U251 cells infected with plKO, sh1 and sh5. The incidence of tumor initiation was measured using ELDA 
platform. (C) Quantification of the oncospheres formed in the indicated conditions (n = 3). (D) mRNA levels 
of the indicated genes in sh1 U251 cells relative to plKO cells (n = 3). 
 
We went feeper and further evaluated the effect of SOX1 silencing U251 glioma 
cells. First, we performed cell counting experiments that revealed a significant reduction 
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of more than 70 % in cell growth rates in SOX1-silenced U251 cells [Figure R3-9A]. 
Moreover, when analyzing the number of PHH3 positive cells, we detected a reduction 
of the positivity by a mean of 90 % and 50 % in the case of sh1 and sh5, respectively. This 
indicates that cell proliferation is dramatically impaired when SOX1 expression was down-
regulated [Figure R3-9B].  
 
 
Figure R3-9. SOX1 knock-down reduces proliferation of U251 cells in vitro. (A) Relative cell growth at day 5 
comparing plKO with sh1 and sh5 U251 cells (n = 3). (B) Quantification of PPH3 positive sh1 and sh5 U251 
cells relative to plKO U251 cells (n = 3).  
 
Moreover, we investigated the effect of SOX1 silencing in vivo. When injecting 
subcutaneously plKO and both shSOX1 (sh1 and sh5) U251 cells in immunocompromised 
mice, we observed a significant decrease in shSOX1 cells tumor growth [Figure R3-10.A]. 
Indeed, both shSOX1 U251 cells formed subcutaneous tumors reaching less than 75  mm3 
in 40 days after injection, while control  tumors grew to an average of 550  mm3 in the 
same period of time [Figure R3-10.A]. Moreover, the tumors formed from sh1 and sh5 
U251 cells present a significantly lower weight [Figure R3-10.B]. 




Figure R3-10. SOX1 knock-down reduces tumor progression of U251 cells in vivo. (A) Tumorvolume after 
subcutaneous injection of plKO, sh1 and sh5 U251 cells at the indicated time points (n = 12). (B) Picture and 
average weight of the tumors generated in A. 
 
To further characterize the impact of SOX1 silencing at molecular level in vivo, we 
performed immunohistochemistry analysis in the tumors generated after subcutaneous 
injection in order to corroborate the impaired tumorigenic ability. Indeed, sh1 and sh5 
U251 cells derived xenografts displayed lower number of SOX1, KI67, SOX2 and PML 
positive cells than those derived from control cells [Figure R3-11].  
 
Figure R3-11. SOX1 knock-down reduces tumorigenic ability of U251 cells in vivo. Representative images of 
the immunohistochemical staining of KI67, SOX1, SOX2 and PML in tumors generated in figure R3-10.A. 
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In summary, SOX1 genetic silencing induces a strong tumor suppressor phenotype 
in glioma cells by impairing self-renewal, proliferation, tumor initiation and progression 
capacity of both glioma cells and GSCs. 
SOX1 activity is not mediated by WNT/β-catenin signaling 
pathway in glioblastoma 
Since SOX1 has been described as tumor suppressor in different cancer types 
through the Wnt/β-catenin signaling pathway (Guan et al., 2014; Tsao et al., 2012), we 
examined the activity of different proteins belonging to this pathway after SOX1 silencing 
in glioma cells and GSCs. CTNNB1, also known as β-catenin, immunofluorescence and 
immunohistochemistry analysis did not show any clear differences between plKO and 
shSOX1 U251 cells nor in its expression neither in its nuclear translocation, neither in vitro 
nor in vivo [Figure R3-12.A-B]. Moreover, we analyzed the expression levels of β-catenin 
and MYC, a well-established β-catenin downstream target (Santos et al., 2016), by RT-
qPCR in SOX1-silenced GNS166 cells, but we did not observe any significant modification 
in their expression [Figure R3-12.C]. To pursue the association between SOX1 and β-
catenin, we turned to human GBM biopsies. The results at cellular level were confirmed 
in the datasets of TCGA cohort, where the correlation analysis did not find any association 
between SOX1 and β-catenin or MYC expression levels [Figure R3-12.D]. These results 
suggest that SOX1 oncogenic activity is not mediated by β-catenin signaling pathway in 
both GBM cells and clinical samples. 
We also studied the expression of CYCLIN D1, also known as CCND1, an additional 
β-catenin downstream target (Santos et al., 2016). In this case, shSOX1 GNS166 cells 
presented diminished levels of CYCLIN D1 [Figure R3-12.C], and interestingly, its 
expression was significantly correlated to SOX1 in the TCGA datasets (p-value < 0.005) 
[Figure R3-12.D]. These results postulate CYCLIN D1 as a putative mediator of SOX1 
activity in GBM. 




Figure R3-12. SOX1 activity is not mediated by the WNT signaling pathway in GBM. (A) Representative 
images of CTNNB1 immunofluorescence staining in U251 plKO and sh1 cells (n = 4). (B) Representative 
images of CTNNB1 immunohistochemical staining in U251 plKO, sh1 and sh5 derived subcutaneous tumors 
(n = 4). (C) mRNA levels of CTNNB1, CCND1 (CYCLIN D1) and MYC in GNS166 plKO and sh1 cells (n ≥ 2). (D) 
Scatter plot of log2 of the fragments per kilobase of exon model per million reads mapped (FPKM) of 
CTNNB1, MYC and CCND1 vs SOX1 expression. In the x-axis, the correlation and its statistical significance 
are included.  
 
Ectopic SOX1 overexpression could promote GSCs 
proliferation and self-renewal 
Finally, we introduced a construct encoding SOX1 gene sequence in GNS166 cells 
in order to overexpress this gene. We confirmed this overexpression by Western blot 
analysis and RT-qPCR [Figure R3-13.A-B]. First, we analyzed whether SOX1 overexpression 
modifies the expression of different stem cell and differentiation markers. In this context, 
we found that SOX1 overexpression slightly increased SOX2 and PML stem cell markers 
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expression [Figure R3-13.A-B], whilst decreased GFAP, CNPase and p27KIP differentiation 
markers’ levels [Figure R3-13.C].  
 
Figure R3-13. SOX1 overexpression augments stem cell markers’ expression and diminished differentiation 
markers expression. (A) Western Blot analysis of SOX1 and SOX2 proteins in GNS166 cells transduced with 
ectopic SOX1 (n = 3). (B) mRNA levels of the indicated stem cell markers in GNS166 cells transduced with 
SOX1 relative to control (GFP) expression (n ≥ 3). (C) mRNA levels of the indicated differentiation markers 
in the same cells (n ≥ 3). 
  
Phenotypically, cells with SOX1 overexpression exhibited moderately higher cell 
growth curves [Figure R3-14.A] and proliferation rates compared to control cells, since 
they present a higher percentage of PHH3 positive cells [Figure R3-14.B]. Altogether, 
these data reveal that SOX1 activity is not only necessary for the maintenance but might 
also promote proliferative and self-renewal activity in GSCs. 
 




Figure R3-14. SOX1 overexpression augments GSCs proliferation capacity. (A) Relative cell growth at day 5 
comparing control (GFP) to SOX1 overexpressing GNS166 cells (n = 6). (B) Representative images and 
quantification of PHH3 positive cells in SOX1 overexpressing GNS166 cells compared to control (GFP) 







































The complete development of the cerebellum occurs postnatally and it is a well-
regulated process by different signaling pathways (Leto et al., 2016), where cerebellar 
granule cell progenitors (CGNPs) undergo a rapid proliferation stage followed by a 
differentiation and migration one (Komuro and Rakic, 1998; Kuhar et al., 1993). When a 
dysregulation of this process occurs and CGNPs continue proliferating, MB tumor can be 
generated (Grimmer and Weiss, 2006; Marino, 2005; Northcott et al., 2019). This is the 
most common solid tumor in childhood (Bartlett et al., 2013). Even if 70 % of the patients 
survive, treatments used nowadays generate incurable side effects (Musial-Bright et al., 
2011; Saury and Emanuelson, 2011). Regarding adulthood brain tumors, GBM is the most 
common and aggressive brain tumor (Ostrom et al., 2014). It presents a very low survival 
rate (Stupp et al., 2009). For both tumors, the current therapy is ineffective. One of the 
reasons to explain the failure of current treatments could be the existence of the CSCs, 
whose presence has been demonstrated in MB and GBM (Galli et al., 2004; Singh et al., 
2003; Singh et al., 2004b). These cells are the responsible of treatment resistance and 
tumor recurrence, since they can stay in a quiescent stage for long periods, thus evading 
therapies targeting proliferative cells (Recasens and Munoz, 2019). Considering all this 
information, it seems clear the necessity of finding new therapies for these tumors’ 
treatment, and that targeting CSCs is the most successful strategy. 
For this aim we considered ERBB4 and SOX1 genes. On the one hand, ERBB4 is a 
tyrosine kinase receptor implicated in embryonic development (Segers et al., 2020; 
Tidcombe et al., 2003) and described to play a role in cerebellum development (Pinkas-
Kramarski et al., 1997; Vullhorst et al., 2009). On the other hand, SOX1 is a transcription 
factor also implicated in early development (Aubert et al., 2003; Kan et al., 2004; Pevny 
et al., 1998; Venere et al., 2012). Moreover, both of them have been related to different 
types of cancer (Guan et al., 2014; Hyman et al., 2018; Hynes and Lane, 2005; Lin et al., 
2013; Muraoka-Cook et al., 2008; Naresh et al., 2006; Su et al., 2009; Tsao et al., 2012; 
Vermeulen et al., 2016), acting as tumor suppressors or oncogenes. Moreover, they have 
been correlated to stemness and proliferative capacity (Birchmeier, 2009; Williams et al., 
2015; Wright et al., 2008). Thus, we hypothesize that ERBB4 and SOX1 could, on the one 
hand, play an essential role in cerebellum development and, on the other hand, in the 
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development and maintenance of MB and GBM tumors and cancer stem cells activity. 
We specifically hypothesize that ERBB4 and SOX1 could play an oncogenic role in MB, and 
that SOX1 also could be is implicated in the carcinogenesis of GBM. Moreover, this implies 
that they are implicated in CSCs proliferation and self-renewal capacity, thus contributing 
to therapy resistance.  
My thesis results demonstrate that ErbB4 has an important role in cerebellum 
development, by governing and maintaining CGNPs’ proliferation and migration. 
Moreover, we demonstrated that both SOX1 and ERBB4 are enriched in the CSC pool and 
that their silencing decreases the proliferative and self-renewal capacity of both 
differentiated and stem-like cells. In addition, we found that ERBB4 is overexpressed 
specifically in Group 4 MBs and that SOX1 presents higher expression levels in SHH MBs. 
Finally, we have showed also that both genes high expression is related to poor patients’ 
survival. Specially, GBM overexpressing SOX1 are related to poor clinical outcome. 
Considering all these results, we suggest ERBB4 and SOX1 as new prognostic biomarkers 








1. ERBB4 is required for cerebellar development and 
medulloblastoma malignant phenotype  
As mentioned before, cerebellum development is a postnatal process, well 
regulated by different signaling pathways that direct embryonic developmental 
processes (Leto et al., 2016). If deregulated, these pathways can let to MB formation and 
progression (Dey et al., 2012; Grimmer and Weiss, 2006; Zurawel et al., 1998).  
ERBB4 is a tyrosine kinase membrane receptor essential for the normal neural 
development and maintenance and involved in cell migration control (Fornasari et al., 
2016; Mei and Xiong, 2008; Ortega et al., 2012). Indeed, its genetic deletion leads to 
neurodevelopmental deficits affecting neuronal migration in multiple brain structures, 
from the cortex to the cerebellum (Perez-Garcia, 2015).  
Considering all these evidences, we hypothesize that ErbB4 could be considered 
as a key player in neural progenitors’ and cerebellum development regulation and MB 
formation. 
 
1.1. ErbB4 directs CGNPs migration during cerebellar 
development 
In this thesis we firstly wanted to assess the role of ErbB4 in cerebellar 
development. It has been described that both CGNPs and radial fiber express ErbB4 in 
vitro and in vivo (Rio et al., 1997). To investigate the role of this receptor in the 
cerebellum, we first investigated ErbB4 expression in wt mice cerebella. Our analyses 
indicate that ErbB4 and its active form, P-ErbB4, are expressed in the EGL of the 
developing cerebellum, the proliferative layer of the cerebellum (Fujita, 1967). This may 
lead us to think that this membrane receptor is involved in the CGNPs proliferative 
capacity. Moreover, we took advantage of ErbB4 KO mice to investigate the cerebellar 
structure and different cell types’ localization, finding an aberrant cerebellum 
development. As previous works have also demonstrated (Perez-Garcia, 2015), we found 
that migration of CGNPs was defective. First, we observed ectopic cell clusters in the EGL, 
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differentiated into neurons, since they expressed NeuN neuronal marker (Mullen et al., 
1992). In a normal cerebellum development, these cells must be located in the IGL. Thus, 
we concluded that ErbB4 is not guiding CGNPs differentiation process. Same results were 
obtained by Perez-García (Perez-Garcia, 2015). Second, we observed GFAP-positive radial 
fibers misalignment, a starting point from where CGNPs migrate to achieve the IGL 
(Chedotal, 2010). These results point out the essential role of ErbB4 in the CGNPs 
migratory capacity and in the cerebellar structures formation. In fact, the importance of 
ErbB4 in different progenitors and neurons migration has been previously described. 
Indeed, lack of ErbB4 has been associated to a loss of GABAergic interneurons migration 
to the cortex, where Nrg1 acts as their chemoattractant (Flames et al., 2004). Moreover, 
lack of ErbB4 causes defects in cranial neural crest cells and cerebellar granule neurons 
migration (Golding et al., 2000; Tidcombe et al., 2003). It has been also described in vitro 
that Nrg ligands induce radial glia fibers formation (Rio et al., 1997) and that Nrg1/ErbB4 
signaling promotes CGNPs migration by Akt/mechanistic target of rapamycin kinase 
(mTOR) signaling pathway (Yao et al., 2013). Finally, after neuronal migration, it has been 
demonstrated that Nrg1/ErbB4 signaling plays a crucial role in the neurite outgrowth 
induction in different cell types, such as hippocampal neurons (Gerecke et al., 2004), 
cerebellar CGNPs (Rieff et al., 1999) and PC12 cells, which have a neural crest origin 
(Vaskovsky et al., 2000). These findings reinforce our conclusion regarding ErbB4 
essential role in the Bergmann glia formation, and thus, for the CGNPs migration during 
cerebellar development. 
When this receptor ligands were analyzed, we were not able to detect the 
expression of the most investigated ErbB4 ligand, Nrg1, at protein level. However, we 
detected its expression in mRNA levels in vivo, so we then concluded that our negative 
result regarding Nrg1 expression in cerebellar tissue was probably due to technical 
difficulties, such as no appropriate antibody concentration or not selecting the correct 
antibody. Moreover, we detected Hbegf expression, another, although still controversial, 
ErbB4 ligand (Sweeney et al., 2000), at protein and mRNA levels. Interestingly, we found 
in vivo that Hbegf expression increases during cerebellar development, reaching the 
highest levels at p18, when cerebellum is totally developed. These results contradict 






gradual expression decrease after p13, even with persistent detectable transcripts 
(Nakagawa et al., 1998). Nevertheless, their measurements were done in rat cerebella, 
so this difference can explain the contradictory results. Moreover, in contrast with Hbegf 
expression, our results show that Nrg1 expression remains at the same levels in the whole 
cerebellar development, same as ErbB4 expression. So, we hypothesize that Nrg1 could 
be the ligand of ErbB4 in this process and that this one is the reason why both present 
same expression pattern. Regarding Hbegf ligand and ErbB4 receptor locations, 
surprisingly, we did not observe a colocalization, since we detected Hbegf expression in 
the IGL of the cerebellum, as other study has also described (Hayase et al., 1998), whereas 
ErbB4 seems to be located in the EGL. In addition, and confirming our results, Hbegf has 
been described to be expressed in the whole cerebellum (Piao et al., 2005), specifically 
in Purkinje cells, which present strong signals (Nakagawa et al., 1998). In line with these 
results, those obtained by treating CGNPs with Hbegf ligand were consistent, as we were 
not able to activate the ErbB4 receptor with this ligand in vitro. These results 
demonstrated that Hbegf is expressed in the developing cerebellum, so it must have an 
important role in this process. However, it does not seem to be related to ErbB4 signaling 
pathway. Although ErbB4 activation was not reach with Hbegf, we were able to achieve 
a high activation of the receptor when we treated these cells with Nrg1, demonstrating 
that this ligand may have a role in ErbB4 activation and function in cerebellar 
development, in accordance with what Yao et al. has described about the promotion of 
CGNPs migration by Nrg1/ErbB4 signaling pathway (Yao et al., 2013).  
Although the role of Nrg in cerebellar development has been described in several 
studies [(Gilbertson et al., 1998; Rio et al., 1997), the Hbegf implication in this process 
has not been well characterized. In fact, even if Hbegf has been describe as an ErbB4 
ligand (Elenius et al., 1997b), other studies have described that Hbegf does not activate 
ErbB4 in the absence of EGFR expression, and thus, it is presumably not its ligand. Instead, 
Nrg1 is able to activate ErbB4 in the absence of EGFR (Riese et al., 1996b). This might 
explain why we can activate ErbB4 in vitro with Nrg1 but not with Hbegf treatment.  
Altogether, we concluded that ErbB4 directs CGNPs migration during cerebellar 
development, but the role of Hbegf and Nrg1 ligands in regulating this process remains 
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still unclear. Thus, further investigation will be needed to understand Hbegf-ErbB4 
dynamic and interaction in vivo in this developmental process.  
1.2. ErbB4 protects CGNPs and medulloblastoma cells from 
apoptosis 
ErbB4 is known to protect ventricular myocytes (Fukazawa et al., 2003), neurons 
(Yan et al., 2017) and PC12 cells (Erlich et al., 2001) from apoptosis. Our data confirms 
this protection tendency as ErbB4 is also protecting CGNPs and MB tumor cells from 
apoptosis in vitro and in vivo. In fact, after treatment with dexamethasone apoptotic drug 
for CGNPs (Noguchi et al., 2015) and hNRG1, as an ErbB4 activator, both CGNPs and MB 
tumor cells are more resistant to apoptosis. Since NRG1 could activate other ERBB 
receptor family members, we confirmed the implication of ErbB4 specifically, and no 
other members implication, in this apoptosis protection by using ErbB4 KO mice CGNPs. 
In fact, results show that CGNPs coming from ErbB4 KO mouse were not resistant to 
dexamethasone treatment when treated with hNRG1. Thus, we demonstrated in this 
mouse model that ErbB4 was the ErbB receptor family member responsible of this 
apoptotic protection.  
On the one hand, since ErbB4 protects CGNPs from apoptosis, we hypothesized 
that it might drive their proliferation and thus, facilitate MB formation. On the other 
hand, once the tumor is formed, ErbB4 might help in its progression by protecting tumor 
cells against apoptotic stimuli, such as anticancer therapies. Thus, according to all these 
findings, we suggest that ErbB4 would be implicated in MB formation and progression. 
1.3. ERBB4 expression is higher in Group 4 MBs and 
correlates with poor prognosis  
Once we observed that ErbB4 presents an important role in cerebellum 
development and protects both CGNPs and MB cells from apoptosis, and to prove our 
hypothesis of ERBB4 role in MB formation and progression, we moved to investigate the 
expression of this receptor in clinical samples.  
In silico studies showed that ERBB4 expression was elevated in MB samples and 






prognostic significance of ERBB4 expression, and provide the first evidences of ERBB4 
expression as a negative prognostic biomarker in MB. Moreover, its levels are higher in 
Group 4 MBs comparing with other MB subgroups in the four studied cohorts. While we 
were carrying out this project, results regarding aberrant ERBB4-SRC signaling in Group 4 
MB were published (Forget et al., 2018). Interestingly, when considering only Group 4 
patients’ data in the survival analysis, ERBB4 expression levels appeared to be even more 
significant.  
Thus, we suggest that ERBB4 expression could be used as Group 4 MBs biomarker, 
and that its expression could be also a very useful tool as prognostic biomarker, 
specifically in this patients’ subset.  
1.4. ERBB4 promotes tumor progression and its silencing 
activates apoptosis 
To specifically asses the role of ERBB4 in MB, we silenced this receptor expression 
and then performed different functional assays. My thesis results demonstrated that 
ErbB4 experimental silencing significantly impairs cell growth and cell viability as a 
consequence of apoptosis induction. Although few studies have related ERBB4 with 
cancer malignant and aggressive phenotype, similar results have been observed in some 
tumor types. For instance, it has been observed that after ERBB4 suppression in human 
gastric cancer cells, their proliferation was markedly inhibited both in vitro and in vivo 
through PI3K/Akt signaling pathway inhibition (Xu et al., 2018), while another study has 
confirmed these results in melanoma cells (Prickett et al., 2009). All this information 
reinforces this thesis results. Furthermore, regarding cell apoptosis activation when 
inhibiting ERBB4, this phenotype corresponds to the results found in vivo in CGNPs and 
MB cells, where we saw an ErbB4 protective function in response to apoptotic stimuli. 
Moreover, as mentioned before, several works have related ERBB4 with apoptosis 
resistance (Erlich et al., 2001; Fukazawa et al., 2003; Yan et al., 2017).  
These finding are interesting from the point of view of new therapeutic strategies, 
since we can hypothesize that ERBB4 inhibition could suppress tumor cells viability and 
activate their apoptosis, achieving tumor reduction.  
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1.5. ERBB4 plays an important role in MBSCs maintenance 
CSCs have been described in many tumor types (Clarke et al., 2006) including MB 
(Aldaregia et al., 2018; Singh et al., 2003), and they have been described as therapy 
resistance and tumor recurrence responsible (Azzarelli et al., 2018; Kumar et al., 2017). 
Regarding MB cells stemness capacity, our results revealed an enrichment of ERBB4 
expression in the MBSCs population, since oncospheres grown in stem cell specific media 
present higher expression levels of this receptor. It is worth to note that ERBB4 
expression increment when culturing the cells in stem cell specific media, and that it was 
specially increased in DAOY and UW228 cell lines, but not in the other cell lines. This could 
be explained by the fact that the other cell lines express intrinsically higher levels of the 
receptor, thus it is more difficult to see a statistically significant increment when culturing 
the cells in stem cells specific media. Moreover, since ERBB4 knocked-down cells present 
a decreased oncospheres formation capacity in vitro and tumor initiation in vivo, we 
confirmed the relevance of ERBB4 in MBSCs activity.  
Altogether, we demonstrate that high ERBB4 levels are involved in maintaining 
MBSCs population. These results are the first ones demonstrating the high expression of 
ERBB4 in MBSCs. Moreover, even if these results are the first ones relating ERBB4 
expression to MBSCs, this receptor has been previously related to stem cell function 
during embryonic developmental processes (Birchmeier, 2009) and to CSCs in human 
colon cancer (Williams et al., 2015). These results make sense of our results, since ERBB4 
has been related to stemness ability in other tissues. 
In summary, we concluded that ERBB4 expression is necessary for MBSC 
maintenance, and that it likely regulates the interplay between self-renewal and 
differentiation and behaves as an oncogene in MB. Thus, the inhibition of this receptor 
would be a promising new therapeutic approach, since it would not only reduce the 
viability and activate the apoptosis of the bulk tumor cells, but also the MBSCs, which 
remains in a dormant state and are not sensitive to conventional chemo- and 






1.6. ERBB4 silencing upregulates response to stimulus and 
cell death signaling pathways 
Finally, the work performed in the first chapter of this thesis shows evidence of 
the altered pathways when silencing ERBB4. After performing a transcriptomic analysis 
of DAOY cells with ERBB4 silencing, we have observed a downregulation in cell signaling, 
morphogenesis and development related pathways and an upregulation in response to 
stimulus, such as growth factors, cytokines, drugs or stress, and cell death. These last 
findings are considered as advantageous to contemplate a therapy against ERBB4 
receptor, since an upregulation of response to stimulus, such radiotherapy or 
chemotherapy, may reduce tumor resistance, and cell death increase will help for tumor 
size reduction.   
The selected genes to be validated seem to be promising therapeutic targets too, 
specifically, the parathyroid hormone-related protein (PTHLH) and TP63 genes. On the 
one hand, PTHLH appears upregulated with ERBB4 silencing and when translating to 
clinical samples, it negatively correlates with ERBB4 expression and its low expression 
levels are related, just as expected, to poor prognosis. PTHLH has been described as a 
SHH target gene (Sterling et al., 2006), which led us to hypothesize that it is more related 
to SHH driven MBs. Moreover, this protein high levels have been related to better 
prognosis in breast cancer (Tran et al., 2018), which goes in the same direction as our 
results, since ERBB4 silenced cells, which are less tumorigenic, express higher levels of 
PTHLH. However, there are several works that have related PTHLH with cancer 
progression and osteolytic bone metastasis (Katoh and Katoh, 2009; Yao et al., 2019), 
which contradicts our results. Thus, we hypothesize that PTHLH role in cancer could be 
tumor type dependent.  
On the other hand, ERBB4 silencing triggers TP63 downregulation. In the clinic 
TP63 positively correlates with ERBB4 and its expression is related to worse prognosis. 
Moreover, both of these genes have been related in different manners to cancer. TP63 
has been associated also with cancer and with ERBB4 signaling pathway (Forster et al., 
2014; Orzol et al., 2015). TP63 gene encodes p63 protein, one of the p53 protein family 
members implicated in the regulation of normal stem cells and cancer stem cells 
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(Galoczova et al., 2018). Specifically, TP63 is well known for its role in epidermal 
development. Moreover, it has been described to regulate luminal progenitor function 
and lactation via NRG1 (Forster et al., 2014). Regarding tumorigenesis, several works have 
related this transcription factor to cancer, as playing tumor-suppressor and oncogenic 
dual roles (Orzol et al., 2015). Even if TP63 gene almost never presents mutations in 
human cancer, its activity is often increased in several cancers (Orzol et al., 2015) and 
also implicated in CSCs (Nekulova et al., 2011). All these results propose p63 as a 
transcription factor that might be mediated by ERBB4, and thus, used as biomarker and 
new therapeutic target in MB.  
Thus, with these analyses we found two different genes that are regulated in 
some way by ERBB4, and that seem to be good prognostic biomarker and therapy target. 
However, more studies need to be done in order to investigate their role in MB. However, 
even if we found some signaling pathways altered with ERBB4 silencing, more 
experiments would be necessary to find the signaling pathway from where ERBB4 
silencing is specifically causing the discovered phenotype.  
 
As a summary of the first chapter of this thesis, our work has identified an 
important role of ErbB4 in cerebellum development, ERBB4 expression as highly enriched 
in the MBSCs pool and its inactivation as significantly impairing their proliferative 
malignant properties and tumor initiation and progression. Taken together, our data 
depict a previously unknown role for ERBB4 as a central player of MB biology, prognosis 
and therapy. 
More specifically, we postulate that ERBB4 has an important role in cerebellum 
development, governing and maintaining CGNPs’ proliferation and migration. But it is not 
clear which one is the specific role of ErbB4 in this brain structure development, and 
which are the ligands that are activating the receptor in this process. So, further 
investigation is needed in order to clarify these aspects. 
Moreover, we revealed that ERBB4 is overexpressed in Group 4 MBs, the most 






patient survival. Furthermore, we demonstrated that ERBB4 inhibition has the ability to 
reduce MB cells viability and MBSCs stemness ability. Altogether, these results enable the 
stratification of the patients in terms of ERBB4 expression levels. The prospective of this 
work is to achieve an effective ERBB4 inhibitor that could be used in combination with 
traditional chemo and radiotherapy in Group 4 patients or in patients with high ERBB4 
expression. The objective of this treatment combination is, first, to target both tumor 
bulk cells and MBSCs, thus avoiding or hindering tumor recurrence and treatment 
resistence, and secondly, to reduce the doses of the current therapies in order to reduce 
















2. High SOX1 expression is a hallmark of SHH 
medulloblastomas and its inhibition depletes tumor 
malignancy 
As mentioned above, MB is generated due to a dysregulation in cerebellum 
development process (Grimmer and Weiss, 2006). Different genes and signaling 
pathways that direct this embryonic process has been also implicated in tumor formation, 
such as WNT and SHH pathways, that are related to MB formation (Dey et al., 2012; 
Zurawel et al., 1998). There are several evidences that a lot of transcription factors that 
participate in developmental processes act also as oncogenes, by reactivating necessary 
processes for tumorigenesis (Suva et al., 2013). Among these transcription factors, SOX1, 
is a transcription factor essential for maintaining the neural progenitors’ proliferation. 
However, its continued expression leads to neuronal differentiation (Kan et al., 2007). 
SOX1 absence causes epilepsy (Malas et al., 2003), but its lack could be partially 
compensated by the other members of the SOXB1 subgroup of transcription factors, 
SOX2 and SOX3, since it has been demonstrated an overlapping expression pattern of 
these factors in neural progenitor cells (Bylund et al., 2003; Venere et al., 2012). 
Interestingly, SOX1 is also implicated in cerebellar development, as it has been described 
to be expressed in the Bergmann glia progenitors (Alcock and Sottile, 2009; Sottile et al., 
2006). Considering all these evidences, we hypothesize that SOX1 could be considered as 
a key player in neural progenitors’ and cerebellum development regulation and MB 
formation.  
2.1. SOX1 could be a better prognostic biomarker for SHH 
MBs 
In the second chapter of this thesis we wanted to assess SOX1 relevance in MB 
formation and progression. For this aim, we took advantage of publicly available cohorts. 
We first investigated SOX1 expression in human MB samples. It is worth to note that it 
has been previously described that SOX1 is a negative regulator of WNT/β-catenin 
signaling pathway in several tumor types (Guan et al., 2014; Mojsin et al., 2015; Song et 




al., 2016; Tsao et al., 2012; Yang et al., 2015). Interestingly, the results show that SHH 
MBs present higher SOX1 expression levels, which are associated with shorter patients’ 
survival. We wondered whether SOX1 could be used as a patient stratification biomarker 
in this MBs subtype and if it could be a better biomarker than the SHH signaling pathway 
genes expression. To achieve this goal, we investigated the expression levels pf SHH 
signaling pathway different member genes, such as SHH, SMO, PTCH1, GLI1, GLI2 and 
GLI3. We found a positive correlation between these genes and SOX1 expression. These 
results reinforced the probable relation between SOX1 and this signaling pathway and 
also our hypothesis that SOX1 could be a good SHH group biomarker. Surprisingly, only 
one of the SHH signaling pathway genes (GLI2) seemed to be a good subgroup and 
prognostic biomarker, since it was the only one presenting the higher expression in SHH 
subgroup and this high expression was correlated with poor prognosis. The lack of SHH 
signaling pathway genes overexpression in SHH subgroup can be explained since 
mutations that lead to constitutive activation of the SHH pathway in medulloblastomas 
have been identified, usually targeting the PTCH1, or less frequently SUFU or SMO, 
leading to expression of the oncogenic transcription factor GLI1 (Pietsch et al., 1997; 
Raffel et al., 1997; Reifenberger et al., 1998; Taylor et al., 2002; Wolter et al., 1997). 
However, the correlations between SHH pathway genes and overall survival present 
worse statistical results than the ones obtained with SOX1 analysis, highlighting the 
potential of SOX1 as a significant biomarker of SHH subgroup. Regarding the evidences 
relating SOX1 with SHH signaling pathway, a single study has described that SHH 
supplementation to human embryonic stem cells increases SOX1 expression in vitro (Wu 
et al., 2010), so the relation between them needs to be further investigated.  
Moreover, as we have demonstrated in the third chapter of this thesis that SOX1 
is regulated by SOX2 in GBM, we wondered if in MB SOX1 could be regulated by different 
SOX family members. We investigated the relation of SOX2, SOX4 and SOX9 with SOX1 
and with MB overall survival, not finding any significative relation between SOX1 and the 
other SOX members. Thus, we concluded that in MB SOX1 is not regulated by other SOX 
family members. 
All this thesis chapter data confirms the SOX1 expression significance for patients’ 






genes, and thus, reinforcing our hypothesis. Moreover, the evidence of SOX1 expression 
involvement as a negative prognostic biomarker in MB is determined for the first time in 
this work. Indeed, SOX1 has been related to several cancer types, but not always with an 
oncogenic role. In fact, low SOX1 expression has been correlated with shorter overall 
survival and poor prognosis in ovarian cancer (Su et al., 2009), human hepatocellular 
carcinoma (Lou et al., 2015; Tsao et al., 2012), and esophageal squamous cell carcinoma 
(Kuo et al., 2014; Rad et al., 2016). Until this thesis, high SOX1 expression has not been 
correlated with shorter overall survival.  
This thesis data and obtained findings demonstrate tumor type dependent SOX1 
role in cancer. This SOX1 divergent role could be explained by two different theories. On 
the one hand, it has been demonstrated that SOX1 expression is modulated by epigenetic 
status, since low expression levels of SOX1 and a better prognosis has been related to 
these gene’s promoter methylation in different tumor types (Guan et al., 2014; Kuo et 
al., 2014; Tsao et al., 2012). On the other hand, the cellular plasticity and heterogeneity 
could explain this SOX1 divergent role, since it has been described that SOX1 is one of the 
19 neurodevelopmental transcription factors that are active and have higher expression 
in GSCs than in differentiated cells (Suva et al., 2014).  
2.2. SOX1 controls tumor proliferation in vitro and in vivo 
After analyzing SOX1 effect in human cohorts, we explored its role in MB cells in 
vitro. For this aim, we knocked-down and enhanced its expression. The experimental 
silencing in MB cell lines markedly reduced their proliferative capacity and cell viability in 
vitro and delayed tumor formation in vivo. However, the overexpression slightly increased 
the proliferative capacity of MB cells.  
As it has been mentioned, SOX1 presents higher expression in SHH subgroup 
patients. In line with this, the results obtained in this chapter demonstrated that SOX1 
silencing generates a more severe phenotype in DAOY and UW228 cells (SHH subgroup 
cell lines) than in D283Med cells (Group 3 or 4 cell line) in the performed experiments. 
This fact further demonstrates the importance of SOX1 in SHH subgroup MBs.  
As mentioned before, both this thesis second and third chapters are the first 
evidence that postulate SOX1 as an oncogenic and not as a tumor suppressor gene, thus, 




relating SOX1 with tumor cells proliferation. Moreover, even if SOX1 has not been 
described as tumor proliferation inductor in any other tumor to date, its expression has 
been related to proliferation in early neuronal progenitors (Kan et al., 2007) and cortical 
neural progenitors (Elkouris et al., 2011). Considering that MB tumors are originated from 
neural progenitor cells, the implication of SOX1 in MB proliferation seems coherent. 
2.3. SOX1 is overexpressed in MBSCs and mediates their 
activity 
This work results reinforce the SOX1 importance in cancer stem cells, since we 
found in this study that SOX1 expression is higher in MBSCs, cultured in stem cell specific 
media, compared to the parental cells, cultured in the presence of serum. These results 
demonstrate that SOX1 high levels are linked to MBSCs population maintenance. 
Furthermore, SOX1 knock-down significantly decreased oncosphere formation and self-
renewal capacity in vitro and tumor initiation in vivo. This relation between SOX1 and 
CSCs has not been described previously. In fact, SOX1 lower expression have been related 
with CSCs (Rad et al., 2016). 
Furthermore, we detected that silencing of SOX1 expression downregulated 
NESTIN, PML, ERBB4 and CD133 stem cell markers expression (Dahlstrand et al., 1995; 
Ito et al., 2008; Singh et al., 2003; Zhou et al., 2015), and increased the well-known 
differentiation marker p27KIP expression (Ayrault et al., 2009). An interesting study has 
demonstrated that p27KIP levels are regulated by SOX1 in hepatocellular carcinoma (Tsao 
et al., 2012), reinforcing this protein relevance and its regulation by SOX1 activity. 
Moreover, SOX1 has been found within the genes’ set with elevated expression in 
CD44+/CD24- and CD133+ breast cancer stem cells (Wright et al., 2008), relating also 
SOX1 to this stem cell marker. 
Altogether, these results show that SOX1 regulates the interaction between 
proliferation, self-renewal and differentiation processes that are necessary for MBSCs 
maintenance. Besides, our results firmly establish that SOX1 behaves as an oncogene in 
MB, in contrast to other tumor types such as hepatocellular or nasopharyngeal carcinoma 
(Guan et al., 2014; Tsao et al., 2012), cervical (Lin et al., 2013), lung (Li and Li, 2015), or 






these results, together with the results obtained in this thesis third chapter, are the first 
one relating SOX1 to malignant phenotype in cancer. Thus, further research must be done 
in order to clarify SOX1 role in CSCs and in other brain cancers to consider if maybe it can 
be related to this phenotype in neural origin tumors.  
2.4. SOX1 knock-down alters cell response, motility and 
cellular morphogenesis related signaling pathways 
This thesis transcriptomic analysis shows multiple pathways and genes alteration 
in SOX1 knocked-down cells. Specifically, we revealed an upregulation in genes related to 
cellular morphogenesis and a downregulation in genes involved in cell response and 
motility. Among these signaling pathways, a reduction in motility could be beneficial for 
tumor treatment. In fact, as mentioned before, 30 % of MB tumors present metastasis in 
the moment of the diagnosis (Park et al., 1983), so reduced cellular motility could induce 
a metastasis diminution. Moreover, even if SOX1 has not been identified as involved in 
tumor cells metastasis, it controls neurons migration (Ekonomou et al., 2005), and 
considering the neuronal origin of MBs, this information can explain our results of 
reduced expression of cell motility related genes in SOX1 knocked-down cells.   
Moreover, we identified and validated in the microarray analysis a set of 6 genes 
(IL6, VCAM1, CEACAM1, IGFBP3, SOD2 and SEMA5A) as downstream targets of SOX1 
activity in MB cells. IL6 is implicated in a wide range of inflammatory processes and it has 
been reported as an inductor of MB cells proliferation and viability (Chen et al., 2018). 
VCAM1 and IGFBP3 have been also related to MB, the first one showing higher expression 
in SHH subgroup (Liang et al., 2015) and IGFBP3 showing higher expression levels in high 
risk MBs (Svalina et al., 2016). CEACAM proteins are implicated in cellular adhesion, 
proliferation, differentiation and tumor suppression, but some of the members of the 
family, such as CEACAM1 are associated to the malignant phenotype of some tumors 
(Kelleher et al., 2019). SOD2 has been related to treatment-related ototoxicity in cisplatin 
treated MBs (Brown et al., 2015). SEMA5A has a dual role in cancer, since it has been 
demonstrated to be a good prognostic biomarker and suppress proliferation and 
migration in colon cancer and lung adenocarcinoma respectively (Demirkol et al., 2017; 
Ko et al., 2020), but it drives melanoma and pancreatic cancer progression (D'Aguanno et 




al., 2018; Saxena et al., 2018a). All these genes appear to be downregulated with SOX1 
knock-down. Among them, CEACAM1, IGFBP3 and SEMA5A genes seem to have a special 
interest, since they presented a positive correlation with SOX1 and exhibit the highest 
expression levels in SHH MB subgroup patients, following the same pattern as SOX1. Even 
so, none of them presented statistical differences when analyzing the correlation 
between these genes’ expression levels and overall patients’ survival. Thus, further 
investigation might be done in order to investigate the specific relation between these 
genes and SOX1.  
Moreover, as SOX1 is a transcription factor, it can regulate a wide range of genes 
expression. In this work the specific SOX1 direct targets that are activated or/and 
inhibited to give rise to the phenotype we found in the cells when inhibiting SOX1 are not 
demonstrated yet. So next steps will be directed to finding this target genes, with the 
objective to discover more targetable molecules in order to achieve a good MB 
treatment.  
 
Altogether, in this thesis second chapter, our work has identified that SOX1 
expression is highly enriched in the MBSCs pool and that its knock-down significantly 
impairs human MB cells proliferation, self-renewal and tumor initiation and progression. 
Thus, we hypothesize that SOX1 is a master developmental transcription factor that 
governs cellular plasticity, heterogeneity and motility. Furthermore, we disclose that 
SOX1 is overexpressed in SHH MBs compared to the other subgroups and that this high 
expression is associated with shorter overall patients’ survival. Moreover, when 
comparing the prognostic and subgroup biomarker potential of SHH signaling pathway 
genes with SOX1, we observed a more promising role for SOX1 than all the genes analyzed 
regarding prognostic and subgroup biomarker. Collectively, our data detail a previously 
undescribed SOX1 role as a central player in MB biology, prognosis and therapy. 
Moreover, it is the first time that SOX1 particular role in MB progression and MBSCs pool 
maintenance has been identified. Hence, we have identified in this work that SOX1 







Regarding the prospective of this work, the identified role of SOX1 in MBSCs, 
together with the results obtained when inhibiting SOX1 expression, are interesting for 
the translational point of view. As mentioned in this thesis, MBSCs are responsible for 
tumor recurrence and treatment resistance, and targeting them is the ambitious 
challenge of cancer research. Thus, the establishment of a gene related to tumor 
proliferation and MBSCs activity allows new studies in order to found an effective SOX1 
inhibitor that will target both MBSCs and tumor bulk cells, thus reducing tumor 
recurrence and therapy resistance. Moreover, as current therapies cause very severe side 
effects, the best approach would be a combined therapy with SOX1 inhibitors, but using 















3. SOX1 presents an oncogenic activity in glioblastoma 
As mentioned before, several transcription factors that direct developmental 
decisions might also act as oncogenes by promoting reactivation of programs required 
for tumorigenesis (Suva et al., 2013). Among them SOX1, the transcription factor that we 
investigated in this thesis, is an essential transcription factor for proliferation 
maintenance in the neural stem/progenitor pool. Based on this evidence, SOX1 might be 
considered as a key player in neural development through the neural/progenitor pool 
homeostasis maintenance. In the second chapter of this thesis, we have identified the 
oncogenic role of SOX1 in MB. Then, we wondered if it would have a similar effect in a 
non-developmental brain tumor. Thus, we investigated the role of this transcription 
factor in GBM. It is worth to note that prior to this study, little was known about the 
impact of SOX1 in GBM and in the GSC population maintenance.  
3.1. SOX1 high expression levels are associated with a 
reduced survival in GBM 
In the last chapter of this thesis, we wanted to stufy the role of SOX1 in GBM, the 
most common and aggressive brain tumor in adulthood. For this aim, we first investigated 
SOX1 expression in human brain samples. SOX1 mRNA expression analysis in a GBM 
patients’ cohort from Donostia University Hospital indicated that SOX1 expression was 
slightly up-regulated in approximately 60 % of tumor tissues compared to healthy human 
brain tissues. Moreover, taking advantage of the publicly available TCGA cohort data, we 
found that SOX1 high levels were associated with shorter patient survival. All these data 
confirm the SOX1 clinic-pathological and prognostic significance in GBM. In fact, as 
mentioned before, SOX1 protein and/or mRNA low expression has been correlated with 
shorter overall survival and poor prognosis in ovarian cancer (Su et al., 2009), human 
hepatocellular carcinoma (Lou et al., 2015; Tsao et al., 2012), and esophageal squamous 
cell carcinoma (Kuo et al., 2014; Rad et al., 2016). Indeed, together with the second 
chapter results, it is the first evidence correlating SOX1 high expression with poor 
patients’ outcome in cancer.  




As mentioned in previous chapter discussion, the SOX1 dichotomic role in 
different tumor types is conceivable. In fact, SOX1 expression could be elevated or 
decreased depending on the epigenetic status or the cellular heterogeneity and plasticity 
(Guan et al., 2014; Kuo et al., 2014; Tsao et al., 2012).  
3.2. SOX1 is enriched in GSCs and its knock-down inhibits 
their activity 
Regarding cellular heterogeneity and plasticity, our data revealed that SOX1 
expression is enriched in the GSCs population, cultured in stem cell specific media, 
compared to parental cells, cultured in the presence of serum. Moreover, we found that 
patient-derived GSCs have higher levels of SOX1 expression than conventional cell lines. 
Moreover, these levels decrease when the GSCs are induced to differentiate in the 
presence of serum. These results demonstrate that high SOX1 levels maintain GSCs in an 
undifferentiated state and that the differentiation process decreases the expression 
levels of this transcription factor. In agreement with this idea and as mentioned before, 
SOX1 has been identified within the set of 19 neurodevelopmental transcription factors 
that are active and have higher expression in GSCs than in differentiated cells (Suva et al., 
2014). Furthermore, mapping of chromatin accessibility, before and after differentiation 
with BMP treatment, identified several enriched motifs for SOXB1 family members, 
mostly SOX2 but also SOX1, as regulatory regions that failed to be completely silenced in 
GSC settings (Caren et al., 2015). Moreover, SOX1 has been observed among the genes 
set with elevated expression in CD44+/CD24− and CD133+ breast cancer stem cells 
(Wright et al., 2008) and in invasive prostate cancer cells, where SOX1 promoter was 
hypomethylated (Mathews et al., 2010). Furthermore, one study has used SOX1 high 
expression as GSCs characteristic marker (Bielecka-Wajdman et al., 2017). Together, 
these results postulate that SOX1 enrichment in the CSCs population is likely to be 
mediated by temporal and context dependent epigenetic changes. These findings are 
supported by the evidence that, during tumor initiation and progression, cancer cells 
epigenome undergoes multiple alterations thus presenting broad domains of promoter 
hypermethylation, that contributes to carcinogenesis. This process is induced through 
tumor suppressor genes and epigenetic regulators inactivation; and also, by the induction 






transcription factors important for self-renewal, and therefore, are under selective 
pressure to maintain or increase their expression in the corresponding cancer cell (Caren 
et al., 2015; Dawson and Kouzarides, 2012; You and Jones, 2012). However, we did not 
study the epigenetic status of SOX1 and its promoter in this thesis chapter, so further 
research must be done in order to identify this gene epigenetic status in GBM and in 
GSCs. 
Regarding SOX1 role in GSCs activity, we knocked down its expression directly in 
GSCs. We then observed a marked reduction in their proliferative and self-renewal 
activity, accompanied by a delayed tumors’ formation when cells were xenotransplanted 
into immunodeficient mouse brains. The same approach with U251 cells generated 
similar results to the ones obtained with SOX1 silencing in GSCs. Indeed, SOX1 knock-
down significantly impaired self-renewal and proliferative capability in vitro and tumor 
initiation and progression in vivo. These results indicate that SOX1 expression is necessary 
for GSC maintenance, that is likely regulating proliferation, self-renewal and 
differentiation interplay. On the contrary, SOX1 overexpression in GSCs moderately 
increased cell growth, proliferation and stem cell markers expression. A complementary 
study showed that elevated SOX1 in differentiated glioma cells barely enhanced sphere 
formation and weakly induced CD133 stem cell marker expression, but failed to initiate 
tumors in mice that received an orthotopic xenograft (Suva et al., 2014). These results 
support the notion that SOX1 elevated expression is essential for maintaining, but not 
sufficient for promoting GSCs self-renewal. Several additional factors might cooperate to 
activate stem cell-like properties. Indeed, POU3F2, SOX2, SALL2, and OLIG2 have been 
shown to be the essential core set of transcription factors for GBM propagation, which 
are within the 19 transcription factors set (including SOX1) required for successful 
reprogramming of differentiated glioma cells into GSCs (Suva et al., 2014). In summary, 
our results firmly establish that SOX1 behaves as an oncogene in GBM and that it is 
regulating glioma cell plasticity. This activity contrasts the evidence available for other 
cancer types, such as hepatocellular or nasopharyngeal carcinoma (Guan et al., 2014; 
Tsao et al., 2012), cervical (Lin et al., 2013), lung (Li and Li, 2015), or breast cancers (Song 
et al., 2016), in which it displays tumor suppressor activity. These data underline the fact 
that SOX1 activity is cancer context dependent. 




3.3. SOX1 promotes tumor cells proliferation independently 
from WNT/B-catenin signaling pathway 
This thesis results have also shown that when knocking down SOX1 expression in 
conventional U251 cell lines, the cells lose their proliferative capacity and viability. They 
also form less and smaller tumors when injected into immunocompromised mice 
subcutaneously. In regard to these results, and as it has been mentioned before, to our 
knowledge, this thesis results are the first ones relating SOX1 with tumor cells 
proliferation promotion, even if this transcription factor has been related to neuronal 
progenitors’ proliferation before (Elkouris et al., 2011; Kan et al., 2007). 
Furthermore, we wanted to find the pathway through which SOX1 was acting to 
develop the oncogenic phenotype. It has been previously shown that SOX1 is a negative 
regulator of WNT/β-catenin signaling in several cancer types justifying its tumor 
suppressor activity. In GBM, however, we have not detected any remarkable effects of 
SOX1 silencing in the expression of β-catenin and its downstream target MYC at cellular 
level in vitro, in tumors in vivo, as well as in clinical biopsies. Therefore, the SOX1 
oncogenic functions in GBM seem to be β-catenin independent. Similar to these results, 
SOX1 overexpression in the embryonal teratocarcinoma cell line, NT2/D1, did not affect 
WNT signaling activity (Mojsin et al., 2015). Regarding SOX1 modulation consequences, 
at molecular level, we detected that SOX1 expression gain and silencing, in GSC and U251 
cell, modulated SOX2 (stem cell marker), PML (Iwanami et al., 2013; Martin-Martin et al., 
2016; Zhou et al., 2015) and cell cycle regulators (such as p27KIP and CYCLIN D1) 
expression (Buttitta and Edgar, 2007). These results suggest SOX2-PML and p27KIP-CYCLIN 
D1 as downstream molecular effectors by which SOX1 functions in GBM governing self-
renewal and proliferation programs. Additional studies have shown that SOX1 alters SOX2 
expression in human laryngeal squamous cell carcinoma (Yang et al., 2015), regulates 
p27KIP levels in hepatocellular carcinoma (Tsao et al., 2012), and modulates CYCLIN D1 
expression in hepatocellular and nasopharyngeal carcinoma as well as in breast cancer 
(Guan et al., 2014; Song et al., 2016; Tsao et al., 2012). Altogether, data presented 
reinforce the relevance of those genes underlying SOX1 activity. However, further work 






As a summary of the last chapter of this thesis, our work has identified that SOX1 
expression is highly enriched in the GSCs pool and its inactivation significantly impairs 
their malignant properties including proliferation, self-renewal ability, differentiation 
capacity as well as tumor initiation and progression. Based on our results, we postulate 
that SOX1 is a master developmental transcription factor, governing and maintaining 
cellular plasticity and heterogeneity associated with diverse regulatory programs. 
Moreover, we reveal that SOX1 is overexpressed in a subset of GBM human biopsies and 
that its high levels are associated with shorter overall patient survival. Taken together, 
our data pointed out a previously unappreciated SOX1 role as a central player in GBM 
biology, prognosis, and therapy. 
The prospective of this work is similar to the ones in previous chapters. The 
importance of SOX1 as a prognostic biomarker may enable patients’ stratification 
considering low and high SOX1 expression tumors. Afterwards, our proposal is to apply a 
SOX1-targeted therapy in combination with the standard treatments, with the aim of 
eliminating both tumor bulk cells and GSCs, thus reducing tumor recurrence chances 
[Figure D1]. However, to achieve this objective safe SOX1-targeting drugs that can cross 
the brain blood barrier must be found. 
 





Figure D1. Schematic representation of this thesis prospective. The prospective of this thesis is the 
stratification of the patients based on ERBB4/SOX1 levels. Then, to treat the patients’ tumors that present 
higher ERBB4/SOX1 levels there are two options: i) treat these patients with conventional treatments, 
which will target and eliminate tumor bulk cells, but not CSCs. Thus, this CSCs will proliferate and tumor 
recurrence will occur, normally generating a more heterogenous and aggressive tumor. ii) treat these 
patients with a combination of conventional treatments and ERBB4/SOX1 inhibitors. This combination will 
target both tumor bulk cells and CSCs, leading to the eradication of the tumor and a better prognosis for 
















































1. ErbB4 is expressed in the inner EGL of the developing cerebellum, where and 
it is requiered for the correct organization of Purkinje cells and astrocytes, 
and, in consequence, to ensure the correct CGNPs migration to the IGL.  
2. ErbB4 activation protects CGNPs and MB cells from apoptosis in vitro and in 
vivo. 
3. ERBB4 presents a higher expression in Group 4 MBs, which correlates with 
poor prognosis. We therefore postulate ERBB4 as a good subgroup and 
prognostic biomarker for MB. 
4. ERBB4 silencing inhibits cell viability and activates apoptosis in MB cells in 
vitro, and it is required for tumor progression in vivo.  
5. ERBB4 plays an important role in the maintenance of MBSCs, where ERBB4 is 
highly expressed. 
6. SHH MBs present higher levels of SOX1 expression, which correlates with poor 
prognosis.  
7. SOX1 constitutes a better prognostic biomarker than genes of SHH signaling 
pathway in the case of SHH MBs. 
8. SOX1 silencing inhibits MB proliferation in vitro and in vivo.  
9. SOX1 is overexpressed in MBSCs, mediating their activity. 
10. High SOX1 expression levels are associated with reduced survival in GBM 
patients, postulating it as a possible prognostic biomarker. 
11. SOX1 is enriched in the GSC population and its knock-down inhibits their 
activity.  
12. SOX1 promotes tumor formation and proliferation in vitro and in vivo, being 
its activity not mediated by the WNT/B-catenin signaling pathway in GBM. 
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